var title_f3_63_4080="Skin changes of chronic venous insufficiency";
var content_f3_63_4080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin changes of chronic venous insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longstanding edema in this patient with chronic venous insufficiency led to moderately advanced pigment changes on the medial and lateral ankles, which extend onto the dorsum of the foot. The left medial ankle displays a healed venous ulcer below the malleolus; the right lateral ankle has a small, active, venous ulcer (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4080=[""].join("\n");
var outline_f3_63_4080=null;
var title_f3_63_4081="Triclabendazole: International drug information";
var content_f3_63_4081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triclabendazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13451103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Egaten (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F13451104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Egaten",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13451105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F13451106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Fasciola hepatica",
"     </i>",
"     (sheep liver fluke) infection",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F13451108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 10 mg/kg as a single dose, may repeat in 12-24 hours for severe infection",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13451107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17103 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4081=[""].join("\n");
var outline_f3_63_4081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451103\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451104\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451105\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451106\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451108\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451107\">",
"      Product Availability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/17103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/17103|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4082="Sclerotic chronic GVHD";
var content_f3_63_4082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple firm, sclerotic plaques are present with areas of shallow ulceration. Dyspigmentation is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4082=[""].join("\n");
var outline_f3_63_4082=null;
var title_f3_63_4083="Hypoglycemia (low blood sugar) in diabetes mellitus";
var content_f3_63_4083=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/63/4083/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4083/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/63/4083/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4083/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/63/4083/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4083/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/63/4083?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LOW BLOOD SUGAR OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hypoglycemia, also known as low blood sugar, occurs when levels of glucose (sugar) in the blood are too low. Hypoglycemia is common in people with diabetes who take insulin and some (but not all) oral diabetes medications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY DO I GET LOW BLOOD SUGAR?",
"     </span>",
"    </p>",
"    <p>",
"     Low blood sugar happens when a person with diabetes does one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Takes too much insulin (or an oral diabetes medication that causes your body to secrete insulin)",
"      </li>",
"      <li>",
"       Does not eat enough food",
"      </li>",
"      <li>",
"       Exercises vigorously without eating a snack or decreasing the dose of insulin beforehand",
"      </li>",
"      <li>",
"       Waits too long between meals",
"      </li>",
"      <li>",
"       Drinks excessive alcohol, although even moderate alcohol use can increase the risk of hypoglycemia in people with type 1 diabetes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      LOW BLOOD SUGAR SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of low blood sugar vary from person to person, and can change over time. During the early stages low blood sugar, you may:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sweat",
"      </li>",
"      <li>",
"       Tremble",
"      </li>",
"      <li>",
"       Feel hungry",
"      </li>",
"      <li>",
"       Feel anxious",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If untreated, your symptoms can become more severe, and can include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty walking",
"      </li>",
"      <li>",
"       Weakness",
"      </li>",
"      <li>",
"       Difficulty seeing clearly",
"      </li>",
"      <li>",
"       Bizarre behavior or personality changes",
"      </li>",
"      <li>",
"       Confusion",
"      </li>",
"      <li>",
"       Unconsciousness or seizure",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When possible, you should confirm that you have low blood sugar by measuring your blood sugar level. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .) Low blood sugar is generally defined as a blood sugar of 60",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (3.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     or less.",
"    </p>",
"    <p>",
"     Some people with diabetes develop symptoms of low blood sugar at slightly higher levels. If your blood sugar levels are high for long periods of time, you may have symptoms and feel poorly when your blood sugar is closer to 100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (5.6",
"     <span class=\"nowrap\">",
"      mmol/L).",
"     </span>",
"     Getting your blood sugar under better control can help to lower the blood sugar level when you begin to feel symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Hypoglycemia unawareness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypoglycemia unawareness occurs when you do not have the early symptoms of low blood sugar. As a result, you cannot respond in the early stages, and severe signs of low blood sugar, such as passing out or seizures, are more likely. Being unaware of low blood sugar is a common occurrence, especially in people who have had type 1 diabetes for greater than 5 to 10 years.",
"    </p>",
"    <p>",
"     Hypoglycemia and hypoglycemia unawareness occur more frequently in people who tightly control their blood sugar levels with insulin (called intensive therapy).",
"    </p>",
"    <p>",
"     People who drink excessive amounts of alcohol, are tired, or who take a beta-blocker (commonly used to control high blood pressure) may not notice their low blood sugar symptoms, or may not recognize that the symptoms are due to low blood sugar.",
"    </p>",
"    <p>",
"     Hypoglycemia unawareness can also occur in people who take certain oral diabetes medications (eg, Micronase&reg; [glyburide]), especially in elderly people with heart or kidney disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Nocturnal hypoglycemia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low blood sugar that occurs when you are sleeping (nocturnal hypoglycemia) can disrupt sleep but often goes unrecognized. Nocturnal hypoglycemia is a form of hypoglycemia unawareness. Thus, if you have nocturnal hypoglycemia, you are less likely to have symptoms that alert you to the need for treatment. Nocturnal hypoglycemia can be difficult to diagnose, and can increase the risk of hypoglycemia unawareness in the 48 to 72 hours that follow.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      LOW BLOOD SUGAR PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The best way to prevent low blood sugar is to monitor your blood sugar levels frequently and be prepared to treat it promptly at all times. You and a close friend or relative need to learn the symptoms and should",
"     <strong>",
"      always",
"     </strong>",
"     carry glucose tablets, hard candy, or other sources of fast-acting carbohydrate.",
"    </p>",
"    <p>",
"     Glucose tablets are recommended since they have a pleasant taste, but you are not likely to eat them unless your blood sugar is low. Candy can be tempting to eat, even when blood sugar levels are normal, especially for children with diabetes.",
"    </p>",
"    <p>",
"     Low blood sugar can be frightening and unpleasant, and it is common to be fearful of future episodes. This may lead you to keep your blood sugar level high, which can lead to long-term complications.",
"    </p>",
"    <p>",
"     It may be helpful to discuss fears of low blood sugar with a healthcare provider. In addition, ask about blood sugar awareness education. Blood sugar awareness training can improve your ability to recognize low blood sugar earlier.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      LOW BLOOD SUGAR TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     When you are low, you should check your blood sugar level as soon as possible. However, go ahead and treat yourself for low blood sugar if your monitoring equipment (blood glucose meter, test strips, lancet) is not readily available. Treat yourself quickly, especially if your blood sugar is less than 40",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (2.2",
"     <span class=\"nowrap\">",
"      mmol/L).",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If your blood sugar is 51 to 70",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.8 to 3.9",
"       <span class=\"nowrap\">",
"        mmol/L),",
"       </span>",
"       eat 10 to 15 grams of fast-acting carbohydrate (eg,",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       cup fruit juice, 6 to 8 hard candies, 3 to 4 glucose tablets).",
"      </li>",
"      <li>",
"       If you are less than 50",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.8",
"       <span class=\"nowrap\">",
"        mmol/L),",
"       </span>",
"       eat 20 to 30 grams of fast-acting carbohydrates.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This amount of food is usually enough to raise the blood sugar into a safe range without causing high blood sugar levels (called hyperglycemia). Avoid foods that contain fat (like candy bars) or protein (cheese) initially, since they slow down your body's ability to absorb glucose.",
"    </p>",
"    <p>",
"     Retest after 15 minutes and repeat treatment if needed. If your next meal is more than an hour away, eat an additional 15 grams of carbohydrate and 1 ounce of protein. Examples of this include crackers with cheese or one-half of a sandwich with peanut butter. It is important not to eat too much because this can raise your blood sugar above the target level and lead to weight gain over the long-term.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Glucagon",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your low blood sugar is severe, you may pass out or become too disoriented to eat. A close friend or relative should be trained to recognize severe low blood sugar and treat it quickly. Dealing with a loved one who is pale, sweaty, acting bizarrely, or is passed out and convulsing can be scary. An injection of glucagon stops these symptoms quickly.",
"    </p>",
"    <p>",
"     Glucagon is a hormone that raises blood glucose levels. Glucagon is available in emergency kits, which can be bought with a prescription in a pharmacy (",
"     <a class=\"graphic graphic_picture graphicRef50427 \" href=\"UTD.htm?20/23/20848\">",
"      picture 1",
"     </a>",
"     ). Directions are included in each kit; a roommate, spouse, or parent should learn how to use the injection before an emergency occurs.",
"    </p>",
"    <p>",
"     It is important that the glucagon kit is easy to locate, is not expired, and that the friend or relative is able to stay calm. You should refill the kit when the expiration date approaches, although using an expired kit is unlikely to cause harm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucagon should be injected in the thigh or abdomen. The injection sites and technique are similar to an insulin injection.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Remove the needle protector and inject the entire content of the syringe (a clear solution) into the glucagon powder. Do not remove the plastic clip on the syringe. Remove the needle from the bottle.",
"      </li>",
"      <li>",
"       Swirl the mixture gently until the powder is dissolved. The solution should be clear. Do not use the solution if it is discolored.",
"      </li>",
"      <li>",
"       Hold the bottle upside down and withdraw the contents into the syringe (1 mg mark on syringe for adults and children over 44 pounds [20 kilograms]). Children under 44 pounds need one-half the dose, and only",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       the solution should be withdrawn (0.5 mg mark on syringe).",
"      </li>",
"      <li>",
"       Choose an injection site in the abdomen or thigh (",
"       <a class=\"graphic graphic_figure graphicRef74461 \" href=\"UTD.htm?27/61/28624\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Insert the needle into the skin (",
"       <a class=\"graphic graphic_picture graphicRef61722 \" href=\"UTD.htm?17/57/18322\">",
"        picture 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Press the plunger to inject the glucagon.",
"      </li>",
"      <li>",
"       Withdraw the needle, and replace the syringe in the storage case (do not attempt to re-cap the needle). Press lightly at the injection site.",
"      </li>",
"      <li>",
"       Turn the person to his or her side. This prevents choking if",
"       <span class=\"nowrap\">",
"        he/she",
"       </span>",
"       vomits.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Symptoms should resolve within 10 to 15 minutes, although nausea and vomiting may follow 60 to 90 minutes later. As soon as the person is awake and able to swallow, offer a fast-acting carbohydrate such as glucose tablets or juice. After the person begins to feel better, he or she should eat a snack with protein, such as crackers and cheese or a peanut butter sandwich.",
"    </p>",
"    <p>",
"     If the patient is not conscious within 10 minutes, another glucagon injection should be given, if a second kit is available. Emergency help should be called immediately.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      LOW BLOOD SUGAR FOLLOW UP CARE",
"     </span>",
"    </p>",
"    <p>",
"     After your blood sugar level normalizes and your symptoms are gone, you can usually resume your normal activities. If you required glucagon, you should call your healthcare provider. You provider can help you to determine how and why you developed severely low blood sugar, and can suggest adjustments to prevent future reactions.",
"    </p>",
"    <p>",
"     In the first 48 to 72 hours after a low blood sugar episode, you may have difficulty recognizing the symptoms of low blood sugar. In addition, your body's ability to counteract low blood sugar levels is decreased. Check your blood sugar level before you eat, exercise, or drive to avoid another low blood sugar episode.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     A family member or friend should take you to the hospital or call for emergency assistance (911 in many US communities) immediately if you:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Remain confused 15 minutes after being treated with glucagon",
"      </li>",
"      <li>",
"       Are unconscious (or nearly unconscious) and glucagon is not available",
"      </li>",
"      <li>",
"       Continue to have low blood sugar despite eating adequate amounts of a fast-acting carbohydrate or receiving glucagon",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Once in a hospital or ambulance, you will be given treatment by IV to raise your blood sugar level immediately. If you require emergency care, you may be observed in the emergency department for a few hours before being released. A friend or relative should drive you home.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H121\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334468\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334505\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22071?source=see_link\">",
"      Diagnostic dilemmas in hypoglycemia: Illustrative cases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=see_link\">",
"      Factitious hypoglycemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=see_link\">",
"      Insulin-induced hypoglycemia test",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"      Insulinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3255?source=see_link\">",
"      Postprandial (reactive) hypoglycemia",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Endocrine Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.endo-society.org/\">",
"      www.endo-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/63/4083/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/63/4083?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4083/abstract/1\">",
"      Cox DJ, Gonder-Frederick L, Julian DM, Clarke W. Long-term follow-up evaluation of blood glucose awareness training. Diabetes Care 1994; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4083/abstract/2\">",
"      Fanelli CG, Paramore DS, Hershey T, et al. Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes 1998; 47:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4083/abstract/3\">",
"      Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 1992; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4083/abstract/4\">",
"      Weinger K, Kinsley BT, Levy CJ, et al. The perception of safe driving ability during hypoglycemia in patients with type 1 diabetes mellitus. Am J Med 1999; 107:246.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_63_4083=[""].join("\n");
var outline_f3_63_4083=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LOW BLOOD SUGAR OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY DO I GET LOW BLOOD SUGAR?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           LOW BLOOD SUGAR SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           LOW BLOOD SUGAR PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           LOW BLOOD SUGAR TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           LOW BLOOD SUGAR FOLLOW UP CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/61/28624\" title=\"figure 1\">",
"           Glucagon injection sites PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/23/20848\" title=\"picture 1\">",
"           Glucagon kit PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/57/18322\" title=\"picture 2\">",
"           Glucagon injection PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4084="Spiramycin: Patient drug information";
var content_f3_63_4084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Spiramycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     see \"Spiramycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4004351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rovamycine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702954",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to spiramycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12005 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4084=[""].join("\n");
var outline_f3_63_4084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4004351\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021978\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021980\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021979\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021984\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021985\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021987\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021982\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021983\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021988\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021989\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=related_link\">",
"      Spiramycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4085="Trimethobenzamide: Drug information";
var content_f3_63_4085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethobenzamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/2/29732?source=see_link\">",
"    see \"Trimethobenzamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=see_link\">",
"    see \"Trimethobenzamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nausea, vomiting:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 300 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 200 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV):",
"     </b>",
"     I.M.: 200 mg, followed 1 hour later by a second 200 mg dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F231414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=see_link\">",
"      see \"Trimethobenzamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nausea, vomiting:",
"     </b>",
"     Children &gt;40 kg: Oral: Refer to adult dosing. (Injection is contraindicated in children.)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Consider dosage reduction or increasing dosing interval in elderly patients with renal impairment (specific adjustment guidelines are not provided in the manufacturer&rsquo;s labeling).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6200347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;70 mL/minute: Consider dosage reduction or increasing dosing interval (specific adjustment guidelines are not provided in the manufacturer&rsquo;s labeling)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 100 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 100 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tigan&reg;: 100 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F231383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Administer I.M. only; not for I.V. administration. Inject deep into upper outer quadrant of gluteal muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Administer capsule orally without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6839846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Glycopyrrolate, hydromorphone, midazolam, nalbuphine, pentazocine.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of postoperative nausea and vomiting; treatment of nausea associated with gastroenteritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tigan&reg; may be confused with Tiazac&reg;, Ticlid",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trimethobenzamide may be confused with metoclopramide, trimethoprim",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, depression, disorientation, dizziness, drowsiness, EPS, headache, Parkinson-like symptoms, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic-type skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Blood dyscrasias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site burning, pain, redness, stinging, or swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, opisthotonos",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethobenzamide or any component of the formulation; injection contraindicated in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: The risk of CNS adverse effects (eg, coma, EPS, seizure) may be increased in patients with acute febrile illness, dehydration, electrolyte imbalance, encephalitis, and gastroenteritis; use with caution. May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS) which may be confused with CNS symptoms of primary disease responsible for emesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Allergic-type skin reactions have been reported with use; discontinue with signs of sensitization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Trimethobenzamide clearance is predominantly renal; consider dosage reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to the risk of EPS adverse effects combined with lower efficacy, as compared to other antiemetics (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use capsule formulation with caution in children; antiemetics are not recommended for uncomplicated vomiting in children, limit antiemetic use to prolonged vomiting of known etiology. Use of injection is contraindicated in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6200344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F231398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Concomitant use should be avoided (sedative effects may be additive).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1628164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Safety and efficacy have not been established in pregnant patients. Trimethobenzamide has been used to treat nausea and vomiting of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F231408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tigan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $247.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Trimethobenzamide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $163.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tigan Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (2 mL): $16.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trimethobenzamide HCl Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (2 mL): $2.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6839849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (at baseline)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ametik (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts centrally to inhibit the medullary chemoreceptor trigger  zone by blocking emetic impulses to the vomiting center",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antiemetic: Oral: 10-40 minutes; I.M.: 15-35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via oxidation, forms metabolite trimethobenzamide N-oxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 60% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: ~45 minutes; I.M.: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% to 50%, as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG (American College of Obstetricians and Gynecologists) Practice Bulletin: \"Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/63/4085/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/63/4085/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg CM and Clahsen J, &ldquo;Evaluation of Trimethobenzamide Hydrochloride (Tigan&reg;) Suppositories for Treatment of Nausea and Vomiting in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 96(4):767-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/63/4085/abstract-text/7359291/pubmed\" id=\"7359291\" target=\"_blank\">",
"        7359291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10023 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4085=[""].join("\n");
var outline_f3_63_4085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231401\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231419\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231403\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231414\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231404\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6200347\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231368\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231383\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839846\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231382\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231426\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231417\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231386\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231372\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300179\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6200344\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231398\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1628164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231408\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231388\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839849\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038853\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231371\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231385\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/2/29732?source=related_link\">",
"      Trimethobenzamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=related_link\">",
"      Trimethobenzamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4086="Epidermal basement membrane zone";
var content_f3_63_4086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    The epidermal basement membrane zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 513px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIBAgwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiioL+4FnY3FyyllhjaQqOpwCcfpQBPRXEf8ACwrX/nxn/wC+xR/wsK1/58Z/++xWvsKnY29hU7Hb0VxH/CwrX/nxn/77FWPDPjJ9b0u+v5NJuLKKCRljSaRS8iBQdxA+7kkgDJOACcZwOfFVI4SHtK2i/rsJ0ZrodfRXEr8QbQsAbKcAnk7hxWprfiiLSVgd7WSVJgSrIwxRUnGlVhRnpKd7LvbfyD2FTsdFRXEf8LCtf+fGf/vsVrS+J4U0FNUFvI0THGwMMjnFVWkqHKqmnM0l6voDoTXQ6GiuZ0PxbBq9y8EVrJGyru+ZhzVK58e21vcywtZTFo3KEhh2OKmE4zrSw8fjjq1/XqHsKnY7OiuI/wCFhWv/AD4z/wDfYrUt/FMM2iy6kLaRY4zjaWGTTxE1hlF1dLuy9X0D2FRdDo6K4u38fWs08cQspgXYLksOMmruteLodJuUhltZXLIHyrClOcYVo4eXxy1S9A9hU7HT0VzOieLYNWnkiitZI2Rd3zMOaoz+PraGeSJrKYlGKk7h2NEKkalaWHi/fja67X2D2FTsdpRXO3HiiK30aPUJLaTZJjam4Z5rK/4WFa/8+M//AH2KMNUjilKVF3Sdn6oPYVOx29Fc8niaH+xDqUlu8cWOFLDJ5wKyf+FhWv8Az4z/APfYpYepHEuSou/K7P1XQPYVOx29Fcjpvje3v76K2SzlRpCQCWGBxml1Xxrb6dfy2slnK7R4ywYYOQD/AFqude3+rfbtzW8r2v23D2FTsdbRXEf8LCtf+fGf/vsUf8LCtf8Anxn/AO+xW/sKnYfsKnY7eiuI/wCFhWv/AD4z/wDfYrqND1JNW0yG9jjaNZCwCsckYYj+lTKnKHxIidOUPiRfoooqCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK+fPj34du9X+IlpL/ZctzYN4fuLb7QdDn1NI5mY7Qoi+5JzlXP3euKq6/wCIfiLo/hLQbPw9o/iay1G10aBmQwreQySK20o2LaRzIUGSGkiA4xk9QD6NqtqN/aaZZS3mpXVvZ2cIzJPcSCONBnGSxIA/GvGYPE3jseOblLi21y+0phO8UGn2Bto7cJCSEc3NriRi/Csk5BIHGODxus6n8QvFHhPxlpepaX4guNPudHjntIrvTj56z+egMW5LaEM23JKqrAAZDEZoA+oFYMoZSCpGQRyCKWoNPUrY2ysCGEaggjkHAqegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/xD/wAgDU/+vWX/ANANaFZ/iH/kAan/ANesv/oBoA8Rqo+oWqajHYGZTeOpcRLkkKO5x0HucZqnY6x/aOoGPT7dpbGMsst4x2oWHG2P+/z1PAGOpPFWtN0y004TfZItrzOZJZGJZ5G9WY8n+leve+x7Kd9irp+lTLftqGp3TXV3ysSKNkUCnsq9yR1Y5PpgcV6X4K+fQtVj/wA8iuLrsvh+d1rqsfcopH614XEsP+E6bXT/AIb9SZq0Tja7Ob/ia+BUc/NNaHH5f/WrjK6/wDKsq31jJyJF3BT+R/pS4ji4YeOKgvepyT9ddvRu1/Qc9rnIV2elf6V4BvoTz5JJH4HdXI3cJt7mWFusbFfyNdZ4GPnabqtqf4kzj6gj+lLP6sfqccVHaMoyX5L8wnsUPAcmzxAi/wB9Cv6g/wBKzvESeXrd4v8A00J/PmpfCsvk+ILNunzEfmDUnjKLyvEV16Nhh+Q/wpRXJnj7Sp3+fMl+SD7Ri12Ef7v4eOe7v/7PiuPrsLr5fh7APV//AGbNVn+rw0f+nsP1/wAwl0OVsTi9tz6SKf1roviAP+JlbH1hFc1AcTxn0YfzrqfiCP8ASrJvWI/0qcdpnGFfdT/IHuiHwA3/ABOJF/vRH+YrG1WMnWrqMdWnYD8WrS8DNjX4x/eQj+VLcQ7/ABt5Z6faFJ/Q1zSq/Vs2xFT/AKd833WD7Ro+O3EFpYWMfCqu4j6DA/nXI28TT3EUSfedgo/E1v8AjyTfrzL2RAv6k1B4Nt/tGvwAjIjBc/y/rV5W/wCz8l9qt0pS9W72/RBHSNzT8bzLbW1jpkPCIgYj9B/WuRrX8Wz+f4gu2zkKwUe2B/8ArrIr0Mhwyw+AprdyXM33vr+Vl8hxVkavhX/kYLP/AHj/AOgmpfGX/IyXn1X/ANBFQ+GWZNahkSJ5mRXYRoQGchTwMkDJ9yB71h+KPEyNrt295pOtWZJGVezaUr8o6+VvH61y3/4Xn2VJf+lsTaUtSxRWIvirQy4WTU7e3c8Bbk+Sc+mHxWpbXdtdrutbiGZfWNww/SvoVJPYaaexPXrvw/8A+RTsvrJ/6MavIq9d+H//ACKdl9ZP/RjVy4vZHLi9kdDRRRXCcAUUUUAFFFFABRRRQAUUUUAFFFFABXOfEfXLnwz4E13WrBIZLqwtHniSYEoWUcbgCDj6EV0dZXirQrbxN4b1HRL95o7W+haCV4SA4Vuu0kEZ+oNAHM6P8TvDs/hxdQv9RRJYEt47zybeVkW5lQHyY8Kd75P3FLMO9Raj8YvAmm2dvdX+ui3inlmgUSWk4cSQ7fMRk2bkZd6/KwB54zWc3wQ8LHQrrRll1FdLmlhuUtd8bRwXEabPORShG5hncDlTk/LWloXwr0XRtY0PUre4uTcaRLcywLHb2ttG5niWN96QQxg4CDBwD6kgAAA07/4g6BY6mdNuZb+HUGWZoIptNuYxcmJSziJ2j2yHA42Fs5GM5Fc34Q+Lln4h0jwxfS2a6cdYe4Robg3GUMSsx8phBsmGFyTuUDoCSCKktPgz4dtvFyeIvtepy3yXkt6BK0TZaRSrK0nl+ayYPCs5xjjvmbSfhHo+m2mhWsep6xNa6JJcPYxSvDiITIyuhIjBYfMSMknPcjigC/p3xV8F6gm+DWlSP7G1+r3FtNArwKdrOrSIobBBGBk5HSpI/if4QfT768fVjBFZCMzpc2s0EoEgzGVidA7bu21TntWIPgp4XbTtNsLiXUri1sdNm0tEkmQb4pH3lmKoDvDdCMDjoakl+Dmg3UN6dSv9YvtQuRbhdQmmjWe38j/VeXsjVBj3U575oA2p/iT4XtZXiv766sJUs5b8pfafc2zGGM4dgJI1JI/uj5j2BrI0T4taRqPifxLp1xBPY6do9vb3Q1GeKZEkjki8wlw0Y8rHAG45fPy1Q+InwsuPF9x4US81Nr+HTb15r27viiXEtuQMwKsMSoQxUZzjA9a3dW+GWi6prPiK+up7/wArxBbRW2o2aughlEa7Y3Hyb1ZR02sBnqDQBs+FvGGieKZLuLRbuSWe0EbTwzW0tvIgkXcjFJFVtrDkHGDXQVx/gD4f6X4IFwNLlaXzo0jJeztIWwucZaCGNnPPVy3889hQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVj/8ACRae3iNdDt3e51BUMk6wpvW2XGR5rdELdgeT1xjJoA1mkRXRWdVZzhQTgscZ49eK426j8Q30OrX+rOmm6bFbTpb6ZEVkeT5SPMnk5Ge4ROB3Zug09H8LQWmsTaxqNzLqesOWWO5nwBbxk/6uFBwi4xkj5m7k8Y0fEP8AyANT/wCvWX/0A0AeIDpS0UV7J7QV13w6fFzfp3aEH8s/41yNdP8AD1sa3Ip/ihb+YryM+jz4CpH0/NEz+FnN3C7J5F/usR+taXhW6+ya7avnCs2w/j/9fFVNVXZql2vpM4/U1WRijq6nDKcg+9dEqaxuC5P54/mtyt0bnjS2+z6/MR92UBx/L+lX/h0//Eyuo/70JP5f/rp/jZRdadpuoIOHXafxGR/Kqvw/JGutjvC38xXz1Or9ZyK0lrGyt/hkrfhYzesDJgP2XXk7CO5wfwatj4gR41eKXtJEPz5/xrE1j5dYvCOomc/qa6PxyBNY6ZdDoykfmAf6VtOo1jsFW/ni0/8AwG6/FlPdHIV19583gC3I6Bhn865Cuvk4+HaZ/v8A/s9dOf8AxYVr/n7H9Ql0OVtEMl3Cg6s6r+ZrpfiC4+3WkfdYsn8f/wBVZXhaD7Rrtqp6Bt35Dj9cVN4zuDP4guP7seIx9AP8SaVf99nVKC/5dwcv/Arx/wAgfxCeDTjxDbf8C/kavTEDx8x7ed/7LWV4cs0v9US2ledI5FZWaCZonAx2dSGU+4INZmqeFdIh8Wusq308azrn7TqNxMSOOpeQk/jXLjoe0zGvBPV0GvvbE782hueNht8RXOemAf0o8E6vpVleXc17qdjbhIhzLcInU+59qyfG/gjw5bapGV0PT2V48/vYRJk5OT82eenNbXw+0LR7e21GddKsF2BSCLdBgjPI4rDE1ovh9OO1orz0kl+hLb5DjNS8XaA+oXLf23prM0jNtS5Rjyc9Ac1W/wCEp0k/6ueeb/rjayyf+gqa2lVUXaihV9AMCnV9dSp+zhGC2SS+4u0g8HeJIBraPDpmt3G1SQE02ZT/AOPquPxqn4g8Q3VzrN3JB4d1lsueG8iM8cc7pRXc/D6IfaLy4bjYgUfjn/AVy95L593PL/z0dm/M5rwMK1VzmvJbwiot+tmv1Ek3Lc51tQ1eUFV0AgHgie7jAP8A3zu4rLutEuL1t03hfw2GzkO85Zx+UIx+BrsaK+icb7sbjfdnEf8ACLap/wAut3b6ee3kXF0yg/7vmqp/KvWPhl4W8YW+k2VxJ49llsd7k2R0uIjAcgjexL849e9c9Xrvw/8A+RTsvrJ/6MauTExUUrHJioqKVjxb4oaDr1x8VtV1BdGv9R8KeXp39p2tvA5a+iVnykZAPmBWKsyDkgdhmtS78QfEhfF2rRW8U9ppkL3K2dt/ZszxywCEmBkZbVlWTdgkPMBn5dg4z2HiL4mWfhvxJrVlqUdzcQ2RsUSK2tFDh7ksq/vGmw4yv91Nvq3bIj+L02o+NvDelaRot0LO8uL+z1FLkRLPBNbBdwUibZhd25j82VI25ORXGcRheJdb+IunfD3w9c2J8S3PiG9snubllsYSkMwjQ+S8SWjuPmDbQdnLMC/3QOev9P8AFUd947vpNO1W41DVV0a7htpNGW4tpiPJE3DQsA8WWUKSCBliGK7h3sf7QPg+Wy1K6ij1CSOyt1u8R+Q7TRmdYcqolypDOp2ybG2nOK1dW+L2l6Rq9zpupaHrsFxayW0dxlbdliNwSIslZjnOO2cZGe+ADC0XWfiB/wAJxD9tGqSaRJ4kv7BoJNORYksVjBglDiMNjcSA5bDYxzXs1eWaj8cPDGnaRBeXVvqEc0k91btZyGCOWN7fHmglpRGeowFcls4UE8Vk+Jfi4up6h4Xg8GNei1n1zTba9vWhi8l4rhC/kDcS+8qVJKrgYI3A8EA9poryRvjTpOk+GLbVtcSeaGWaeIywJb25HlzNFxA9y0jYxnKbsgE4XoIrL4yJZ3Pih/Eunvb6fp+rLptjNEYk85mUFVdnmADEbm3HagUckHigD2CisDwN4r03xp4dg1nRjJ9lld4ysu3cjKxUg7SVPTqCQRgg1v0AFFFBOBk8CgArCv8AxboNg7Jcapb71OGSMmRgfouTXnXizxFd+KdSaw0yV49LQlfkOPP/ANpv9n0H4n2ow6dpum4WdfNlH8K9BXRGhde8dMMPde8d8/xH0IEiMXsvuluRn88VE3xJ0z+DT9Vf6RIP5vXGC/iQ/uLRFHuKf/aU2PlijH/Aa0+rrsa/V12Opf4lWw+5o+on/e2D/wBmNVpPigi9NFuf+BSqP6Vzj3lw/G1R+FVZkmmHzY/KqVCPVDWHh1R05+KoB/5Asn/gQP8A4mlX4qp/Fo0o+lwD/wCy1xh0/PUUh0/2qvq8Cvq9PsdynxUtP+WmlXY/3XQ/1FWE+KWkH/WWGpof9yMj/wBDrztrEDtUT2YHaj6tAPq1M9UtviV4elcLJJdW+e8kBI/8dzXUabqdjqkJl067huYwcExuGwfQ+lfPMtqKbp13eaNfpeadMYZ07jow9GHce1Zywyt7pEsKre6z6UorB8G+I4fEulfaEXyriM7J4s52Njt6g9j/AIVvVyNNOzOJpp2YUUUUhBRRRQAUUUUAFFFFABRVa4v7S3vLW0nuoY7q6LCCFnAeXaNzbR1OAMnHSsTS9L1q41xtU17UPLjiLraabZOwgRTkb5WIBlcjsQFXsCRuoANL1rU9Y1xhY6cbbQrdnjlu7xGjluXGRiGM4IQHq7dcfKCDurY0vS7HSYJIdNtIbaOSRpnESgb3Y5Zj6kk9TVyigArP8Q/8gDU/+vWX/wBANaFZ/iH/AJAGp/8AXrL/AOgGgDxGiiivZPaQVt+DJvJ8RWuTgOSv6ViVNYzm2vYJx/yzcN+Rrkx9F18NUpx3advW2n4iaurGh4rhMGv3akYy24fiKya634hW/wDpdteJykqbSR69f6n8q5KuXJK6rYCk072Vv/AdPxtcIu6TOzt1/tHwI8a/NJb5P0wc/wAqp/D0f8TuRvSBv5ineA7xUu57KU/JcL8ufUf/AFv5Vd8IWLWPiK/hccRoQD6g8ivma8/qSxmDk92px9JSV/ktF95EtFJHJ6qd2qXh9Zn/APQjXT3ym88CW0nUwEfodtcpeNvvJ29ZGP611fgyVbzTL7S5TyVLL9CMH/PvXoZ1CVHB4fERX8Jwb9O3zdipbXOOrr9V/ceBbJDx5jL+o3VyrW8i3Rtyv70P5ePfOK6rxwwgsdNsl6IpY/gABW+azjXxmDoxd7ycv/AUn+VwlujM8FMF8Q2+e4I/SqviVduu3gP9/P6Unh2byNcspP8ApoF/Pj+tXfG8Pla9I2OJFDD+X9Kb/d56m9pU/wAVL/JB9ok8BR7td3Y4SMn9RWdr0u/XbyQdRKR+XH9K3fASCNL+5Y4CKFz+ef6Vyk8hmnkkPV2LH8TU4P8AfZziZdIRjH77P9GC+JnXeO1E1lp12vQgjP1Gf6UaR/oPgi+nPDT5AP1+WnXqtf8Age0ZAWdGRAPfO2m+MGFjoun6bGe25vfA/wATXz2Ck6lCjlfVVZJ+kdZf+lP7ieyOOooq1pVob7UYLcfxtz9Op/Sv0GvWhQpyq1HZRTb9EaHUWA/sjwbPO/yzXX3fXngfpzXG11Pjy6U3FvYxcJAuSB0yen+feuWrw+HaUpUJ4yp8VVuXoui9N2vJkx2uFFFFfQlBXrnw+/5FS0/3pP8A0Nq8jr1z4ff8ipaf70n/AKG1cmL2RyYv4Uch4oj8F3vjfVbDUtC1O/1FYLS91C4tEmkWMRu32cFI33sd2TiNGGDluBxZ8MaD4M1vW9Uk03Sry2v9C1u4kef7VLGTdyqjSupWTJRxtBU4U4I2468/8QvhHeeI9Y8aahYJo0c+s2Npb2sswIeOSOQNIzEISAyqoyMk4APSqvi34TeINWXxAlvLoMkGqatPehbmNWdI5IEjUrI8EnluGXJCrkjo6nmuE4Dv3+GXhV9JutKaxuzpNyu17D+0roW6jzFk+SLzNifOoOVA7joSDb1fwD4a1jUb2+1HTfOurx7eSd/PlXe0BJiOAwA25PTr3zXkLfBHxDMFmu7vR5r9IdIjS4eWRnU2ylZ8MY8jcOB6jrik1L4H69cWUNoL3T5NNgvdQki01ZxFFFDOwMZjZ7eURuoyOI8jPysKAPWm+HXhjavlWE0Ei3U96k1vezwzJNNjzWWRHDqGwMqCBx0rI8P+FPAnieSHxBpUNxeGC9jkE73d0A1za/u1kdHcB3XBG9gS3OSc1xqfB3WRryaq1xpr3S6vpd6s807yzi3ggEc6GTyl3M5HoFbqdvQZ0vwS1eDw8NMsLLw6txb391dW12bgeXIshPl+fbPaSJJsU4Ck/Lj5WGaAPTbz4T+C7u0W2m0dxCEliYR3lxGXSSTzXRyrgupf5trZAPTFXLr4c+Frm4vppdOkEl7LHPNsu50HmxgBJVCuAkgCj51w3Xnk10ej20llpNlazNE0sECRO0MYjQlVAJVBwo44HYcVboAp6RpsGlWS2tq93JEpJDXV1LcycnPLyszH8TxVyiigArmPiPfvYeErwwttln226nuNxw2Pfburp688+McxFhpUAPD3DOR/uoR/7NV0leaRpSXNNI5bQ4UstIkuuA7fKlVUQyMWbknmnRzh9PhhU/dOSKtWqDivSWl2ektLsSO3qdYBVlFGKwfFOtHTI1htsG6kGQT/AAD1/wAKm5N2zTuJLa0TfczRxL23sBn6VmTeJdKjOFeST3SM/wBcVzem6XdatN5s7O5bq7HNdRa+HLKIfviCfepcrCckiKLxLpMjYZ5Ivd4z/TNbFv5F1EJLeRJUPdTmsjUPDtlIhMLKDiuVuIbvRbrzLWZkIPVTwfqO9ClcE77HoElsPSqk8HHSk8P65Fq1udwCXKD50/qPar8qg1SZSbMCePGazblRzW/dR9axrpetaXuaJ3Nb4aas2leLIIS2Le9/0eQf7X8B+ueP+BGvda+Ynle2mjnj4kiYSL9VOR/KvpuNxJGrryrAEfQ1w4mNmmcGKjaSY6iiiuY5QooooAKKKKACsC38T2t94jbSNLhnvjAWW8uoQPItGAyEZycFycDYuSM5OKh0271/VNeMzWo0vQrZnQJcKGub1hld2AcRRg8jOWbA4UdegtreG1i8q2hjhjyW2RqFGSck4Hckk/jQBk6L4asdK1G81EGa71S7J829umDy7M5EanACoOyqAO5ycmtuiigAooooAKz/ABD/AMgDU/8Ar1l/9ANaFZ/iH/kAan/16y/+gGgDxGiijBPQGvXlOMFeTse3FN6IKKkWCRuimpFtJT2Fcssww0N6i+80VCo/snXW5/t3wc0I+a6teg7nHT8xxXE1veGbmXStSV3BMEnyyDtj1q/4n0AC5N5ZZa3m+YheimvmMFmeHy3FVKDl+7m+aLts3uvyS7adWT7CcJKEla+xy1rO9tcxTRnDxsGFekWd3FLNc38YG02qsW/76OK4aPS3Y8hq67TtP+y+HxatkNdSANk4wpIz+gryuK8VhcSqdWm2pJ2em8d/wdreoVqDgve6nnxOSSepq7ot82m6lDcr0U4Yeq9609S8PSWtyyKC0ZOVPtUVtoM9xMsaJyTyfSvoavEGBxGHfNGXI1rotvv3/U2WG5o83Mrf15HTrp1pN4ifUFYGGOMSN/d3Y45+nP5GuO8QakdT1KSb/lmPlQf7IruZLa3SGHSUO2Ar+9YE5PHAzXJaj4duLS4ZAC8eflb1FfLcO5lRo1+fFc0pJcsNF8Ovn/Wtm0Y0aXtHa9vUxInMciOvVSGH4V1/jyITWun38fKsuwn8Mj+RrBGkTd1NdVYwm+8PixmUNNCQyox+8FOQPy4r183zijCvQxsE/cbT06S0/wA7ebKrYeVO0m0UwP7J8EnPyzXZ6f73/wBjXHV13ifzNSkgSNXWKJfukY5Pt/nvWFBo91PcLDEhLMeuOB7mtshzLD0cPPE4mXLOo3J3T0vsttuq9Qjh58vN+p0nhWbzPDN3GOXt38xR9MMP1zXO+I9Q/tHVZZQcxr8ifQd67XTrS20y6gsomBLwssn+0exP5muF1TTpbG9mhZThWO0+o7V52QYrB1c0r4ub5b35b9m3d+v/AAUZwhKT91eZRrrfBlqtrBcatc/KiKRGT+p/z71k6Dok+p3K7lZLZTl3P8hWj4t1WMoumWGBbxcOV6EjsK9jN8cswqRyzCSvzfHJP4Y/5v8A4D3FKMr8tjnb65e8vJriT70jFvp7VDRRX1NKnGlBU4KySsvRAFFFFWAV658Pv+RUtP8Aek/9DavI69c+H3/IqWn+9J/6G1cmL2RyYv4UdFRRRXCcAUUUUAFFFFABRRRQAUUUUAFeafGVv3miL6mY/ls/xr0uvL/jKc3+iL6JOf1jrWh8aNsP/ERyVn0Fa9ueKyLQcCta2GQK9GR6MiyWwK83uZjqmtyyk5Vnwv8AujgV6LdqfskxX72w4/KvMdFcLexk+tZkI9FjePTNNQDG4iufudSlkckMRmk1m+81ljU8AVlsxqYrqKMerLZvZv75qnfzPOvznOKUGmSAHOaoqxQ068bTtSiuE6KcMPVe4r1CNxJGrqcqwyD6ivJbzh+K9F8LzGbQbRm6hdn5Ej+lAMuXQGDWJeL1rduBkGse8XrVoqJhXi/I/wBDX0lpBzpNkT1MCf8AoIr5xvB+7b6GvozRP+QLYf8AXvH/AOgiuXFdDlxfQu0UUVyHEFFFc3ZeJn1XxA1joli91YWsjxXuou/lwxuuR5cfBMrhhhsYVectn5aANS41rTrfWbTSZbpP7SulaSK3UFn2KMlyAPlXtubAzgZyQKy9P8PXLa82s67qL3t1E7iyt4gYre1jOV4TJ3yFTgu2epChRwdHR9C07SJr2ext9txeyma4nd2kklYk4y7EkgZwFzhRwABWnQAUUUUAFFFFABRRRQAV5/qmtar4mt9V/wCEfMFp4fs1ljl1CWPzHvmQEOkC5ACAgqZDnJztHG6ul8c38mleCvEGoQyGKS00+4nVx/CUjZgfwxUA06LR/h6dOt4vKitNMMKp6BYsfnxQBxMOj4Awqj8KnTR1zlq2R0or5ea53eTu/M+oVeSVloUE02NanSziUfdFWqKFFIh1JPdlf7LF/dFXrOfyEMbLviP8NQ0VlWw9OtHlmiJLnVpHO23jHTX1Fw+nTR2SymMXHmA4OcZZccD8TXTXMxnkDEYA4A9K8yvrRNP8TXmnzri0vsyxHsN3Ufg2fwxXWeE757nTzbXB/wBKtD5T56kfwt+I/UGojgaUZKrq2tNXex87leOqzxE8PiXeSvb5dPu1R06XCPGEuF3AdCKDcRxKVt0257mqtFcrymg5X1tva+n9fPyPf9mhDycnr61ajuQyeXcDcvr6VWorpxGDpYiKjJWts1uvQcoqW5a+zW7HIlAX0xTJ2gR4jbgh4zkP0+oqCiuT+y/aWWIm5pbL/PX/ACFyd3ctu1tcfNICr98d6r6jqdlpGnXN037uGCNpJJCOgAyaZXN/ES1+2eCNZhEqRH7OXDOcDK4bBPvjH410YPJaNWvTo1Zy5HJK19tTKrHkptrWy2PP7j4leIbu5a80nS7GO1U7lFzveVh7lSAPpg/jXongjxjp3jfTpZriwMF9auI7iFju2kjIIPcHn06Gvn+y8VR2unNA4CtjBBr0X4BWF39m1nWLiJ4re+eNINwxvCbssPbLYz7Gv07i7hHK6OXurGn7OcGlFp6vW1tb30u+69Lnz+WY+viMQoyd1r8j166mZ7cwWwEEZGPl4OKwJNFTtW5Ta/NKGCo0I8sEfV0pulpE52TReOAKpT6Q652iuwppQHqBXXCdSn/Dk16M09vf4kmcE9nMp5U0xoJF6iu8a3jbqoqvNp8Tj7orsp5pjKf2r+qB+wlvG3ocOQR1Fet/D7/kVLT/AHpP/Q2rjJ9IUZKV23gZfL8OQp/dklH/AJEavSoZjLF+7ONmjzMxpRhGLg7m/RRRXQeSFFFFABRRRQAUUUUAFFFFABXlnxgOdY0kekMp/Nl/wr1OvKPi83/FQaaPS2b/ANC/+tW1D40b4f8AiI521A2itO27Vk2zcCtO2bpXoSPQkaPVa8o1W2fS9WmhwQFbKH1U9K9WUjFc74t0f+0oVkhwLmIHbn+IelZkI4oXBdtxPNTpPnrWU4eGRkdSrKcEHqKcs/rQUapmFQTz8cGqfn1E8maACVtxzXo3hOMx6HahhyQW/Mk1wOmWb6hex28f8R5PoO5r1O2iWGJEQYVQFA9AKYmEw4rIvR1rZl6Vk3g4NOI4mBffcf6GvorRP+QLp/8A17x/+givnXUB8j/Q19F6N/yB7H/rhH/6CK58V0ObF9C5TXkRGRXdVZztQE4LHBOB6nAJ/CsmbxHp8fiKHQ4nkuNSdd8kUCFxbJgkPKRwgOMDPJJ4BAJFbT/C1vFr0ut6ncS6nqe5xbSTgbbOM9EhQcLxwW+83OTjAHGcQyyi8Q3/AIga7v5E0zSLV3SCyiKySXfVRJM+CFXHKovPQs38I6QAAYAAHXiiigAooooAKKKKACiiigAooooA5X4sf8ks8Zf9gW9/9EPWz4j/AORe1T/r1l/9ANYvxX5+GXiqMcebplxDn03xlc/hnNbXiP8A5F7VP+vWX/0A0AcwOn4U6mjp+FOr5g+iQUUUUAFFFFAHN+OdLa/0nz7dc3lmfNjx1I/iX8R+oFYmlaki3VlqyHEMo8i6x0GejH6HB/Ou+I4rzG/gtvD2rX1hfTxW2l3SmWKSVwqICehJ4GDx+VXDX3e58vndCVCtDGUt7pP1W337P5Hp1LWH4UvXuLBra4z9ptD5T5/iH8J/Lj8DW5UbH0WHrxxFKNWGzCmk+9VdUlkhtN0DBZDJGgJGcbnVTx+NZl3YzNemS5s01EGNVViFTbgtkcn3ruwmDhXadSooJ338rei69zDFYqVG6pwcnp+N/V9Oxu5HqPzoyPUfnXPizA+74ei/7+L/APFU1rIk8eH7fHu6/wCNej/ZGF/6CV/5L/8AJHB/amI/6B3/AOTf/InRFlAJLAAe9eLfEfxY2s3iabpebiAv5dvFGc/aZP75/wBkdu3GfTE/xB8U6Tb2V7pUVnFFqCEI3kk5BOMruU46ZBHvitTwP4FNhYRatd2qjVJghNs53eXHuB25J4bA5x9PWvo8vyzC5Io4/FTvKWkE1Za/a3eluuy73aZxVsfiMepUadNpL4v8tUvyZreC/A+i6Ho8ceoQ2F/qMh8yeeZFf5z2XPRR0H5967RZYEUKskYAGAAQMVQdWIH/ABJoD/wIf41HskBz/Ytv+a//ABVeJisPTxlR1a+Ku3rq1/8AJaHXTxlajFRhh2kvX/I1PPiH/LWP/voU8EEAg5B5BFZiGUKcaRCp+q//ABVLZ2N0lrArX08ZVFBjCxkLx0Hy9PxrzMTgaFKKcKyf9eVzsw+MrVW1Ok1/XnY1KKKK8s9IKbTqKAGkA1veERjRR/13m/8ARjVh1u+Ef+QMP+u83/oxq9HLvikcOP8AhRs0UUV6x5YUUUUAFFFFABRRRQAUUUUAFeR/F0/8VNYj0tM/+PtXrleP/F1v+KttB/05L/6G9bYf40b4b+Ic/bngVo27dKzID8oq5C2K9FnpM1Ufilfmq8b5qUNWdjMyNX0O11E7pFKS/wDPROD+PrXK3nhW9iY+Q0cy9sHafyP+NegE0xgKLAebr4e1MnH2Y/8Afa/41oWXhK6kINzLHEvovzH/AArtgBmpVwKLDKOk6TbabGVt1O4/eduWNaOcUxmqNmosIfI3FZ10cg1Yd+KzL+9t4ZYYpp445Z2KxIzAGQgZIA78DNUhoy9S/wBW/wBDXs3h7WtU1S9tINO00waLap5d1e3qtG0zhcbIE4JAbGZGwvGFDZyPAru1v5r6S6v7kJDEWEFrbsdpGCN0h4LHH8PQe55r6j0z/kG2n/XJP5CuXEvY5cU72GabpljpguBp9pDbfaJnuJjGgBkkY5Z2Pcn1PsKuUUVyHGFFFFABRRRQAUUUUAFFFFABRRRQBynxWOPhx4iz3s3H44ra8R/8i9qn/XrL/wCgGsb4pf8AIian/wBsv/RqVs+I/wDkXtU/69Zf/QDQBzA6fhXnPiP4lS6L4g1iyOjxzWOlSWcdxOLzbK32n7uyLyyGwc5G4cc/T0YdPwrm4fBWir4uvvEk9ql1qd15O1riNHFuY12gxEruUkdTnsOlfOU3BN86ue9NSaXKYPh/4k2R0ie68SzRW04vLuGOO1t5ZT5UDkGRlUMQAMFmOFHtWtqvj7RbS21JrKSbUbiytTculrbyyRgeWZFDSojIm4Due/Ssm6+Enh65WAtJdedDPcTrLIkE3+ubcylJYmQgHplcj1rRtPh/p9k98tlf39taX8IhvLSJYFhnxF5eceXlDt7IVHt2rR+xbuiF7VaGfp/xR0mSxtb7VNunWsmlx6lKJEnMse+RY8BfJAdNzgBw3PULj5q63Rdf03WobuTTrguLSZoLhZYniaJ1AJDK4BHBB6Vx9z8JdHu9NFld6nq80a6cmlIzPCGWBJklUDEYGQUAyQeM9+a6vQvDtpo17rNzbPPI+q3Jup1lIKq20LhcAcYHfNTP2Vvd3HD2l/eM5vE9xq7mHwfZrfLnDalOSlmnrtYfNKfZPl9WFZHiTwY0unnVtQvJ9W1uzImjklG2KMD7wiiHypx35Y4GWNegqoRQqgKoGAAOAKU8jBqOe3w6EYjDrEUpU5vdHB6PqYSa01QEeTNiC59B6N+B/TNd7XnE1ouka7eaXKoFhejzIc9Bnt+B4+mK63wtdtPpv2edibm1PkyZ6kD7p/EY/HNEtVzHhZHXnSnPB1d1f71v9+6+ZLqZmuJjaw7FCKlwWYE52vnHX/Z/Wrmnztc2kcrgBmByB064qlcuU1icj/nyP82qbQiTpNuT1IJ/U16+KoQhl9KaWrf53/yR34atOWOqQb0S/wAv82aFcH8UPGkXh2x+yW9ykN/MuWlbpbRk43n3J4X357VteNPEsHhrSzK2Jb2XK20GeXb1Poo6k/1IryfwToE/jfXpb3Ui9xo8Um+6nfj7ZN/cH+wO46Acd+OzJMspunLMcbpShtf7T6LzV/v2721xuJlzLD0Pjf4LuaXwi8HJf3C+JNUiY26tusI5DkyHvM3rz0/P0r2iuVk8JiwlM/hW9fRpCcm2VPMs5PrCSAv1QofXNIPFFxpb+V4s05tPQdNQtyZrNvdnwGi/4GAo/vGvPzbMq2a4h16j8kuy7I2wmHhhKfs0vV9zq6K4nxb8RNN8M6rPY3VhqVy1vZLqE0tssRSOFpPLBO6RSTu7KD1pmofEnS7HXLzTprDU/Ls7i2tri8EcfkxvOoaPI378HODhODXmqlN6pHS6kV1O5orkv+E3tV1qbS7jStWgvBbS3VujwoTdpGcHy1Vy2T2DhSc1Uf4jadE13Bc6bqkGpW93BY/YHWIyySzKWjVWWQx8gE8uMY5xS9nLsHtI9zuKKx/Cuv2fibRo9S08SrEzNG0cyhXjdWKsrAEjIIPQke9bFS007MpNNXQUUUUhhW74R/5Aw/67zf8Aoxqwq3fCP/IGH/Xeb/0Y1ejl3xSODH/CjZooor1jzAooooAKKKKACiiigAooooAK8a+MDY8Y2w/6cU/9GSV7LXivxlOPGNt/14x/+jJK2w/xm+G+Mwbd/lFW43rJt5OBVuOSvRPSNWN6sK+etZcctWEmpNCaNAMKQ81WSWpBIPWlYmxJinCoTIKb5tAE5NRuwxUTS1gfbdUvNVISFbPTYHZWaYbpLkjI+UA/InfJ5PoByQCWTXoJNX/s6zSS6ljJ+0PFjy7fjIDt03Hj5Rk85IAqnFpltbX9xfEyT3kxOZpm3Mi5yEXsqj0H1OTzV/8AdxBhEiIGYsQoAySck/Umqs0nWnbuUl3KmoNmN/oa+ltP/wCPC2/65r/IV8w3r5Rvoa+oLVdtrCvogH6VyYroceL6EtFFFchxhRRRQAUUUUAFFFFABRRRQAUUUUAcr8Uv+RE1P/tl/wCjUrZ8R/8AIvap/wBesv8A6AaxfimQPAmpZIGTCo9yZkAH51teI/8AkXtU/wCvWX/0A0AcwOn4U6mjp+FOr5g+iQUUUUAFFFFABRRRQBzPjvS2vtKF1bj/AEqzJlTHUr/Ev5DP4Vj6Nqax3Njqat+4uQLa59m/hb8/0Jrva81mtU0rX73SJV22V2PMg9gfT6HIq4fyvqfL51Rlhq8MbS7pP16fetGdjfHGrzf9eR/ma831v4kXdjPHovhu2hmuYFxcTzgsqsedqgEZODyfwxXUjVSdk17uEot2tZCFJzICfT1BB/GvE/EC3PhzxFeXbxS/Zbp/MSUoQAx6qfQ5zj2r9G4ewWExtGlTxNnZOyb3ev8AVjlq4it7apXw6fK0tbdHYuz3Op+M/GlnYaveR2s96whaUAgRoASUQc4JwfxNfRmlafa6Vp1vY6fCsNrAgSNF6Af49896+dfhvpV/4s8dafqUUMi6dYTC4luCMKWXkID3JOOPTNfS1edxvWhGvSwlFpQhH4Vsn/nb+tT18khJ05VZrWT3fUKTqOaWivhz2zzjx58NP+Eq8Rzar9vsofN04afsuNP+0PDh2bzYn8xdknzYBwcVa074a6bF4m1DV9TuJ9SNw9rLDDM7hY3giCB3AfbKxxuyy8HpXe0Vr7adrXM/ZQvex5zoPgHWNK8Q6xrUniSC81HUEeMXU2nky26HlET97sCBsEjZzjt2gT4Xsr3F0mp2lvfNqNtqcC2mn+VaQywqy/6nzCTvDHcd4JOOmK9Noo9tPe4exgc/4I8OL4X0FNPFy11M0slxNOU2eZJIxZiFycDJ4GTwOproKKKzbcndlpJKyCiiikMK3fCP/IH/AO283/oxqwq3fCP/ACBz/wBd5v8A0Y1ejl3xs4Mf8KNmiiivWPMCiiigAooooAKKKKACiiigArxT41YHiy0Pf7En/ox69rrxP43DHiuzPY2Sj/yI9bUPjN8N8ZyukPEb+3W4XdCzhXGccHjP9a2bSzjQ25mGdks/nc8FY1U4/HkfjWFoKCXVrRXPyCQM3+6OT+gNba3BawbP+se0muDjsXlA/ktcOZVqkKyhTk1dJP5qaT+/8keiRQFDpVxMR+8WaNAfQFXJ/kK0fLiGsyRFB5MKFmXPXamT+ZH61iPJ5Oh26/xXEzSn/dUbV/UvWpNJ/p+pSj+KzWUf8DCf/FUVq03ObjJ2lzpeWsIfg7tDDS2Wa5MbjIMchH1CEj9QKuQrFizWXgGNp5TnnaCcD8l/8erH0qXZHeXJ/wCWUJUf7z/J/Ik/hV538y7WIH/WWC7fqIw2PzU1WNrTdeSjJqKX3NJ3/Cafql2Altyk0Ctg7muFjAB7EHI/lSX/AJcNujR9TNKuc9QNuP5n86bZyCO60iNR8qobk/7TZJ/9kA/CqEs2/Q4mJJKXDjP+8qn/ANlop1pyxMXzPlvtfvzxX4xT+YDjpMOoz2N4zStcRTmKNDIRGCw+8V6Ejnk9Aas3AgktrqS3ViFnjiiJPJBD5/PANLo0m2LT1J5nu3VfwVQP1aodIYJbxSOMiOWWcqe5iQFR+bVjVxVSMqjTfuvTz95tr/ySy9Wuoh2pRwQLqbRqCEuRBFyflHzEn/x0D8TWVqqJClpsBBeAO3PUkn+mKe8pfQZHyWY3YLn0+Q4/P5vyqDVX36dpkx+95bRH32ucH8mA/CunDupTnGMpN+81v2h/wG/V3Ay2UzTJGOrsF/M4r3j4geO7XwVf+HItQjgW01W8NrJdT3IhS1AXdvJIwR2wSPrXifhuE3fibSoAM77qIH6bhn9K9+8S+FLHxDqmg397LcpNo119rtxEyhWfbtw+QcjB7Y+tdmJeqOLFPVI5Tw58YNC1X+2ZLlkht7TVW0uze0dr1tQIGQ8SRIWORzhQ2BzmtOT4reDUs7S6GrPLBdWsl7EYLK4lPkxsVkchUJXaQchgCMHPSsrVfgr4Y1N7+W6kvmuLvVH1fzH8mTypWADKqPGyMhAHyurfWpl+EOg7Ywbm9Upp13pn7iK2t1MVxne2yKFUDjPBCj3BrmOQm1b4r+G4NE1O+02/t5pLCGC5dbtLi3jMMzqqSBhC7Mp3cFFYZxnA5FHx78UrbSNY0fSfD0kN7fya9aaVqAe2maKBJc7gJRhBKOMLuJHOV4OFvvgt4dvNOmspb3VhFLpNro7FZY9wht3V0Yfu/vkoMnpjOAKtXvwl0W51p9QGoatDE+sxa81nHJF5Ju4/4+Yy+Dzld2OeMcUAaCfFDwa11LB/bcaeWs7+bJDKkMgh/wBb5cpUJJt77GNPPxJ8Mrp1lfyXGoRWt9cRWto8ulXaG4kkUsgjVogXBCnBUEdOeRWDpPwV8OaNdzzaRNPaLJ521PsVjMYhIrKwWSW3aTbhiMFyMcEEZFLpfwV8Oac1u0F1qW+HV7fWRt8iJDNCGCL5ccSxqmGOQqqTxzQBt6b8T/CGpXNpBbasVe6E3lNPazQoTCCZVLugUMoGSpIIGDjkU21+KXg64tLq5GsiKC2tReu9xbTQBoC20SpvQeYpYgApkEkDvWZD8HPDapYRyzajPDaXN7ciKWVNspu02Sq+EB24JxggjuTRZfCHRrWEq2p6pdSJpy6TbSXa2032a1DhvKVGhKMDjGXVzg9aANqb4i+HIbO1uJ59RiF27JbRSaVdrNPtQOzJEYt7qFIJYKVHrVa9+Kvgyzggmk1gyRT2R1FHt7SecfZw+wyHYhwAwIOcEYOcVkaX8GNB0lbaTStR1ey1C3uZ7mK9gaBHQzIEkRY/K8lUIA4WMYxxTovgv4YgtEtbWTUbeBdGm0MIkqH9zLIZHfJQnzCzE56c/doA2h8TfCHkX0rawqLZpFJKJLeVGZZf9UY1K5lDdtgbPatjw74o0fxFYXV5pV3vhtJnt7kTRPA8EifeWRJArIR7gVxmp/BXwvqcVxHeyajKJbK0sQWkT92LcYjdRswW9dwKnJ+Wuq8FeELDwjp9xZ6ewkjnk8xz9jtbfnAGNtvFGp6dSCffHFAGJLeN4+1HT4tMil/4Ra0uI72e/kQot9JGwaKOEHlkDhXZ8bTtAUtkkdb4j/5F7VP+vWX/ANANcvYQv4J8Q2mmxEnwtqbmK0Qn/kH3OCwiH/TJwDtH8LDaOGUDqPEf/Ivap/16y/8AoBoA5gdPwp1NHT8KdXzB9EgooooAKKKKACiiigArnfGWhvrFgj2pC39s2+Fjxu9VJ9/5gV0VFBjiMPDE03SqLRnmOm6bq19d3c08LWskSpIUmyuSCRuHFdz4OWIGefWlhZ7pVZDIAAwGcgZpZyRf34H/AD5L/wChtUGjWxezsmuyZrZVB2KOf17fSvo3GnSwdKp1b/M8jK4ujOpg3JuKXz3v+pZTUrJdYuLG2CpCCDGUxsyRyox75/WtKsPxNpkUNj/aVlKTGhCsMcgE4/Q4rQ027+1WNvMylTKmeRwT3wfzrxsTTalzdz6FxjyKUNtvmXKKjlljhiaSZ1jjUZZmOAB7msGLxjolzepa6ddPqMpcIxsIXuEjOcZd0BVQO+SK5lFvYycktzoqK8RsfGfiQeN5lub+4/sdfEk2kfPDb+Rt2ZjjXavneZu/iPy4xk5zU/wl8SeL/Ea6dcTXt3d21zp8z3M95pyx28FwJCsXlFFj8wYHzAMe/IPTZ4eSV20ZKvFu1j2eivEE8a+J5vAeiyRX5n1u+1yWxPkQxRySxI75WLepjVsKOXz9Say1+IniW60C0caylrc22iXepTTC2j/0meKfyxCwZcdBzsxkng4prDSfUX1iPY+g6K4aLVbzXfFHhy0ilkt0t7EarqMcTlQWddkUTY7ZMjbT/cGc13NYyjy7msZc2wUUUVJQVu+Ef+QOf+u83/oxqwq3fCP/ACBz/wBd5v8A0Y1ejl3xv0ODH/CjZooor1jzAooooAKKKKACiiigAooooAK8f+OtqVv9JuwPleN4ifQggj/0I/lXsFct8SNCfXvDM0Nsge8gYTQjuxHVfxBP44rSlLlkmaUZcs02eC6VdCz1C3uGG5I3BYeq9x+Wa6NIhDNbIzB0hdrCVh0MMuTG/wD48x/AVyDho3ZJFZHUlWVhggjqCK9D8N6QbuwgkujyYhG2P4lDblz6kcYPtXDnMVHlqLrp+evyTl82n0PXp03M5XUtw0zTGIxsWSBh6MJCx/RxWlct5Qvy3SKwggP++RHx+jf9812k3h6yliKMmQWL88/Me/1rkfGOmT2dvI6NuieYzSk9WY8DP05x/vGuKlifbVIU5K2r/Gal+jXq0aOhpeLuZVhJv0nUkH3lEcv4BsH/ANCFaNrITqGiue9oWf8A3VMgP6LWDolwY9SjXYZI5QYpEH8SsMH8e49xXead4dEkULzMQyQeRxwCvOfzyfzrfM5+ynKDXxXf3w5LfekyadJzV9kc/YzkP4fc85kaEj1Uv0/8fNU5z5Whlc/eu2C++1Rn/wBCFdrJ4ZhiNtJbn57VxJGp+7kHPT6iuE8SRy2bWlo4IWJG+Y/xsWJJ/LaPwqcHWVbEKKVru/4zkvuuvx7BOi4rmTuiWaZv7H0+4hbBgldGx/C2QwP4/wDstbGVGox4GLeW7CsB0CXMY4/LP5VkeE7OTUTcwMQbZwoce4OQR79R9Ca72HQoVRcjOAmMn+6ML+Q6VjmElCbpLVrm/wDJ7P71eSXy8yoUeZc0nY88tw0Wkan5v3S0cSj1kDZ4+ihvzqDX28mW3sQf+PSIRv8A9dCSz/kTj/gNd5qegIgimhUEwMZEjb7hY9yO/IH5V5fch1nkExJkDHcSe/eu/L6v1qtKctLa282lFfcl/wCTeRFSk4a3ujr/AIR2JvvG9tIRlLVHnb8to/VhX0FXnfwa8PzaXo0+oXkZjnvipRWGGWMdD7ZJJ+mK9ErurS5pHk15c09AooorIxCiiigAooooAKKKKACiiigAooooA5X4p25n+H2uyRj/AEiztjf25zjE0H76M57fMi81ra5Ks/hfUJY87JLORlz6FCaqfEL/AJEHxL/2DLn/ANFNT7448ET/APYPb/0XQBhjp+FOpKWvmD6IKKKKACiiigAooooAKKKKAMq4IGo32f8AnyX/ANDap9F50m0PrGKo6pKkN9dGQlRJarGhx1beePrV7RVK6TaKwIIjHB4r38bb+zqPr+h4mEv9fq+n6jb60LrNty8Uo/exbsbvce/FZ1jaS6xaR6fpWty6fYxAu4t4o3mbLA8NIGC4Of4SeeoxXQ1y2pWFzpl6b7Sw2GbP7sfMhPbHdT6V5mHr2fLI+gUVWg6bdn09RbbwZoxnL6nBJqt5E2GfUpWudrDuqOSqeo2gV0scaRRrHEioijAVRgAfSsHT9UmvfMvbgKk0bCOVVBAZR3we4610NZV4tS30IlS9m7M5QJ4ItvEVxKF8Nw69HvmmfEC3K8ZZ2P3hxnJP41l6v4o0DSdJ0ex0Oy0vUtF1KeSx8uzlj+zoPLZ2G1QVIOCCvH3qhvfhxLc6R4i0YauiaRrN1Jeuv2Um4jmd1fiXzMMoZRwUyRxnvUB+GEk+oDULvWUa+k1E6hOYbPy4mPkmIIqbyV4OSSzZql7PrI5Xz9ESeFb7wJqfhfS0u9M8MaU2sRpdDSZBAC7ElVOwhd5yCAdvrW7N/wAIRdXVvos3/CNzXNgW8mxfyGe3IG5tsfVMAZOAOma5C/8AhHd3eh6RpP8AwlE4srCCKLyTA/ls6Sb/ADAiyhckcfOHx1GKyl+Gup3XilbORLiHw9E+qObqURLKxu49nylJXL+oLInAwQc8Vam22pdybzVk4no9jrHhG3lv9XtNZ0nN5NHFc3IvkZWkVMImS2AdoOFGO5x1Nb9he2uo2kd3p9zBdWsgyk0EgdHGccMODzXmmnfCb7K2nu+rRPNaX9letMIZ2ecWwdVR/MuHAyHwCoULg/KRgDsvAvhv/hFdCOm/avtQNxNOJPL8vHmOW24yemcZzWVRQteLuawc72krHRUUUViahW74R/5A5/67zf8Aoxqwq3fCP/IHP/Xeb/0Y1ejl3xv0ODH/AAo2aKKK9Y8wKKKKACiiigAooooAKKKKACiiigDmPE3gjRvEMpnuoXguiOZ4CFZvrwQfxGawh4U17TSYtOvLae3XhPNi+bHv8yjNeiUVnVpqqkpdP66nRSxM6Wi2POW07xWv/LraP9MD/wBnNVdQ8K+I9bs5be5SxtVbGGaQknn0Ga9QorGGDpxkpdvQ2ePqWskl9/8AmeM2Xwr1m0uo50vdPZozkKS/P/jtbUdr4ngGxtJhOOMiXP8AIV6ZRWmIoRxElKe4qeOqQXK1dHm/k+J24TSIc+82P5iszVfh7rmuGKa6msbRlz+73M5GfUgY7V63RU0cNCjNTjugnj6klypJHk+m+ANc0G3uJbK5s7uQjIhwQWx2BJAz9SBVHSNR8Q6jqA082E9helSwivLCRAQOu2Tf5bfgxr2ainVw0KsnN7v0/VBDHVIqzs/68jzZPD3iS9BDXlmiglWKqOCOo6tzWxovw80XTrpbu4SS+uwdxe4IKhvUKAB+ea0J/Bnh+XVf7TTTY7XUTJ5r3Nm720krZzmRoypfJ6hsg96frll4ie8+06FrFnCgQKbO9s/NjYgnJDoyupOf9ocdKqjRjRu49fT9LEVcXUqqz0Xkb1FYuq6te6TYWk0uj3mpSsALgabsfymxyQrsrMucgYBPtU+n65Y3ul/2humtbYNsb7dC9qyNnGCsgUjkgA9D2zWpymnRSAhgCCCDyCKWgAooooAKKKKACiiigAooooAKKKKAMD4hf8iD4l/7Blz/AOimp9//AMiRP/2Dz/6LpnxC/wCRB8S/9gy5/wDRTU+//wCRIn/7B5/9F0AcN481e50DwbrGq2MImubS2eWNGBIyB1OOw6n2Fcle+K7nwno2mXN3qr+I7rVWto4YDEqbHkDnePIjLeWdpCjY7ZB5Pb0PULi0tLKafUZoILNFJlknYLGq99xPAH1rlrH/AIQCeFtNsP8AhFZIryYqbWH7OVnlA5GwfeYfQmvnoNW1Vz3Zp30Z5Z498Y63eR3t7H/a+gyt4cExsmlkiaGUagkZcDCnJXOGwCVb8K+ha41P+Ffra3cKf8IqLazj8i5QfZ9kEbSbtjjoqmTBweN3vWnL4u0JoJTZavpl5cLFJJHBDdxs0mwEsAASeMc8cU6j5klGNrCprlbcnub9Fcf4T8faJrvhq31W41DTbCRokkuLd71CbYucKHJxjPGMgZzWtF4p8PzXcFpFrulPdXABhhW8jLyZ6bVzk59qzcJJ2aNFOLV0zaorIsvEmh380kVjrOmXMsSNI6Q3Ubsig4LEA8AHgmrGk6vpusQNPpGoWd/CrbWktZllUH0JUkZqXFrdDUky/RRRSGUNW/1Nv/18Rf8AoYq/WVqhmmmMEJRPIRblmYZyQxwMfUc1es5/tNrHKV2lhyM5wa7q2HnDDU6jWjb/AE/yOOlXhPETgt0l/X4k9MlQSRshJGRjI7U+qQeYWlrdNIMTMqmPbwAf1zz1/SuelQnVTceheIxcMO4qf2i3c2p1S3DLtS6QbZFIwG9/p6Vh+Fr6WeB7e6YtNEAQx6kcjn3BFak00trdRTQuFVvkbPI9s/rWH4Zs7n+2NQDZVooyw44fLZx/OumX7+Ca3O+EbUpcz06eRg/FjTdQ1GbQ/wDhHLe4XxDDLLJbX6IfLt08pt6yN0w/yqBnrz2NcD4h0PVbXQfD1z4L0PULRtV0ttCvbaS3fzLbcwPmycZ4Jly5x1B719AKQygryCMinVzwruCStsccqKk27njFv4d0jS/iDq0X/COzyaZDoMdmkv8AY8sqSSIGDAMIyGYptGRnPTnGK6z4JWX9n/DbSLV7Cawuo0IuYprVoHMueSQygtxj5uc+vFd3RSnVclZ+Q40lF3QUUUViahRRRQAVu+Ef+QOf+u83/oxqwq3fCP8AyBz/ANd5v/RjV6OXfG/Q4Mf8KNmiiivWPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhvLW3vbaS3vIIri3kGHilQOrD3B4NTUUAY2ieGNH0E3J0Oyj04XAAZLfKxgjPKx/cU89hz3qtpGneJLC/iW71631TTefM+02Ijuehxh42VDzjP7sV0VFAHOXXiS4stUa1vfD2sLal9sd7bxrcxOCcZKxsZF/FMe9bL6lYpqK2D3tst+yCQWxlUSFCSAwXOcZBGfY1arN1rQdJ1yERa1pllfxjotzAsmPpkcfhQBpUVjahokj6Xa2Wjand6OLXAia2WOTKgYCsJFYFfyPvRarrlhotx9rltdZ1BGJhEUX2QSLxhWyzjd15GAeOBQBs0Vi6BrdxqcssN7omp6VcRAErdLGyN/uyRsyn6ZB9qs6Nrela3B52janZahD3e1nWUD6lSaANGiiigAooooAwPiF/yIPiX/sGXP/opqff/APIkT/8AYPP/AKLpnxC/5EHxL/2DLn/0U1Pv/wDkSJ/+wef/AEXQBxXjPQ/+El8K6no32j7N9thMXnbN+zPfbkZ/MVxv/CrB/aQuv7YI/wCJpY6kVFtgn7NEY9md/wDFnO7t6HrVb+wdK/6HK0/79S0f2DpX/Q5Wn/fqWuWOWSirKp+B68qkJO7X5lL/AIUog0O80xdZUrLbC1huZIZ3mjjE6TbSDceWVyvRUXk59c6158LPtGqT3g1jYZdVn1PaLXOPMi8vy87+3XPf0quNA0s/8zlZ/wDfuWl/4R/S/wDocrL/AL9yVX1Cp/z8/Ajmpfy/mUo/gzI2nJb3fiBZJYbO3sLd47HYqxRTiY7lMh3MSMZyAB2NdD4w8AXfiPxJa6i/iCeKyt7m2uksnjd0R4jk7QJFX5h1LIxB6EDIOX/wj+l/9DlZf9+5KP8AhH9L/wChysv+/clH9nzbv7T/AMlHzU7Wt+ZHF8HovsNtaT6zI0UdrfWzmO32M4uH3ZzuONvpzn2rqPh/4OPhNb5pbqK7uLoRK86rOHfy1Kgt5s0mTg4+XaB0xjGOb/4R/S/+hysv+/clH/CP6X/0OVl/37kpSy6clZ1PwHGdOLul+Z6pRXlf/CP6X/0OVl/37ko/4R/S/wDocrL/AL9yVn/ZH9/8DT6yux6JL/x/XvvZj+bUuinOmxexYf8AjxrkvC6afo9zfRrrlvfrNbn51DKFIzx831rHGj6devLcP4qtLVpJHbyWVyV+Y9xxXq4jL+fBQp82z3t6njYatFY+o/L/ACPVKqyY/sTTvaVR+orzb/hH9OHA8Z2OP92SurupbKXwTBp/9qW4KhY/P3cYyBvx1x39a48PgfYqS5r38gzavFum/P8AVHSyoskbIwBBGDmqHgq+NzJKk3yXCphkPU4OMivPv+Ef0/8A6HOx/KStbTtOuLW18/SdSi1NbZgWltgwaPOeCDyRgc/X61zrBPDLmUr/ACsfQUakKylSelztbSRJIsIf9Wdh/D/62DViuF8T6Xb3tzDJNq8OlqIwMyhsSH2x6f1rG/4R/T/+hzsfykrOGWKqudTtfyIrVVTm4nqdFeWf8I/p/wD0Odj+UlH/AAj+n/8AQ52P5SVX9kf3/wADP6zHsep0V5YPD2nn/mc7D8pKd/wjth/0Oen/APkSj+yP7/4B9Zj2PUaK8u/4R2w/6HPT/wDyJR/wjth/0Oen/wDkSj+yP7/4B9Zj2PUa3fCP/IHP/Xeb/wBGNXiP/CO2H/Q56f8A+RK9i+HUSweE7SJJ1uERnUTL0kAc/MM+tbUcF9WblzXv5WOTF1VOKSOloooroOAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzJfD+jy6vDqsmlWLanCSY7swL5q5BBw+M8g+tadFAHOaloWrPqMt7pPia9szIQTaTwRXFtwAOFIDr+Dge1Wdf1HWNPmjbTtCOq2u3MnkXaRzqc9FSTahGO+8fStqigDHuvEenafpFrqOtzDR4J2EY+3ssRRznCsclQeD3x71pWl1b3lus9nPFcQPyskTh1P0I4qVlDKVYAqRggjIIrNTQdNgsb210+1j05LwlpnsVFu7MQBv3Jg7sAc9eBQBB43t5LvwZr9tAu6abT7iNB6sY2AH5mq32qO9+HQuoDmKfSxKh9VaLI/nU+haNf6VdP52v3+pWRQhIbyOIvG2RyJEVSRjIw2Tz1ryoeKNQ8FRaj4O1nTEu7ZxIunnRpvtTWUEmTGlwhCsiLnCtjGMDnG4gGh/wguif3J/+/po/wCEF0T/AJ5z/wDf010TWGrg8Wch/Ef40Cw1j/nyk/Mf414f1nF95fifRctP+ZfejnD4E0X+7cD/ALa0n/CC6L/duP8Av5/9aulbT9YI4sn/AO+h/jUX9l60T/x5v/30v+NH1nF/3vxBQpfzL70c/wD8IJon924/7+//AFqP+EE0T+7cf9/f/rV0P9l63/z5P/32v+NL/Zet/wDPk3/fxf8AGj6zjP734hyUv5l96Oe/4QTRf7tx/wB/f/rUf8IJov8AduP+/v8A9auiGla2f+XNv+/if40v9k632sz/AN/U/wAaPrGM/vfiHLR/nj96Oc/4QTRf7tx/38/+tR/wgmi+lx/38/8ArV0f9k65/wA+f/kVP8aP7J13/n0/8ip/jR9Yxn978Q5aP88fvRxl1odnouo7bFZNstpMWDtnkAY/nUfhvwlpmqaLbXlyJ/Ol3btsmBwxHp7Vr6/Z39rqlp/aEXl+Za3IT5g2cKueh9xT/A+n6tceGLWS0gDw7pApMijP7xs9TX0WJq1/7IpTV+a+vf7Z87hlTWb1U5K1t76fYIP+EC0b/p5/7+f/AFqhu7KIeG4tP+b7Ot+YOvO3ft6/Sup/sjX8/wDHsv8A39X/ABrnr6KddKaF0AuV1Igrn+LzPWvPy+rXm5e1vtpcz4jUFGk4yT16P0G/8IFo3pc/9/P/AK1bHhzS7Lw3cEWrSiK5OyQSNuGQCQf5/nWiuka3jm3T/v4tZniDRtX/ALPZ5lWGNGU71kBIycdvrXBGtim1z81j6aEKM3y8618yl408NSTkTRKktkoyVMgQpzzyeMVSt/BGiTwRyp9p2OoYfvR/hVifQZLiyty9xNLgcquTWnoOl6rPpqfZUQxoxQbnAIwa1q1K0F+5v8japGHs05yV1pfYyP8AhA9G/wCnn/v5/wDWo/4QLRfS5/7+/wD1q6c6HrnZIf8Av5Sf2Frx/gg/7+Vj7fG/3jC1H+dfecwfAWjf9PP/AH8/+tR/wgOjet1/38H+FdP/AGDr392D/v5/9aj+wNe9Lf8A7+f/AFqPb43+8FqH86+85j/hAdG9br/v4P8ACj/hAdG9br/v4P8ACurXQdcHX7P/AN/D/hTxoWtett/38P8AhT9tjf7xN6P86OR/4QHR/W6/7+D/AAr0TwJbJZ+HIbaHPlwySIuTk4DkCsxND1jPJtv+/h/wra8KRvFpbxy48xbiYNjpnea68JOvKT9te3mcONdPlXI0/Q2aKKK7jzgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvqN0ljp9zdyglIImlYD0UEn+VcZ4Y082Xwqee4AbUtQsXv76XvJcSpvck+gJ2j0VQBwK3fH8/2XwJ4juNwXytNuZMt0GImOTSXUH2XwHLb4ZfK04x4bqMRY596AN+iiigAooooAKKKKACiiigAooooA82+LV5Ha6ho5w0kgiuQY0GWAYIAcDtkH8q1vhHIr+CbZQwLRyyhlzypLk4I7HBBx71hfEmG50nXl1oKJrWeJbfrlkYZ4A6kEc8e9aPwhgY6fqN+zxgXUy4hVsmPaD94dic9PQCvcqxj/Z0bPa333enyueNSlL6/K63v91lr87Hf147qt4zeJLi1URtaNqAb7R5nyLlwcn6Z5+lel+LXuI/DeoPZ7vOER5XqF/iI98ZrzmOSyGleWFTOOK8yhHdnPndb3o0tra+vkeuAggEHINU9ZD/ANlXRjUNIkZdVPdl5A/MVifDl538MReeSY1kdYC3/PMHj8M5A9gK6d1DoynoRg1zzjZuJ7uFr+1hCta17M84TxJqN1pEzW1gsUynADAkf0rU+GdxcyWuow3hBlWYSHpxuGMcf7tVNOvdGjEtu88jToCJY9rcMOCOnr70eCNWtbrxRew2UTRQvBkBsZJU/wCBNccG+ZNs+jxEIujUjCFtnc7+iiius8AKKKKACiiigArN0H/j3uv+vuf/ANGGtKs3Qf8Aj3uv+vuf/wBGGgDSooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8/+MHiHVPD0Pg9tHuvs5v8AxJZWFz+7V/MgkL70+YHGcDkYPoaq/FP4oL4FuHhhsbbVJYbT7ZPbJcTLOkW/aX2pA6BefvO6DPHpnu9a0XS9dtFtdb02y1K2VxIsN5AkyBgCAwVgRnBIz7muM8F6V4C8Z+G7bU9O8H6RHZLJNBFFc6ZbgptkZHwACACQTwec80Ac7q3xqls9R1aO38PJPZadPp0LzPflJH+2Rh0Kp5RHy9CC3v7U6L4p3V/r+l6fJYT2FzH4hn0S6itruOSKQxx79xZ4NzKc9F8s+/avSn8L6BJ5/maHpTee0TS5tIz5hiGIi3HJQcLn7vbFVLPT/DlwtxqMGh26SwXUlw0k2mGCQ3AGGlXeiksRx5g+8O5oA868O/HA6la6RdalolnplpqunXl9bTy6mWRGt2ZWSX9yNoJX7y7jyPlJrpPhl8Sv+E01rV9Mm0v7FNYQwXCSo8rR3EcqkhlEsMTj8UweoJFXvAcfhHxZ4P0jWdH8OWNvpssE0drDNYwo0MbOyyIFXIUMQ2QDg55rZtfD+l+HLO9n8LeH9Ktr0wkJFawR23nFQSiMyrwMnqQcZJoAzviy+fh5rdkpHn6nAdMgXu0tx+5UD8Xz+FbniX/kXdU/69ZP/QTXFeCTN4o1kah4ruCuu6Udy6H5Hkpp7OCBJyWMzFdwEoOz7wUA7q7XxL/yLuqf9e0n/oJoA0qKKKACiiigAooooAKKKKACiiigDzz4mx3FpqOn6s8TTafBGyScZETEj5iPQ8DPtUXwquEvdV1e5gdEhKovlA4LHJO7HoOmff2rb+JlvczaBDJbRPPHb3KTTxIpYsgDDoOuCVP4Z7VyHg7UINV8dWcmnvFCIY5PPXcFLAqRtA6n5sHHtXvUX7XASXZP8Hf8Txav7vGxfdr8dPwPUdXvF0/TLq7kG5YY2fb/AHsDgfj0ryCTRTNavdtKFldi5RAAgJOcBemPavYdSs49Q0+4tJ8+XMhRiOoyOorxuWW8jEsMTpPbo+wXCA7WGfvY64/yM15eH2ZyZ/8AFByV1Z29T1bwpqA1PQbW48tI2AMbogwqspwcDsOMgehrXrJ8K2VvYaDaxWcwuIipfzh0kLHJPt9O1a1c8rXdj3sNz+xhz72V/uOJfQE/t+8nVIBukYnI5O4Bv61ShitdH8UaaUuIjLJKYmjTAxuGOn1IqfxnpUlx4mtbmFpBmEBgik5wx5P5isPVtBksbk6giOWidZAWOOQc8CuGXuvRbM+poP2sEpz+KNrfgesUUisGUMpyCMg0tdh86FFFFABRRRQAVm6D/wAe91/19z/+jDWlWboP/Hvdf9fc/wD6MNAGlRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4FZ/B/wAS6fZ6Gbe50aa5s4NVtZ0eeVE2XbMUdWEZJK7uVKjpwe9e+0UAeG+HvhNrGkS6DLqdn4c8Sw2Okx6e1jqUzrDbSrIWMsJMLg5B5yqn3xxTJvhFrpktGmbRdStYtb1LUpdNu5pBbzpcriJm/dNmSM5OCpHPDCvdaKAPm3UPgj4uufBWi6CLjwy32HTpIPP2gTR3BnaRWWZrd38vBA2oYznJye/0Po8E9rpFjb3cgkuYoEjlcEkM4UAnJ5OTmrdFAHH+PYVsLzQ/EcAKXNjew2szL1ktriRYnRvVQzpJ9Y63vEv/ACL2pf8AXvJ/6CaxvisM/DrX2/ijtjIp9GUhgfzArZ8S/wDIval/17yf+gmgDSooooAKKKKACiiigArjfjHLJD8MPEbQu6MbUplDg4YgED6gkV2VYfjTUtO0vw/NNrFm1/aySR24s1iWRriSSRUjjCsQpJZlHJA7kjGaAPM9C0HxA/w+1LRPC9mtpYPqrqr6ir6ZPPZsqtJtRISImLlkBWNV2gkAEg1sfBew8R2HwW0Cx+zW+l6tCjL5d/DI21N7H50+RlY56ZPbk5qTxJ8T3t/C9ze6No15/ai6vDocdtfqif6S+zPR8Mq7iM7gCy8Nt+atbwf41/tPwg+p30V3c3dtdy2V1Da6a6SRyo5UqYVklPHGSHYd+OlAD9Tt/HraddC21Hw955icR7LGYNuwcYJmwDmvHbS6uorMW12+nLexnbEsEDwzrPuGCzM5xznsOe9ereKPFzXeg3cGlaZ4livHUbGGk3Kn7wJAO3gkZGe2a8otdUiu9Z1NdR0vXTIFWPZJYzSOuB0PBI617eUuEYylN/1+q1PHzNTlKMYr+v0eh73BqlprFjd2dhfwT3qwMreU3RiMbh6jPccV55aanBFpv2d1CSJ8rIRgqRwQa5r4e+IodP8AEyR3dprIjtIpDAiabMzuD1UgL0Ayfyqzb6pb+JtVuLqXT9WWS6lyrNp8qoo6LltuAAMZJrnrUYUKjhF3WjODHzq14QnFe9qreWn9eZ6l8OUkXw0ryAiOWaR4geyZ/qQT+NdRXJfD3UJZrCfT7hi0liVVGPUxnO38sEfQCutrz6l+Z3Pby9xeGhy7W/Lc5bx3PfWUFnd6ciPIHMTK44wwz6j+7XKeJ5dXvreEGcRQOmXRcDJ/D/Gu78WzJbaJLczRGWOFldkABJGcH9DXK3HiSCTRVuNP08yMDsCsACv5ZrjqrVps+nwEnyRlGF7Nq52Hhmc3Ph/T5G+/5Kq31Awf1Fadc18Prt7rw4nmjbLFK6MPTndj8mFdLW8HeKZ5eJhyVpR82FFFFUYBRRRQAVm6D/x73X/X3P8A+jDWlWboP/Hvdf8AX3P/AOjDQBpUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8VY5JPhn4qEP8ArV0y4kQYzlljZgPxIxWrrsyXHhe+miO6OS1Z1PqCuRWjcwR3NvLBOgeGVCjqejKRgivK5PFtp4R8Op4R8XzSWmprbmysLl42aLUEA2RsrqCA5G0MrYO7OMjBoA9Yoqr/AGjZf8/lt/39X/Gj+0bLH/H5bY/66r/jQBaoqr/aFn/z92/P/TVf8aP7Qsv+fu3/AO/q/wCNADr+7jsLOa6nWdool3MsEDzOR/sogLMfYAmpopBLEkihgrgMAylTz6g8g+xrlPiNZJ4n8C65omn31il3f2jwRNNNhAWHBJGTj6A15XZfCm5h1231OW/8PNImu2180vnEubNbfypoclP4jj5fukDk9qAPbfDWv6b4m0aHVdDuftVhMzqkvlsmSjlG4YA8MpHTtU2t6TZa5pkun6pD51rKVLKHZCCrBlZWUhlYMAQQQQQCK+dx8Gb1fDel6R9q8OCKynvPPSG6SP7ekxPlyOXtpAkkYO0fK5A+6ymqPiLwneQeNtHhEcWq3D3mjML6TzpnsYbZAsq/aDAsTISNxIZGLdY8ngA9vvfBnhSz0x9JudMvJrTU7lCwD3Vw3nD5hKZAWaI5BJkJXLHJbJ56Lw7oWm+HdMXT9Gthb2odpCN7OzuxyzM7EszEnksSa8h8P/DVtK0LwtB9r8PpqWn+IBqt9cRSYM8Aacou7YCzATcBsAZbB9V+E3w6ufBereH7y41HQx9k0y6stQNpOd1xI9wZIzyo3BVIGWwR0HFAHuFeIrcva+L9cEhO43kvX03HH6Yr2T+0LPj/AEu356fvF/xryHx5apN4hu9T0jdJA2BO2Pl8xRtO09xgD8Qeua78vxuHw05LESUVJWu/6/E8vNIycIyjumZPiOeS0uo760bZPH8wYfTBH4jI/Gum8N3axWWwHhlrmNN06617UYLebbbwZUyyzMECpnnGep7AD8a0dYibw/qU9vuEtnuLQTRncNpPAJHQjpzXo46rQqqEaclJ23Tv+J85VjWh/tCi+W9vvOq8DzY8W3EY+7Jasx+odcfzNeiV5v8ADgIb261S7ljgUx+RCsjhSwJBY4POOF/Wu+/tCyzj7Xb5/wCuq/414lZpz0Po8njOOFXMrXbYarB9q0y6gAyzxMo+uOP1ri7S60X+zpgL4yRj5iFByPyFdp/aNljP2y3x/wBdV/xrzq10azi1C4VJYtkzuqAy8MNxA/PFcdbdNH1GXtOMoybVrPQ2Ph5qVrc3uqwWassO5ZUDdT1BP6Cu3rznwvHBpHiZQjosMiPC7DhAevU+64rvf7Qs8Z+12+P+ui/406L93UzzKCVe8dml/kWaKqnULIZzd24x1zKv+NJ/aVjkD7bbZPQeavP61o5xWjZ517Fuiq32+z4/0u355/1g/wAaT+0LPGftdvj18xf8aoZarN0H/j3uv+vuf/0Yas/b7TJH2q3yOv7wcfrVXw+yva3DIQym6mIIOQf3hoA06KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIru4jtLWa4mO2KFGkc+gAya8/0DR4W8AXWv6jbxS67q9kb66uJF3OhdNyxKTyEjBCqB6Z6kk9T46mNv4I8QzAAmPTrhxnpxExqCeH7P8PTCDuEemhM+uI8UAeJEfMcNnDSIJF7ccBh9f8mo1GUThQWjYbeqPgk/5/pTt+G83dtO6NvNX7rcc5H4/wD1qIFZdkRUR/vCrITlH3DHB/A/54rI7t3/AF/X9dRGG5HXax/dqfKPDKQQPlP51JuHmly3yiYHeo6huzD8Bz/Oo1USRBCrDCMmD99cfNx6jpx/Kk8w4MhbGBG3mrzuwMEN+f8A+ugL9f6/r+tBwbEajBDeWCqK3cPjKt+fH86klAImA2/xp0whwwbDDsevP/66Y8eFMJTAy4EeeGxg5U9v8/SncmTd8xPI6fMm5RgMO4/z7UD8mGT5m4bmbzEYAH5lyCTj+8P88VGoDQr9wgq6kD7jY+b/AICef/1VHLcwRtFBNNEsk6g28ZcL5hXr5eeSQMkirP8Ay1YZA/fNGxA4+bjDj8OtAbkUgO11w5VY0bZn50wAMj8z/nmpDzOjBsAzH51HBDYwGH4fp360wDKJHtIYxEqoOWGGJyp7jjp/+uooLuC4LvbXETvHLHHI0bBsMF5VwPun2/8A10AaWiTWsN9bm+j/AHZjJ2dV6nkVam1JkD2cA8y2Vw4A6gbhxj8awYbiBrgWQkiFysTs1rvBfaQcMvcAk8HvjvViHLLHgkkR4DkfMuH6N7cY/wA4ry8Xl3tpyqc262+Vt+2mxwVsGqsnO/T9Do/EL3UtrayT2sSxqQVO7HGf51zSDKKSW+VXUuR86YGcEdxz/npWhrF9cfa59PmZWW1ZQSeA3+FUlUq+wbm8uRkz0ePIwPqP88UZU37Od+/XvZBgE+Rp9/8AIVRmRD8g3Mmf7kmV5x6H/PFMVcJjDYXY+3+NMZGfcf54pQ2IlcbOVV8kfI2GI/4Cef8A9VLKgUPGA2EVlA6OuG3ceox/kV6h3+f9f1/XmNUFQASu7MibgPkb5ejDsf8APvXW+Dry1EVpb3QiXL5KOc5HIHXqK5UHM24lQrTD5gPlYN2YdjwP881Y0q4S2mtt8JIDAlD83Abcdvrwf/11nU2udWDtzuLdk0/0Oy8X3dvbSzQ2owkiqwRF4B7n09K4FOkbAqCY3Xj/AFb8Mcex5/8A1V2PjPWdOudPtxppTKfM/lj7qnjn6kj8q5EjZOijam+V1x1RxwPw/wA9KIXux4hxcIW3W/3o2fDsUiSfaxZtNGiqCrYOzAxgZ7Vbg1Cxa6vybdW83AWPZ0OPT/PSsvRb+eKC9trX7sEXmuDnpnoPWs1ZGR3uBhSUDLKOmcjgjsev/wBevn1Qq42UqsPVXtZ9F57fifM+yniZSqIu3unTadJbRS4/eZKru5XcMYU+tUgcwHkEeVgsV44foy9j71YnnluLlTOfMZXTAfuOeVP+fxqtCcxq25mKCRd38Sjb0Ydx/n2r28JGpGklV3PVw6nGCVTcmbJkGAcsz4GeRuUY2HuPb/8AXXs3w3bf4RtGznJfnGP4j2rxZGxtJ24LxkA/cbAxlT2PT/PFez/DPP8AwiFpkMCGf73X7x611xCu7pHU0UUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFfFvxXfeDvDFvqOmRW0s8l/b2pW4VmXbI4VjwQc46c1J8RfiBpvgK0iutWtp5oHR3zDcWyN8uDgJLMjOT2CBjx9M7Pirw3pXirS/7O122a5tPNSYIszxEOpyrBkYMCD71x3iPwl4Dg1bR7HXv7Rk1LUvPs7Np9TvpZZlZB5sRk8wnYVH3WO3k4GScgEGq/Gvw9p0VxP8AYNXuLO3srTUZrmGOLZHBckCNiGkDHllBABIz3p938VLSS9trS3gvLC8TX7XRbqC7tEmbMysykFJwqggffy5GOUNbE/wt8HT2F1ZS6Putrmzt9PlT7VMN0EBUxJnfkbSq8jk45Jq3N8P/AAxNqUmoSaZuu5NQg1RpPtEvNzCpWOTG7HAJ46HuDQBgaR8YNE1PUdPtY9N1eFdQlu7e2nmSERySWwJkTIlJXgcFgAc9Rzi/4H+J2i+L/EN9olhDcw6hZwi4kV5beZCm4Lw8Esi5BIyCQRmrA+GXhAQWsJ0dWitpLmWJGnlYBrhds2QW5DAkYOQO2KXRfA/h3wWZ9V0DSrt72CwNrGgvJp3aFTvWFBLIQORwOPwFAEnxafHw08SwjmS7sZbKIf3pJh5SD6lnUVteKP8AkXNU/wCvaT/0E1xnhS4n8f3ltrGqS21vY6dMJIdGhZmliuAOGutyqQ65yse3AOGy3GOz8T/8i5qf/XtJ/wCgmgD5zvtQstNjVtQu7SyaePCtNIqRyEN0546Dt+lSWV/a38c02m3EFzHvEn7uUSIWzztYHrz09u/SqHi2wub7wxf2NlHuuZopYY4CwAZiABtJ46n1rlfFMOqpdeHbPTbu5je/tfsM9uspDRBCGaRAOAwVWGR7VmdjbX9f13PQlTMvlruZEkePBPzx5GOPUf4dqQEbN5IIkiwZMZBw38Q9cD/9deW6WPEOpatqc2l3V6BaaldKbie6LxogXEaeWWJOGIOduB69q6TwDYa5ZTXD65NenfF5eJmWSMSAHJB8125JzjCjpgdqLCUrvRHQ2+t6RdSyR2up2ExaYRmNblGy8inAUg9Tg8deO9WrW8trhiYLhJjbvGsgjcGSEgEYcD+vr+FcF/YOrXeieI4RZSWl5NfDU7DfLGVLLtC7SHIDZUjn1HPXHReCtLuNP0GVtQDR6pcyS3F1htzLK0mSODyAuBke9KxSk+xX8V2V6+t+HLy1sWvEtGuDMsLxqDlGAxvZR355rL1GDxPN4uivLS2vLW0WWGSZfte790Y8MGQy7cgnGFT33V3z/wCt5wvmSSAf3JMgY+nX/wDVWXrhmFgotrma2lKrhIxGZzg/djMny5OO/wD9encTjb+vI89j0DxgunLEJb8XP9nEAHUc/wClibkD58D92eR9098nFaFxpXiefU5JJJb9LF7qV5GS92N5XlKqAgOCB5gPHbrSJr2rXPg6TUY9RkGo27XO+OCKDdJtOA0of5cKByUHO4YqWbXtRudR8PW+k6lJc31zFDJc2kcClI4Cu53ZiNwyCCoyPTHqyLR6FGXRvGb2lvCXvFn+xwxEC9UZmE+ZCpDY3FMZPfkZJ4rr/CFvqFrFqI1Jrl41vLgWsssvmusGxdoJJJxy3BOau3eoX1vdy+To0s8PngiQTxCN+pyAWBU/l+FQR6lqYm2f2DfFkZl5nh3DI6H5uR7/AP6qV7lqKT0OmXN7Z6lNcRgtGkeydgArngbT78dR0qmGxO5+dtkysVPDIOeh7j2+v1qZ57rVYZ7hITBaRxqfsLMuIOvXacc4zn39eKrSc+ap3/LGh2/8tEIC9PUf54rzst/hOO9m9e/mc2DdoP1+8VR+5bBXJDJnGEOCGww7Hr/nmpD8zgDO7c525+Zdyg/Kfx/z1ppz9oc7lG53VWUfKcjgMP8APTv1pI2zt3KMq0ZCFuAMHlD/AEr0DsELfK8iFQNsbb8fK2ABhh26/p+NLtAm8kJx5jrsY88jGVP9P50xs+WGzk+XgyY5Hz9HX8v/AK9SkgMGZR/rEfBPByCSUP8ASgW/9fP+v1I+sbShm+aL/W9x82PmH4f/AK60NHgiuNUjiuQVSSQPgfdkJUkY9ORVALggksSiyIZMcjAJww/GpmtX+w/aDcLarJtRCH+8wwCUAOeP8+lYYqt7GlKaV7GVafs6bkRJqeB9jYRWj3JdvsynbIVVccZO5scZ9PamqcorE7g8RHmEcHDE4Yfh/wDrrJ8Y/abjx1oeqadY3WoWtlFLBMYmjSUudmGw7KDnHr+Wa5O6s/FM2um6tIriCzdbmMlbolXDQkpuDSkKwY4wqKAeQW6hYSj7Kkot3/4JGHj7OCj/AF0/r/LY9CkB2OgUthY38vOewGVP+fxplvcQXdw0ttcJOsdy0TSRMCUbOCr4/L/OK80Gi+LI7UKsuoecLW0kRG1DcGmDgS9XwRtB46Htk4qxd6T4qmvbuUzajHD5t9IDHfFWG4A2+cODjPT0zg46V02NebyPQYby3eSW2Se3a5jiV5IlcEDL/KSBypI6f0r3D4boI/ClugBAWSQAH/eNfJs+k+L5DAkrXcasLNZES8CqxQH7RjD8ds469ulfSPwBttWtPARh1szGRb64MHnTea/kl8plsknv15qomdVtrVHpNFFFUYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzx/whXj+78Y6Pf38N9Nf2Oq3051K41BJLRIXjKwGKDzPlAOMgRqee/b6HooA+cdN8K/FaPQdcW4v9fOrzaZJAifa08mS480FZY5TeM0bFcj5YolxwQD11b/wt8QYn8QWtre+JUsLn+zpLVoL+O5kDrETcqDLcxuiF8A7ZFOSNvGce80UAfPHiDQ/ild+FtMtLTSruz1AWczPcWev3EkkU/mMURhJeKDkbfmZpgucAYr3Xwyt+nhvSV1jP9praRC6ywY+bsG/kcH5s9OK0qKAOL8Y28ei69pHii1URSG5h03UCvAnt5nEaFvdJXjIY9FLjvXQ+J/+Rc1P/r2k/wDQTWP8VRj4e63ICQ8EIuEI7PGwdT+aitjxR/yLmqf9e0n/AKCaAPmrxHrB0j7MIbYXE95exQxQu+1A7hjneAcDjsCfrWLc+L5bO8mtbvTlYWUsMFzItzl42n4URgqPMAxznbXUXlnDeWslvd28d1A0Yb7PMofGCORkc8A/4VXGk6VHNHcR6fZA2u17eSOBA8AzkAccD5u3/wBaszsd7/1/X9dDzjRdcvYtVjnutRmaNU1By01w+07JBt3HngAYHBwOgPSt+18etdXSRQaaEv21BLdAZXSGQSLv3FmjDAYXps5z0rrRpWnxTgiys1kPnRCRIU2sGHzBhjuTz69wazr3w3ps+nzWdta21gHMcrrDbwlH2gqCN6Mufm64z79qL3FZxOai+IclxZWRtNEnmkntTPLbRmR/lE7J8u1Dk/KTztHbPatW28Ztda4bOWwKRNqF1YxzCcmVWjQMCU2jg8d8j+epaeF9Gg0230xtPgu4bQyoiXcSyODjOVJHUnJ/HpV6DTLBJY5IbG2O2dZgyxAOjuuGfIH3jgZPejQaUti4smArtt2l4/nxlXO3v6Hiqt3YWt/Zi2v7WK5tgrfup0VyMfMCM8Ec/wD6qsBh5JkyCDGCZNvBIbA3D+v86eE2y+WgOBKRtJ5AbjKn8D/9ekXuZU+i6TLaQJJpuntBAEMO62RkTjBG3GFyfQc470+fQNHmvDJNpNhJPvcAyQIznCgLtcjPHar4IaHzEbrFguV4+/nDD+tPGPNIIHMqPsY8fNk5U/5/GgSS/r+v68xkhBSUkr9xCzEdeAPnH49R/OpcZuSCGO2dWXnkAk8qe446f/rq5pcmn/Z5WvQXkaLAZuDgEjn8qz324lAXg7ZFBbAPHUHseRXFHGc1SVNQbt/XW3y8jnjibzcVF6f8EvQrBp6XcRbfqFxbgTKchI1IJAP+0ePpWc67lUYYMIsgfxrg9Qe44q1DfpJrUy3lt5+AsZk+6w5x82Ov1qaGezAtxHZMjgnaGm38Dk7eOc5xj+dZYV1KVKbUdE3Zfp9/r+hlRUqcJe73/wCGKgJRw7ELuaIs4GQ/HO4djk/5600gqnllORGG8onvvxlT/nt1rR1m/jvh5kSKiCPBbbx94dR+B5qhKuWZduVJk+QnkjGcqf8AP44rrw1WVWmpSVmdNGbqQ5pK3/Bf9f8ABBjhmbJfY0q78cqMcAjuP/rfStDS9Ptr2yneaXblRhU5UkcAj0rPUhpEctn54/nUcjcvO4f569+lRxFgi7SqsyOAoPyPjng9uv8A+qpxVKpVhalKz/rsLEQnONoO39WLk1rcRvHJLFLsaQlX24IVgPwYf546VVvbud9Ljs7SwW8ntf8ASVxMI0RSSGzn8MCrVpqN3ApjgnmTZszFnlRjB4PBHT/PNQW9/cXEExuJAyXDODtAVHCjjIGMHqc1z4mFR8kH7y6rvbr/AMC/UxrxnLljv389v63/AMjDfUdX3Ss2iP8Au3Vx/pSbo8gn05H+eKs2N1evcKLywFmm9h5iyrIrk4G0qO/H+etbNjZm/uxbeZ5XyoVZuqYGBz3FNvoWs7ydC6g+cvzgfI/U4I7f5+tb0sVTnL2cdH6WNIV4SnyLf+v6/qx5n4ev45Nbv7eHVpDpSaZ5vmm+NwEcScuzSDbFJjnZgjA59KzoNbmf4RT3ba9KuoRl1Ey3K+ezeY22NieeU5GMHAGDjIr1SJf3KoUPHmZjb7w+UfdP+evfrQjZSNtzMvksPNA+ZcEnBH4V13NFF9/6/r+kQ6RPHdWFrMkscsU2w+YG3JJuXkg9jXt/wyG3wfaDDDDOMN1HzGvFlPLfcGQjZP3Hxgceh5//AFV7V8NE8vwlbJtK7XcYPb5jTiRW2R1NFFFWc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynxXDn4ZeKWiXc8emzyhf721C2PxxWt4kdZPDOovGQytbOQR0IK1d1Czh1DT7myul3W9xE0Mi+qsCCPyNeeW3ia0sPB03hzxHewWPiGztDaGK5cRm82rtWaHJ+dXGD8uSCdpwRigDzeNeIl24+V02E/MDycqe/3v8A9fWmkbwHViC0X+tHB4/vD/gP/wCutI6XfeawFhckJNvVTG2OecqccdOhqNNM1D9yz2V2XO6PzPIbIB/vDHPU8/zrI7rdP67f1+hV6TRuxEZLoxPVHyAf6H/61MIwmzaAzRf6ls4OG6g/Qf8A66yry28TreP5VgptGwyjZ+7KLwWJJ3AjvjpXRf2deuX2WVxJGGkVl8s7kyM4Bx7/AP1qiNRSdjSdKUVdldRvmIIaQGVDtP30yCT9R/niow+IEcszBFD+av3gQxHI/H/69XG0zUChY2V2yhEKkQsHUjA5Hfv/APWp8ml34Lj7HdByXCyJC2MZB5GPr9ferI/r+v6+4pOoBbkKw8yMOo+UgfNz6f54oD7XY7QG3RzFWPyn1Knscn/PSrv9mX5mI+w3SMzc4hYo29ec8cdP/wBVRNpeoFGX+z7rDRgGIxNgEED5T9B/LrQD02/r+v6uV1HzFctvTzAWI+Zfl/iHce//AOqkB3Bg4B+VGCk/IcYGVPY89P8A9VU/EFrr0NxE1jZ3GwM0hYxYkQcdN2AV5GfT2q9pun6tNp8f2vT5hcSREOqxnYSHPp91sD86hTTlylODUebp/S/r+kJjBHzFtgkQvj5lwD1Hcc/56U1vuOwCHfEOP+Wb4IHHoeP/ANVaB02/aYObO8O2bhvJbcAfXjkcY/ziohpeoDapsbhSYmDDym8tupH0/wA9Kslrp/Xb+v6RWFo+0akW+SVwFAf505/XrSQYxEDsx5uDj7rZx/3yeKw7eHxG1/HE+nXC25fO1UJCryVKnPzEgZxjnnp26ltN1BJZWWxuFJlDBlhYq4Geoxx/n61w4FVVGXtX1MqVKrSuqxTQEhGO/IjcFm+8vBPzDuORz/8Aqp6ncU+7gsowfutuXBKnseP89Ksx6XfrKiCwuwsch6xtlRxypxyPb/8AXQml32xT9huAX2scwMFOCRgjHynmu41X9f1/X6FPd8m/cVdUDFj94ENtww7j3/8A1UBSs3lhVVS7rtP3XyMcHsf8+1ZWraRrcl2DbSTxxxoY0jYtGyEHJJIB3DkenWtrTrHUGjRZrWWWcNG8jCFtrEgndgfdJ/Ks41LycbbGsqMoxUn1I7ZIJbiGG6lMMTR85HzrhumfwH/1qZbhEzFGR5SyeUjgcNkEYYfh1q2dHvWiVXsLp1QOgJhO5OOPqM/5FSR6ZfpKP9BuFyY2LCFtrYHIIxwcn/PWsFQmq7quWltvuOONKSq+0b07FOFmQRiMEHymwgbJ4YnKnv8AT+dNaTIlfd0VG8wjOTwMOPqf/wBdUNS0fXXnWK0inihGVMOCrCRuM5KnKkdvr161p2Gl6r9hR57eeWcwhWmjiY5IIyCMcjj/AD0rWKg6jly69/8Agm7ocqVS2v47f1/wBAuJSgViomwFJ5AORlT+HSo4SGSNt5LZdBIB0yBgMPqf/wBdXv7MvxLJt0+5J3JKVMTbSe+044PP6fhVHVdG1eS1Is0ube480IszxMpwT0PHOcdRWrdlcajzNJf1r/X/AABB0wNqvJCSU/gfBPT8v8MV7d8Ov+RXg4IzJIcHt8xrwjw/o2tQvJHdJLPEyfu4trPgEHJDEdyf0P0r3T4ao0fhK1R1dGVnBVxhh83Q06cuZXMcRFw91nU0UUVqcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBneI9Wi0Lw/qWrXCNJFZW8lwyJ959qk7R7nGB9a48eEYU0C71nxLFFqPiaW2Z5bmdd4tiRnyoAeI0U8DbgnGWJJzWt8VMDwBq5b7gRC+em3zFzn2xnNbPib/kXtR/64P/KgCrRRRWJ6Bztqitp+hySAFJVMbg9xIhP8wKdbFrANOCX8hvIu17lB92T6hSpPqM+gpUBXwlauB81qkcn/AH7IJ/RTVy9xa3sV6MGCUCGf0wfut+BOPo3tWdjtcrtrzf53/X77GmDkZHIorNsCbK5NhIT5RBa2Y/3e6fVe3t9DWlVp3OSUeVhRRRTJMDxEN1yo7C3Yf99SRD+laek/8erj0nmH/kRqz/EH+tJ9Ic/+RUrQ0zhblf7s7/qd39ahfEdM/wCCkXKo627JpVzsOHdfKU/7THaP1NXqz9U/eXOnwf3597fRFLfzC1UtjGn8SM5I1GsxBBhEuxGv+6ls39WroawrMibUbVhzl7mYn2DBB+hrdpQNK71XoFIzBVLMcADJpao64xXS51X70gEQ+rkL/Wm9EZRXNJI58K3m208gxIwjnkB7ebOvH4AAfhV2INYrI8eS9g3lyL18y3PzL+Kg8fQjvS6oBnWHA4ht4sY7bSz/ANa0Zz5OrwNgeXcxmIn1ZfmX9N9ZpHZKd1/XZP8AVl5GDqGUgqRkEdxS1Q0jESTWgz/o0hRQf7h+ZfwAOPwq/Wi1OOUeV2MCX5tWc/8AT/Gn5Qbv61oaGNunKp/hkkH5O1Z4/wCPxW9dTP8A6JIrT0viGZO6zy/q5b+RqI7nRW+BL0/UuVn6r80+nRf37gE/RVZv5gVoVmag+3UonP3ILaaU/X5QP03VctjGl8X3lPw/w2nn+/p6H9R/jXS+Gf8AjyuP+vqX/wBDNed6TYeL0uLaNNb0FTFYxgbtGmOATwD/AKV1+Xr+lbnh6y8aGzn8rX/Dqj7RLkNoczc7jn/l7FVSRljXeR31FeJ/HTUfFc9noPhHwze3T+JrxZr24m0j/RG8qJDjG+X5VZ2UEbycKcZ6HAu/jhrzaG2qaXBpT21poNrqlwlxBI0kkzXP2eaMMsihcMGwdp6dOeNTgPouivnv4neNr3W/CvxF0q+vdG0xLIT2sGkzRn7fdxqqsLhWMoGw5JGI24U896nsvihr+k20+kTppCLYXumWP9qSQSLb2tvcW3meZMnm8lcBc71Uk5+XpQB77RXh3hD4m+JfFWrQ6fJb6ZZQHQptVllEExNxsuXhzERKpRHUBlPzEZ6niucg+MPiXTvCkV1a2+ltDZeH7XV5UuBcTySmS58lkEjzFhwQQzbjkc5zwAfSlFeKaV8VdZvfibaaC40eK1m1m7017Ixv9shihi3pMzeZjEhzj5MYBwT29roAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4q/wDJOPEf/XlJ/KtjxN/yL2o/9cH/AJVj/FX/AJJx4j/68pP5VseJv+Re1H/rg/8AKgCrRVS9vUtiEA3SHnHoPeqd3q0tvD5n2YSKOuHxj9K53JI9WFCc7WW5LparsvbOQZEczjHqr/OP/QiPwp2moJdLNpcfOYw1vJnvjjP4jB/GsY66yXYuo7TKzp5bDzP4lyR29C35VRfxBdR38klvbxxLc4yGJb5lGM9uSMf981n7SKOxYOtO+luu/Xqb8ay3VpJavJt1C0YFZD3P8L/RhkH/AIEKt2+owPaLPO6QHJV1kYDYw4I/OuYhubu6vfNuJWQsnl5j+TAznHHNZ2oWH2XUAznKTcb2OTu7c+/+FL2lldI0WCUnyzlbrp+J10/iLTojhZWlP/TNCf16VHNrpFv5tvavIv8AtMBj8s1y/lwp945rQ0u9RS0OMow71KqSb1NJYGlBXim/UgvtUu7+Qny0QGMx4UE8Eg/0FIl/qaPKUnK+Y29sKvXAHp7Cq9zcGG4dRgAHioTet/eFZuT7ndGhGySirHQWVzf3Fu+blxKoyOB/hWTPqWpx3fnPcEtbxMclF4B/D/Zp2l3xR5CX7Vjy3TTNIS3+vcD/AIAP8n86bnotSKeHSnJOKt6Grp2pX9rOmFjcwwLH8y+pyeh68Vv2PiCWXcJrUZAzlG/of8a5O2uzvlfIJdv0Ax/StfSLoNM24DG2nCbva5GIw0HFycTobXXrGdtrSGF/SUY/XpUurkPb220ghrmEgjv84P8ASuOkMMsjZ+U5pqSTW7J5Ep2K4kCE5XIORxVe1ezOd5fG6lB29TrHj86XW4uu9FX846S8k8zQbW8HWIRXGfYYLf8AjpNUtC1dJLq6a8CwvMykEfd4UDr26VoaXCLjw6lq33fLa3P4ZT+laJqWxx1ISpNc62t+Wv5ErfudeQ9riAg/VGyP0c/lWhWKsxltdEum+/vVX/4EjKR+ePyrVuLmG3AM0ipnoD1P0HerTOecXdLr/kYrfKzt/c1Nf1AH/s1aFgdmo6jCe7pMPoygfzQ1y2q6yY21GKCE/wDHyk4d+20Ien1U1XuLzULi/SR52jMqGP8Ad/J05A4/4FWXtEmegsHOcbvS6/yZ37uqDLsFHqTiua1rUbU/2kouI8m2WFSDnli27GPQEVW0q1jDSyzNvcL1JzXNeLGjh01vJ++zYJolNtBSwkISd23Y7HQ9c03UNbvFtLlWZkjjjBUruC7icZHqxrqfDP8Ax5XH/X1L/wChmvAdJle2mimiOHjYMCPUV754XYNYTEdDcyn/AMeNbUZXuebmFLk5Wuv6GxXnvxp8R6v4d0LSBoKXIudR1a2sWmt1haSNHfBCCU7N7DhSwKgnnHWuo8QeIrTRLzSLSaK4uLzVLr7LbQW6hmJ2lmc5IwiqCWPYdieKpq3hzx5AwB+3xaNquD/rIvJvLds/7O7aT7qfetzzDzO7+J+qw+KvDsUEl1fWCX2s2d/bQ2cMMtx9kiUrjfKRlSS24NHu/ujha6IfF/S9T0vWJ9Bs9SddP0pdUlu3t4nihRoXkXdGZkdz8hUquOccgfMNvUPhf4Rv2DT6bMri4uroPDfXELeZcgCc5SQHDgAFemMgAAmrlv8AD/wvbW+qQW2kxww6nZJp11HHLIqyW6IUVAA3y4ViMrg85zmgDzvTvi+NL1bxDP4iluLrT/P06HT44ooYBEZ7MTNueR1RATk/PIcdATXsWk3yanpdpfRxtHHcxLKqs6OQGGR8yMyH6qxHoTXmuq2fw20638Ui7mvbGOw+yw6wtvd30JwYligVhGwMilMKAu4Hvk5NbNp468G+H7PUdKtTe2lr4chVLqJNJu9tpGMBcnysYI+YHJyuW5GTQBvDwnpH/CSRa9JFdTanDvMMk97PKkG8bX8uNnKR5HHyqOK3qp6RqNvq+mW2oWJlNrcIJIzLC8LFT0JRwGGfcCrlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/FX/knHiP/ryk/lWx4m/5F7Uf+uD/AMqxvixkfC/xY4OGi0q5lX6pEzD9RWz4m/5F7Uf+uD/yoA429ctqk5P97H5VaQB4mRuhGDTNXtnivTMBmOTnPofSq9zci2tmbPzEYUe9cWzdz6dLnjHlMy3LTW9xCgG9cPH/ALw5FUJ7nz4MxjDcOvsRz/8AWqSyaSJJZc+1Z8MU8szxRIzMfmAUZ4J5/X+dYN6HqRppSbexc+3M6q4bAIyKdqd6tzZKpb5h39DSafoF9cXEsBTyymGPmHbgNnHHXqD+Vbdl4ZjNxJbXch+RFcGPvksO/wDu/rTUZsyqV8PTd29V2OUW4aRFPOSKnsxPJcKI1YnPYV22i6Lp8dsT9mR2WWRcv83AdgODx0FbccaRrtjRVHooxVxoPds5quawjeMI3PO7jSNRmmJW3mOe+0iqsemXDMqkbSSVG9gPmH8PP8Xt1r1CqN9pNpes7TRsGcYco5XePRsHn8ap0EYwzWS0a0PP/sLGN0WVM4zJ82DGPQ56MTxjrUQ0i9eTZHCxmI4RSCY19WA6fQ138Xh/SoySLGFiepkG/wDnmtC3ghto/Lt4o4k/uooUfkKFQ7jeatfCr+v/AA55nJpN5boN1vMqjuUNJAbi2jZwDg16jVe6sra6UrPCjg9yOfzoeHtsxxza+k4nmCXOT8/WrCSZ5U102peEopMtZSbD/cfkfnXJX1rc6bOY7hChHr0I9jWEoShuelRxFHEfA9exppMiWE2/GTwKh0DxJNpkxtyjT2xcnYvVcnOR+fSsnM14AsZ2xDqx7/StvQLFFtr2MfeUqdx6kY//AF1UW76EVo0+RqaumW5dVee3FrZpsSOdpFk7/fLLgduop9hCReRz3cpZweS7ZNZcVwtvJcKnZ+D7bRVae9Yn7xJoc+rFHD6OMFZP7zT1mSJdTuFVQVnTH5Zz+hH5VlyXbvbJub95GQce46/nz+dNk+0X4URqTIp4x1p8ejXPmZuv9FbGf36sFb6EA1Lbk9DWMYUopTeqLNjqQUuASQ4rI1bddQSRbTnqK27TRpZF3WFtdNMDyZo1WE+4O7J/CugsfDTko+pTRthAjRwpgN65Y8898Y/nVxhJnPVxVCnfzPO/DelXGoX0cMcT7dw3sRwo7k17f4Z4s7kD/n5l/wDQqhVQqhVACgYAA4FTeGf+PO5/6+pf/Qq7KUeU+bxtd1UtNEc345sruPx74F1yG0uLqzs57qzuRBEZGiFxGAspA/hDIAT2DZ6V5b4r+F+reG9B17UfD+n2R1xPEI1XRrnTYne4KSSbTBKojG2NFdjncV68L3958U6jPpHhnVtSs7Rry5s7SW4itl6ysqFgv4kY45ryK6+K2qwaPoVwmt+E5RqSyPd3qwP9n0p1g8xbeYCckyO3yAkoflPyk8Vseeczrvwj1G58T/8ACO6Pp1stpB4ds7aPWLtZFW3mS4LySwsEO6Y/Mdu5PvnnHB7Xwz8L9W0n4py+Jbu8S6ha9urhLhbtY5fKmUgQyR/Zi0oX5QMzhRgFVBGD5b4g1q68RTa1q+oWRsLu8j8OTSW5z8hM7dM84PUZ7GuxvvjhrNpr2vWVpYW2px2dneTRILU200csLgYdPPkYqAcncsRIGQMUAdZ46+F934i+J2ja9a3VtDo2YG1a1dmD3LW7s8OAAQ3JwckcDvVbW/A3iy+u/iYYYNCEXiqCK3tmfUJQ0Iji8kM48g9VJbAJwRtyc7hy8nxr8RRQagI10HUIoNQtbQapZxEW0aSwGRmYSXCr94bATKg4OeeKNS+NHiu10y5vRZ+H1+w6NBqlxFGxullZrswMscsUxQAjDA/Ng8HPYA908LW13ZeHNMtNSS3S8t7dIZBbymSPKjGQxVSc4zyo/rWpXnek7bL456vbWGEttQ0OC/u41HHnrM0aOfRmTIPrsHpXolABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXjPizxD4gPxE8Xafa+J5dH07R9Fi1GFRb27xmQ5z5hkjLFTjGAyn0NU7f436mbLR7eHwhe6lrM+kRapcwWyzZIdtuIlSKQnP3suVXBxuJoA9yorxu++MuowjxXc2/g2aTTPD24T3UuoJES21WVDGULKx3EHggY6+kd38aruxn1RLzw1AI9MmsFuni1IsfLvFDRsgMI3MAfmU4HoxoA9oorxv/haWpadY65cR6JqOqxWfiG902W4lfdDZwwqreY5t7cusfJxlHIwdznivS9H1+0vvCdtr809qllJaC7kmilZ4UTbuYhmVSQBnkqp45A6UAZvxZI/4Vf4tX+KTSrqJB/ed4mVR+JIH41s+Jv+Re1H/rg/8q5VpLnx/dWXl2lzaeE4JkunluozFJqLowaNVjb5liDBXLMAWwABgk11Xib/AJF7Uf8Arg/8qAKjAMCGAI9DULWVqxy1tCT7xg1PRWNj0VJrZkSW0CDCQxKPZAKqarGyRx3cC5ltSW2j+JD95fy5HuBWhQeh70rDU2ndmfMQuqWVzGQY50aFiDweN6n9G/OnOxGuRKOjWzk/gy4/ma5CTVbiJjaRgLHFKJYQeyhs7foOn0IpL/W7xrh5lYIyQlRtHqf8QK7Fl9W13p/X/AOjku0l2/4b8zsNEYvp0ch/5aO8g+jOT/Wr1Z2gSrJpNuqYHloIyB2wMVo1yyg6b5Jbo55u8m0FFFFIkKKKKACiisjVNdt7QFISJ5+m1TwPqaTko6sunSnUfLBXNSWRIY2kldURerMcAVyniXUFv4BbxwK8DciRxyfp6VQuJ7rUZN91J8o5CjhR9BVpmjks9kRBkjFYSqcysj1aOEjQalLV/gjNESwIC2M44Aqul8be8lcdGVcj86gurg8gHLVDa209y8jpFJKVQuVRcnAPp+Nc93eyPX5Eo3qbBKGuJ53jGE4Y+3+cVnvdhSUtU81/7x+6KjdpbuQ7g0UXQoDjI7Z/WtSytolAwBikUr27I7TwXdWc1mqLAkF6B846l/cE9vbtXTV51BayMQ9tuBU5DKcEV1Ol6xwsGosqTdBIeA319DXVSnpZnhY3CvmdSDv5dTcooorc8sKl8M/8edz/ANfUv/oVRVL4Z/487n/r6l/9Cq47mFfZGvRRRVnMFRXlul3aTW8rSrHKhjYxStE4BGDtdSGU+4II7GpaKAMbw34a0rw2l2ukwSI93L59xLNcSXEsz4Ay0kjMx4AHJrZoooAzrDRNPsNV1HUrWArfagUNzM0jOX2DCgbidoAJwBgck4yTWjRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBiap4S8N6tqAv8AVfD+kX18AALi5so5ZAB0+ZlJ47VJrfhnQdeaJtc0TS9SaIYjN5aRzFB6DcDiteigDKXw5oa2l7ajRtNFte4N1CLVNk+AAN64w3AA5z0pk3hjQJvtHnaHpcn2jyvO32kZ83yhiLdxzsH3c9O2K2KKAMC+8GeF9QDC/wDDei3IaaS4PnWET5lfG+TlfvNtXLdTgZ6VtLbQJai2SGJbYJ5YiCgIExjbjpjHGKlooA4XR4n8FeI7XRA7v4c1RmGneYxb7FOqljbAn/lmyqzIP4SrL0KgdR4m/wCRe1H/AK4P/KsT4prs8F3d6vEunSwahGw6hoZUk4+oUj3BIrb8Tf8AIv6h/wBcW/lQBVooorE9AKCcAk9BRTZFDxsp6EYoA8/1Qxzak8sPC7yR+NVpU8xMdOQfyOa6V/Db7jtmGO2RWXLpV5HKU8lm56gcGvqaVfDzi4Rl/VrGintbobPhBj5U69gQa6Gs3QrA2NqRJ/rH5PtWlXgYycaleUo7EMKKCQASxAA7msm91+ytsqjmeQdo+R+fSuRyS3Kp0p1HaCua1UtQ1O1sB+/ky/ZF5Y/596w77Ub66tA9swijPUJ94fj/AIYrFEKoS0zZJ5571lKr2O+hgE9aj+SNiTVLjVJmiTMFuRwAeW+prKkjjtMhsFx2qF7/AMtgY8ACquo3Zun3xLyetYSlf1PVpUOR2irRJJ7s4xnj2qqk8pf93nJ4471c0nRbrUWyi4jzy7cAf412uk6HaacAyr5k3/PRh0+g7UQpynqLEYujh1y7vsc1b6CVhhub5CiNKiMvRsMwGfbrWxoyLBfW0aDAUXUX5SqV/StbWIjNpd0i8PsJU+jDkfqBXPW2p2w1WOQyAI8zSD/deJT/AOhA10wpNO0UeVLETxEW5dL/AJf8ETVtDTUbzUpYSscsZUYxw3yAn8ea5CMSQTKrggHB5HY16EJwLPXLlGBBdihHfESAfrU2qaJb31qiEBZY0CpJjsB0PtWc6N3pudGGx7opQqarT5aI5u31GK1hVIcEnqaiuI1ugXU/Me1Yt/Z3OmXTRzoRjp6Eeoqa0vMYweax5ujPSVBW9pTd7m9pOtz6ewhug01uOB/eT6eo9q6+2uIrqESwOHQ9xXJxJCLcSzAF2HFVBdXNjP51s+0HquMq31Faxm477Hm18LGu24Kz/BneVL4Z/wCPO5/6+pf/AEKsDRvEVnqLiBpEivB1iLdfp6/zrf8ADP8Ax53P/X1L/wChV102nqjwsVTlT92S1NeiiitDjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+Kv8AyTjxH/15SfyrY8Tf8i/qH/XFv5Vh/Fx2j+GXiZ40MjrYSlUBxuO3pW54m/5F/UP+uLfyoAq0Vm3mpeXcGCFQXH3i3QVQ1LWLy0CssUDIeMkHg/nXM5pHsQw1SdrdToaK5q11m+u4ZDGIFdBnGw/41mSaxqkhI88qPRVA/pUuqkbRy+pJtXSsdxVafULSA4muYlPoWGfyrhpDdzn99NLJ7O5Iq9NZCazjkJCleDU+1b2Rr/Z8YNc8vuNq48SWMeRH5kx/2VwP1xVJfEM905SKJYc9GPzH/CsjybeL77bjTDexxEeWoFQ6kurOqGCope7G/qSXgvJpWW8mkYZ6MePy6VAFiiPzHJo1jUEfy3VskjkCsZrmSU4QGspNJnfSpylFX0Ogg1NYw8RwEYVjTzu8hAyeauaVoN7eyo5jZY+u5+B/9eussvDVrE++4PmnsvRR/jVKE5owqYihhpPW7OOsdMur5wIYmcZwT2H1NdfpHhqG0IkuSJZP7o+6P8a3o0SNAkaqqjgBRgCnVvCio6s8rEZlUq+7HRCKoVQqgBR0AGKWiitjzzG8T3Pk2IiU4eQ4/CuDVdkka4+5LgH2Kkj+eK7fxTZvNEk8fPl8Ee1clIm4of7rZr38DSjKhFw3T1+//gI3pT5U13LGl3rIYrZ2/cTXAZx7K2f12gfjXoYIIBHSvNBEA6MONgIA+td3oU5n02Jm5YfKfwrlzHC8i9r8vw/zuKrJStYsXtlb30JjuY1de2eo+hrh9Z8L3FnIZbPM0HXj7y/Uf1r0Cquqaha6Vp1xfahMsFpboZJJG6KB/P6d68adNT3NMNjKmHfuvTseTa14hGmxQ/aElllkcQwwRYLyuewyQOmSSTgAEmna5qkkdqsMTfNJ39BW7p/hOTxDcS+I9Yiaz1C4XFlaFR/okB6Bx/z1fgse3C/w5PN+K9IutNvoluU+RlwjjlWrB03F6nqwxdOtB20fYzNMib7VE6E+bvBU985r6A8M/wDHnc/9fUv/AKFXmvgTw7LJPFqF3GUgjO6NWHLnsfoK9K8M/wDHnc/9fUv/AKFXVRXU8XM5qVoroa9FFFbnlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/FX/knHiP/ryk/lWx4m/5F/UP+uLfyrH+Kv8AyTjxH/15SfyrY8Tf8i/qH/XFv5UAcQGJvpmbqXJ/WptWx/ZzMe2P51JqNo9vfPIFPlOdwI6AntWbrcrzWwt7dWYk5baM4rgeidz6unapKDjsR6RdKk5AAGRiqdxdhJXAx1NMs9LvySwgm6cfIafH4a1KZizRbc92YCs/easkdv7mM3KUkZWsaxd2kKSWVk1982JI45VRwuOq7sAn2JFQ6b4z0+8iezMz2983S1ukMMv4K33h7rke9dTB4NuDjzp4lHtlj/SrcvgTSby1Nvq0SX0J5KSRjbn8c/nVRhN7o562LoR1jK/lb9f+HOSMsj9M1PaaPqN+wMULlD/EeB+ZrcTwRLoz+Z4U1RrVRz9j1BPtkB9gWIlT8HwP7vatfSNS1qeeSy1jR/sM6xFlvbedZ7VsYHBO1wec7SvY8mqWH7swnnFtIQ+8zrLwcCq/bZ+R1WPn9TW/Y6LYWWDFApcfxP8AMa8m8LfETxEdMgFx9h1nUL7WbjSrcM32SOIRK5DsVVyd23pijTPizq91dyapLplquhx+HF1h7ZbkmYNulB2ny+csm3BIAX5sk/KN40ox2R5lXH1avxSPaqK8ksPiprF1Fp8P/CLqNRvrwW0CSXTwxSK0DSrIGaLdjKlfu9sjOcVn+Nfixq+nR+J7W0062sLuwjmaye5aRmuBFIqtIv7sxsME/KHyDgHHOLszm50e10V4x4k8eeJ9P8Q3Fpaw2QnS70iF4Hut0Ci4aQMqP5IfnaoLHOOoHGDLqPxPv9GttdZreO9v4NWnt4bSSViPKit45X8sxw/dXcTl/XOTwAWDnR7FRXBfDzxRe+JPEviLznI0+O2064tLcquYRPb+Yw3AAtzjr+GKyU+JuoTaZaahBpWni21S+Gn6ekl8yyo/neVunXZ8q8E/KTj5V6tmiw+ZHqTKGUqwyDwa5mDRpF1j54s2wYtk9CK8p8S/FHXbnT7y80uX+zjFoV5M0Sqkqrcw3ccO9WZfmXG7HbnpkV1k/wAVPsvjG60p9PW50+GO6H2qBn3CW3h82SPDIFJxx8pOCRzW9CvOgpKPUFUR3N/oNvcNuiPkt3wOD+FaFhaJZW6wxkkDnJ715OPjBdQ6RfXF5okH2mKLT5IFt7ppEf7Zu2B/3eRtC84DZPApt/8AF3VLXThJ/wAIwiXkGn3GoXcVzdtCUSGZY2CjyySWDBhu24zz05U69WcFCTukHtEexE4HNcTZgeN9ZS/f5vDOnS5tF/hvrhT/AK4+saEYT1YFugU1peIrK98SafYWlrKLbSrwB7+QOVmMOAfKTHTfnDNnhc45II6C3gitreKC3jSKGJQiRouFVQMAAdgBWA9ySkZVYYYAjryKWigYVL4Z/wCPO5/6+pf/AEKoql8M/wDHnc/9fUv/AKFVx3MK+yNeiiirOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5j4o273fw18VwxBjK2lXPl7SQd4iYrjHvir+tXCXfhW6uITmKa28xT6grkVqzxRzwyQzKHikUo6noQRgivM7HXbbw/4Xbwl4juBZ6nZw/YrOS5+RNQiA2xPG54Zyu0MgO4NnjGCQDs6KKKxPQCiiigAooooAKR0WRGSRQyMMMpGQR6GlooA5LVNN8I+CtCudXbRNNs7WwP2r/RrKMMJMbAVAA+c7to/wB7FZEGufD6DWotOvbbRdK1TSrFZFiu44ImtIpFJaIHOFIUncoOMN6Gtz4m6Dc+JPBGpabp/l/bW8uaASHCtJHIsiqT2BKY/GsnVPB1xqup6nrEzKker6OLG+0qSNXckK+0JMHCqQX5OGHHBFMh3voWvM+H3h8ll/4RjT2tbgvhBBG0cwQknA5D7CffB9KlceBbbVVVo/D0eoa9Hn7kW++Rzxk4y4Y+uQx9TXn2kfDTxBZ6F4Lt45YItUinvLrVbuYCYRyT27R/dDLvIBVODjgHkVsD4NWsF/pc9nqeYrS2tLeSO5ieTebc5SRdkiAN/vBwOwo0Fd9jqNItvAmri+0rSbbw9dqiJFdWsEMTrtQkKGUDBCktj0JPQ1R8OyeDfF1xqmnQeGYP+JbdZuI7zTEVBPtC5GRgttC89cYp3w98BTeEdUvrn+1jNbXCbEsoInigQ7ixfa0jgOc4+TYv+zVvwL4Sv/DmseIry91aC+TV7r7X5cdoYTE+MYzvbIwB2HegavpoWdM1vwdaS6m2m32iWr2iIL1onji8tI/kTeRj5V+6M8DoKzLi6+HLaVqmsMvhq4tLqU213OiQuLmQHd5bH+NuAcH2PTmuZb4N3M0evfbPEzXM+qWMlj58lqzSANOJQ7lpTuIA24UKMY4GOdTUPhdJNrN1qtnrKQXcmotfRB7TzI0V7byHQrvBY4yQ2Rg9jRoL3uxZu9X8HRfDqz8UXPh6P+xJbJYxENPjdordyGKMoyAm4AkA4ziorfXvCMvi4QweGLlPEF1YtqAuF0lVmaIx8nfjOSPk92O3vVrUPAFxcfCSDwTbavHCVtUtJLx7XfvReuE3jBOPU4qO18Da7B4xtPEB8RWRmt9IOleWNNIBGNwf/W/89AGx6ZXPejQNTmvAkvgXS/Df26x0y/uNH1+/TTZ59QtIliLKSE3IAq+XvZlyFPzE59a9Pi8K+Horf7PFoWlpB5LW3lraRhfKYgsmMfdJAJHQkV57H8O9Y074fab4NjvIdRtm1VLia8EIgFvbrMJ2G0uxZi4IGOzc4xk+t0McV3ERFjRUjUKijCqBgAegpaKKRYUUUUAFS+Gv+PS5/wCvqX+dRVL4a/49br/r6k/nVx3MK+yNeiiirOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQgEYIBHvS0UAGB6UYHpRRQAYHpRgelFFABgelGB6UUUAGB6UYHpRRQAYHpRgelFFABgelGB6UUUAGB6UYHpRRQAYHpRgelFFABgelGB6UUUAGB6UYHpRRQAYHpRgelFFABgelGB6UUUAGB6UAAdBiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4086=[""].join("\n");
var outline_f3_63_4086=null;
var title_f3_63_4087="Ureterocele US VCUG";
var content_f3_63_4087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Ureterocele in bladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a ureterocele and a left kidney with a duplicated collecting (duplex) system. Ureterocele seen by sonogram (A) and voiding cystourethogram (VCUG) (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin. Illustration reproduced with permission from: DiSandro S. Hydroureteronephrosis: Ureteroceles, duplications, and ureteral ectopy. In: Handbook of Pediatric Urology, 2nd Ed., Baskin LS, Kogan BA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4087=[""].join("\n");
var outline_f3_63_4087=null;
var title_f3_63_4088="Eyelid lesions";
var content_f3_63_4088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eyelid lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Chandak Ghosh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Tanya Ghosh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4088/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/63/4088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that cause lesions of the eyelid include benign and malignant diagnoses. Patients with eyelid abnormalities commonly present to their primary care physician. Primary care clinicians, therefore, must be able to identify serious conditions that require urgent referral and to provide appropriate therapy for treatable benign conditions.",
"   </p>",
"   <p>",
"    This topic will discuss the differential diagnosis of non-acute lesions that affect the eyelid. Eyelid lacerations, blepharitis, and the differential diagnosis of the red eye are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39045?source=see_link\">",
"     \"Eyelid lacerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENIGN NODULAR LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Xanthelasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xanthelasma are cholesterol-filled, soft, yellow plaques that usually appear on the medial aspects of the eyelids bilaterally (",
"    <a class=\"graphic graphic_picture graphicRef67919 \" href=\"UTD.htm?23/14/23778\">",
"     picture 1",
"    </a>",
"    ). They most often occur in middle-aged and older adults.",
"   </p>",
"   <p>",
"    Hyperlipidemia is present in approximately 50 percent of patients with xanthelasma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These lesions are a classic feature of primary biliary cirrhosis, a condition often associated with marked hypercholesterolemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=see_link\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"    </a>",
"    ). They are also common in patients with primary disorders of low-density-lipoprotein (LDL)-cholesterol metabolism; they occur in 75 percent of older patients with familial hypercholesterolemia, and 10 percent of patients with hyperapobetalipoproteinemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    ). Young individuals, in particular, with xanthelasma, appear to have a relatively high prevalence of lipoprotein abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In normolipidemic individuals, the possible association between xanthelasma and atherosclerosis is not clear. Some studies have noted other lipoprotein abnormalities in normocholesterolemic patients with xanthelasma that may increase the risk of coronary heart disease, including low levels of high-density-lipoprotein (HDL)-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Thus, it is reasonable to obtain a lipid profile in patients with xanthelasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xanthelasma are always benign lesions. Therapy is usually undertaken only for cosmetic reasons.",
"   </p>",
"   <p>",
"    Lipid lowering may induce regression of xanthelasma in some patients, although the effect is not consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/5\">",
"     5",
"    </a>",
"    ]. Removal can be attempted with surgery, carbon dioxide laser, or topical 100 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    (TCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], but recurrence is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chalazion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chalazion, meaning \"hail stone\" in Greek, is a chronic inflammatory lesion that develops when a Zeis or meibomian tear gland of the eyelid becomes obstructed (",
"    <a class=\"graphic graphic_picture graphicRef81651 \" href=\"UTD.htm?30/21/31058\">",
"     picture 2",
"    </a>",
"    ). A chalazion may first present with eyelid swelling and erythema and then evolve into a painless, rubbery, nodular lesion. It is seen commonly in patients with eyelid margin blepharitis and in those with rosacea. An inflamed hordeolum will often calm and scar into a hard chalazion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hordeolum'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not indicated since chalazion is a granulomatous condition. Small chalazia often resolve without intervention. For larger lesions, frequent hot compresses may allow them to drain although typically most clear spontaneously in weeks to months. Symptomatic patients with recalcitrant lesions can be referred to an ophthalmologist for incision and curettage or direct glucocorticoid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent or recurring chalazia should be checked histopathologically for possible sebaceous cell, basal cell, or meibomian gland carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hordeolum",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hordeolum is an acute purulent inflammation of the eyelid. It may be sterile or may show both inflammatory cells and bacteria, most commonly Staphylococcus aureus. An internal hordeolum represents inflammation of a meibomian gland just under the conjunctival side of the eyelid. An external hordeolum (stye) arises from an eyelash follicle or a lid-margin tear gland (",
"    <a class=\"graphic graphic_picture graphicRef79059 \" href=\"UTD.htm?2/54/2916\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hordeolum is largely based on case reports, as randomized trial data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both internal and external hordeola can be treated with warm compresses, placed off and on for about 15 minutes at a time approximately four times per day.",
"   </p>",
"   <p>",
"    If, despite continued treatment with warm compresses, the hordeolum hardens into a chalazion and does not reduce in size within one to two weeks, the patient should be referred to an ophthalmologist for consideration of incision and curettage.",
"   </p>",
"   <p>",
"    If there is concurrent preseptal cellulitis, oral antibiotics with Staphylococcal coverage are appropriate. However, cellulitis is uncommon, and it may be difficult to distinguish secondary cellulitis from sterile inflammation.",
"   </p>",
"   <p>",
"    Patients are frequently treated with topical medications containing antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroids. There is little evidence that these are helpful in promoting healing. Patients who have frequent hordeola in the setting of rosacea-associated blepharitis, and who have not found relief with warm compresses and mechanical removal of lid margin debris, may benefit from a topical",
"    <span class=\"nowrap\">",
"     antibiotic/corticosteroid",
"    </span>",
"    ointment combination (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    ). This, however, is best managed under the care of an ophthalmologist because of the ocular complications caused by long-term steroid use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Molluscum contagiosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum is caused by a poxvirus and spread by direct contact or by fomites. It is usually seen as one or multiple small, pale, shiny nodules with central umbilication (",
"    <a class=\"graphic graphic_picture graphicRef68192 \" href=\"UTD.htm?7/42/7841\">",
"     picture 4",
"    </a>",
"    ). A chronic conjunctivitis may accompany the condition if it is located on the lid margin. The diagnosis is based on clinical appearance; biopsy is rarely necessary.",
"   </p>",
"   <p>",
"    Most patients with molluscum contagiosum are not immunodeficient, although approximately 10 to 20 percent of HIV-infected patients develop this infection on the face, neck, or anogenital areas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/11\">",
"     11",
"    </a>",
"    ]. There may be more dissemination with confluent lesions in patients with immune deficiency states; these individuals can have up to 40 lesions on each eyelid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum may resolve spontaneously within one year. Treatment options include simple excision, cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/12\">",
"     12",
"    </a>",
"    ], and desiccation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MALIGNANT NODULAR LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Basal cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal cell carcinoma is the most common malignant tumor of the eyelid, accounting for 85 to 90 percent of all such malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It usually arises in fair-skinned individuals with a history of prolonged sun exposure. It may be associated with basal cell nevus syndrome (Gorlin-Gortz Syndrome) or xeroderma pigmentosum, particularly in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basal cell carcinomas are commonly small, slow-growing, firm, painless, pearly, and indurated (",
"    <a class=\"graphic graphic_picture graphicRef67350 \" href=\"UTD.htm?16/22/16739\">",
"     picture 5",
"    </a>",
"    ). There may be associated telangiectasia. Sometimes there is a loss of lashes associated with the lesions. Morpheaform tumors are less common but more aggressive; these nodules are firm, raised, plaquelike, and often show ulceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One-half to two-thirds of basal cell carcinomas involve the lower eyelid margin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/15\">",
"     15",
"    </a>",
"    ]. In order of declining frequency, lesions are also found in the medial canthus, upper eyelid, and lateral canthus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These tumors are locally invasive, but only rarely metastasize. However, neglected tumors can grow to large size and invade as deeply as bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evidence-based review supported two therapies for basal cell carcinoma of the eyelid: Mohs' chemosurgery and excision with frozen-section control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/16\">",
"     16",
"    </a>",
"    ]. Two large series that evaluated these techniques in patients with basal cell carcinoma reported recurrence rates of 1 and 2 percent, respectively, although follow-up in the latter study was only three months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Cryosurgical techniques are also being developed that are effective at a lower cost, and better preserve the surrounding structures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/19\">",
"     19",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma is much less common but faster growing than basal cell carcinoma. Squamous cell carcinoma can arise de novo or from preexisting actinic keratosis and is more likely to metastasize [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/20\">",
"     20",
"    </a>",
"    ]. The tumor usually is found on the lower eyelid, with a propensity for the lid margin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. Similar to basal cell carcinoma, prolonged sun exposure is a risk factor for this malignancy.",
"   </p>",
"   <p>",
"    Squamous cell carcinomas present as nodules or plaques with everted edges that enlarge and often develop crusting (",
"    <a class=\"graphic graphic_picture graphicRef69166 \" href=\"UTD.htm?9/42/9891\">",
"     picture 6",
"    </a>",
"    ). Unlike basal cell carcinomas, they do not show surface telangiectasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis should be confirmed by incisional biopsy. Wide local surgical excision with frozen section is usually sufficient for cure. Orbital exenteration may be necessary in cases of deep invasion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    ). As with basal cell carcinoma, the two treatments supported by the evidence-based review cited above include Mohs' chemosurgery and excision with frozen section control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/16\">",
"     16",
"    </a>",
"    ]. The reported recurrence rate with the former method is approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sebaceous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sebaceous carcinoma is often mistaken for recurrent chalazion or blepharoconjunctivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/21\">",
"     21",
"    </a>",
"    ]. It is a highly malignant carcinoma arising from meibomian, Zeis, or sebaceous glands of the skin. Five-year mortality rates as high as 30 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/22\">",
"     22",
"    </a>",
"    ] although more recent studies suggest that earlier definitive treatment improves prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/23\">",
"     23",
"    </a>",
"    ] and have found much lower mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/21,24-26\">",
"     21,24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\", section on 'Sebaceous carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sebaceous carcinoma occurs most frequently in the upper lids of females over age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. A nodule that originally resembles a chalazion and then causes loss of lashes as well as destruction of the meibomian gland orifices is likely to be a sebaceous carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef77552 \" href=\"UTD.htm?15/20/15685\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide surgical excision is the main treatment modality for sebaceous carcinoma. Disappointing results have been reported with radiation and Mohs' surgery although no prospective studies have been performed. Excision with frozen section control appears to be the most tissue sparing procedure with the highest cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/16\">",
"     16",
"    </a>",
"    ]. Orbital exenteration may be necessary for large tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Keratoacanthoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratoacanthoma is a rapidly growing hyperkeratotic nodule with a central keratin plug (",
"    <a class=\"graphic graphic_picture graphicRef59550 \" href=\"UTD.htm?27/25/28051\">",
"     picture 8",
"    </a>",
"    ). The growth of a keratoacanthoma occurs over three to six weeks, in contrast to the slow growth of typical squamous cell carcinomas over months to years. Keratoacanthomas may occur on either sun-damaged or protected skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy regarding whether keratoacanthomas are malignant or benign; although they resemble squamous cell carcinomas histologically, most will spontaneously regress with scar formation. On the other hand, there have been reported cases of invasive keratoacanthoma, some with metastases, leading many authors to consider it a form of squamous cell carcinoma and treat it as such. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=see_link\">",
"     \"Keratoacanthoma: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     WART-LIKE LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Squamous papilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common benign tumor of the eyelid is squamous papilloma, a lesion caused by the human papillomavirus. It presents as a frond-like (skin tag) or lobular projection of skin that contains a central vascular core (",
"    <a class=\"graphic graphic_picture graphicRef76858 \" href=\"UTD.htm?21/9/21652\">",
"     picture 9",
"    </a>",
"    ). Simple excision or cryotherapy is curative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Seborrheic keratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic keratoses appear as greasy, brownish, crust-like lesions \"stuck on\" to the eyelid (",
"    <a class=\"graphic graphic_picture graphicRef67714 \" href=\"UTD.htm?5/15/5363\">",
"     picture 10",
"    </a>",
"    ). They commonly are seen in the elderly. Enlargement occurs outwardly; shave biopsy is usually sufficient for this benign condition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Actinic keratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike seborrheic keratosis, actinic keratosis is a premalignant condition. It predisposes to squamous cell carcinoma in 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/28\">",
"     28",
"    </a>",
"    ]. Lesions are usually dry, scaly, and flat with an erythematous base (",
"    <a class=\"graphic graphic_picture graphicRef71298 \" href=\"UTD.htm?22/20/22850\">",
"     picture 11",
"    </a>",
"    ). Biopsy, followed by surgical excision or cryotherapy, is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cutaneous horn",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cutaneous horn usually presents as a dark protrusion of packed keratin from the surface of the skin (",
"    <a class=\"graphic graphic_picture graphicRef65697 \" href=\"UTD.htm?19/4/19521\">",
"     picture 12",
"    </a>",
"    ). It typically overlies an area of malignancy (basal cell or squamous cell carcinoma). Biopsy of the horn and underlying skin is performed for diagnosis of the underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CYSTIC LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Milia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milia are pinpoint, multiple, firm, white lesions that usually occur on both the upper and lower eyelids. They are caused by the plugging of hair follicles (pilosebaceous units) by keratin. Therapy consists of puncture of the lesions with a pin and expression of the contents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Epidermal inclusion cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;An epidermal inclusion cyst is a solitary, slow growing, mobile, firm, round, subcutaneous nodule most commonly found on the upper eyelid (",
"    <a class=\"graphic graphic_picture graphicRef79621 \" href=\"UTD.htm?18/26/18848\">",
"     picture 13",
"    </a>",
"    ). It typically forms after trauma or surgery, or may be congenital. Cysts can become infected or rupture, causing an inflammatory reaction. Surgical excision with the complete wall of the cyst is recommended to prevent recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Dermoid cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoid cysts are usually recognized in infancy, and often grow during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/30\">",
"     30",
"    </a>",
"    ]. They are firm, mobile, subcutaneous cysts found most commonly in the lateral brow or upper eyelid regions (",
"    <a class=\"graphic graphic_picture graphicRef72727 \" href=\"UTD.htm?20/37/21073\">",
"     picture 14",
"    </a>",
"    ). Attachment to the frontozygomatic skull suture often is present and sometimes can extend far back into the orbit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=see_link&amp;anchor=H3#H3\">",
"     \"Skin nodules in newborns and infants\", section on 'Dermoid cysts and sinuses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Orbital imaging is indicated if the full extent of the cyst cannot be palpated or orbital extension is suspected. Complete excision without disrupting the cyst wall is curative. Cyst rupture will produce an inflammatory response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PIGMENTED LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Benign nevus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most eyelid nevi are acquired, presenting in adolescence or early adulthood. The risk of malignant transformation is about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/31\">",
"     31",
"    </a>",
"    ]. Nevi may be seen at different stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Junctional: flat with nevus cells at the interface of the epidermis and dermis.",
"     </li>",
"     <li>",
"      Compound: the epidermal nevus cells migrate into the dermis and produce skin elevation.",
"     </li>",
"     <li>",
"      Intradermal: the cells lie entirely within the dermis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interesting forms are the divided or kissing nevus (",
"    <a class=\"graphic graphic_picture graphicRef77912 \" href=\"UTD.htm?20/14/20707\">",
"     picture 15",
"    </a>",
"    ), which involves both the upper and lower lids, Congenital Blue nevus, which is flat and smooth and may be removed for cosmetic reasons, and the Nevus of Ota, a large, diffuse nevus of the periocular area seen in blacks and Asians that may predispose to malignant melanoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=see_link&amp;anchor=H21#H21\">",
"     \"Acquired melanocytic nevi (moles)\", section on 'Blue nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H16#H16\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Nevus of Ota'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant melanoma accounts for about 1 percent of all eyelid malignancies but about two-thirds of tumor-related deaths from eyelid malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/32\">",
"     32",
"    </a>",
"    ]. Cutaneous melanomas can be classified into subgroups: lentigo maligna melanoma (5 percent), superficial spreading melanoma (70 percent), and nodular melanoma (16 percent) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    ). On the eyelid, however, the nodular variety is the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lentigo maligna presents as a flat melanotic lesion with irregular borders. The superficial spreading melanoma lesion is usually smaller with elevation. Both of these forms typically have a long phase of superficial growth before invasion into deeper tissues. Nodular melanoma is more aggressive and may present as a pigmented or amelanotic nodule that grows rapidly and begins to bleed.",
"   </p>",
"   <p>",
"    Excessive sun exposure, genetic factors, Caucasian race, and changing skin nevi are the biggest risk factors for this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wide surgical excision with regional lymph node dissection if extension is suspected remains the only accepted treatment for cutaneous melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VASCULAR LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Port wine stain or nevus flammeus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The port wine stain (also called nevus flammeus) is a cavernous hemangioma consisting of dilated blood vessels. It is associated with the Sturge-Weber syndrome. This lesion is congenital and usually covers the eye and nearby facial skin, typically in the distribution of a branch of the trigeminal nerve (",
"    <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"     picture 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73978 \" href=\"UTD.htm?0/45/722\">",
"     picture 17",
"    </a>",
"    ). It does not blanch with pressure. It may be associated with ocular and leptomeningeal vascular hamartomas as well as glaucoma and retinal detachment. Argon laser therapy has been somewhat successful at removing these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link\">",
"     \"Sturge-Weber syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Superficial hemangiomas of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial hemangiomas of infancy (replacing the older term \"capillary hemangioma\") occur in 1 to 2 percent of children, with girls more often affected than boys. This benign tumor usually is present at birth or manifests by six months of age. It consists of a bright red papule, nodule, or plaque raised above clinically normal skin. Superficial hemangiomas are believed to be hamartomatous proliferations of vascular endothelial cells. Approximately seventy percent will spontaneously regress by the age of seven years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the propensity of the tumor to shrink on its own, treatment is usually limited to large tumors and those that may cause the lid to occlude the pupil. Continued occlusion could lead to amblyopia and subsequent strabismus. Treatments include intralesional steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/35\">",
"     35",
"    </a>",
"    ], radiotherapy, laser therapy, surgery, and rarely systemic steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of amblyopia\", section on 'Deprivational amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma is an aggressive, reddish, highly vascular, elevated mass that is seen most often in patients with AIDS (",
"    <a class=\"graphic graphic_picture graphicRef80323 \" href=\"UTD.htm?31/35/32307\">",
"     picture 18",
"    </a>",
"    ). It can also be seen rarely in elderly men from Mediterranean regions. The tumor may be lymphatic or viral in origin. Some spontaneously resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4088/abstract/36\">",
"     36",
"    </a>",
"    ]. Cryotherapy, intralesional chemotherapy, surgical excision, and irradiations have been used with varied success with this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34417?source=see_link\">",
"       \"Patient information: Stye (hordeolum) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/51/818?source=see_link\">",
"       \"Patient information: Seborrheic keratosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/56/18305?source=see_link\">",
"       \"Patient information: Chalazion (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyelid lesions may be benign or malignant. The primary care clinician should be able to distinguish potentially malignant lesions, and arrange appropriate referral (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Benign nodular lesions include xanthelasma, chalazion, hordeolum, and molluscum contagiosum. Xanthelasma, yellow cholesterol-filled plaques, are associated with hyperlipidemia in 50 percent of affected patients. Chalazia, hard granulomata may require hot compress application, glucocorticoid injection, or incision and curettage. A hordeolum is an acute purulent inflammation, usually responsive to warm compresses. Molluscum contagiosum, characterized by shiny nodules with central umbilication, may resolve spontaneously within one year. Patients with benign lesions unresponsive to usual treatment should be referred to ophthalmology for confirmation of diagnosis and further treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Benign nodular lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common malignant eyelid tumor is a basal cell carcinoma. Squamous cell carcinomas occur as nodules or plaques, usually on the lower lid. Treatment for either condition is by Mohs' chemosurgery or excision. Sebaceous carcinoma may initially resemble a chalazion on the upper eyelid but, in a progressed state, may cause loss of lashes; wide excision is indicated. Keratoacanthomas grow over three to six weeks; while some may spontaneously regress, they are best treated similarly to squamous cell carcinoma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Malignant nodular lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wart-like lesions include the benign conditions, squamous papilloma and seborrheic keratoses. Actinic keratosis is premalignant and requires excision or cryotherapy. Cutaneous horns may develop overlying a basal cell or squamous cell cancer. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Wart-like lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of malignant transformation of benign pigmented eyelid nevi is about 5 percent. Malignant melanoma are infrequent (1 percent of all eyelid malignancies) but have significant mortality. Treatment is by wide excision, with regional lymph node dissection if extension is suspected. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Pigmented lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/1\">",
"      Vinger PF, Sachs BA. Ocular manifestations of hyperlipoproteinemia. Am J Ophthalmol 1970; 70:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/2\">",
"      Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994; 30:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/3\">",
"      Segal P, Insull W Jr, Chambless LE, et al. The association of dyslipoproteinemia with corneal arcus and xanthelasma. The Lipid Research Clinics Program Prevalence Study. Circulation 1986; 73:I108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/4\">",
"      Watanabe A, Yoshimura A, Wakasugi T, et al. Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 1981; 38:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/5\">",
"      Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 1996; 23:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/6\">",
"      Haygood LJ, Bennett JD, Brodell RT. Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg 1998; 24:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/7\">",
"      Doi H, Ogawa Y. A new operative method for treatment of xanthelasma or xanthoma palpebrarum: microsurgical inverted peeling. Plast Reconstr Surg 1998; 102:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/8\">",
"      Raulin C, Schoenermark MP, Werner S, Greve B. Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med 1999; 24:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/9\">",
"      Ben Simon GJ, Huang L, Nakra T, et al. Intralesional triamcinolone acetonide injection for primary and recurrent chalazia: is it really effective? Ophthalmology 2005; 112:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/10\">",
"      Lindsley K, Nichols JJ, Dickersin K. Interventions for acute internal hordeolum. Cochrane Database Syst Rev 2010; :CD007742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/11\">",
"      Waugh MA. Molluscum contagiosum. Dermatol Clin 1998; 16:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/12\">",
"      Bardenstein DS, Elmets C. Hyperfocal cryotherapy of multiple Molluscum contagiosum lesions in patients with the acquired immune deficiency syndrome. Ophthalmology 1995; 102:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/13\">",
"      Margo CE, Waltz K. Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol 1993; 38:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/14\">",
"      Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999; 106:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/15\">",
"      Doxanas MT, Green WR, Iliff CE. Factors in the successful surgical management of basal cell carcinoma of the eyelids. Am J Ophthalmol 1981; 91:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/16\">",
"      Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology 2001; 108:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/17\">",
"      Mohs FE. Micrographic surgery for the microscopically controlled excision of eyelid cancers. Arch Ophthalmol 1986; 104:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/18\">",
"      Frank HJ. Frozen section control of excision of eyelid basal cell carcinomas: 8 1/2 years' experience. Br J Ophthalmol 1989; 73:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/19\">",
"      Buschmann W. A reappraisal of cryosurgery for eyelid basal cell carcinomas. Br J Ophthalmol 2002; 86:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/20\">",
"      Reifler DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol 1986; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/21\">",
"      Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004; 111:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/22\">",
"      Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol 1989; 33:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/23\">",
"      Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol 1984; 102:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/24\">",
"      Z&uuml;rcher M, Hintschich CR, Garner A, et al. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol 1998; 82:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/25\">",
"      Muqit MM, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond) 2004; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/26\">",
"      Hornblass A, Lauer SA. Sebaceous carcinoma of the eyelids. Ophthalmology 2004; 111:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/27\">",
"      Scully JP. Treatment of seborrheic keratosis. JAMA 1970; 213:1498.",
"     </a>",
"    </li>",
"    <li>",
"     Scott KR, Kronish JW. Premalignant lesions and squamous cell carcinoma. In: Principles and practice of ophthalmology: clinical practice, Albert DM, Jakobiec FA (Eds), WB Saunders, Philadelphia 1994. Vol 3, p.1733.",
"    </li>",
"    <li>",
"     Folberg R. Eyelids: Terminology of eyelid pathology. In: Pathology of the eye (CDROM), Folberg R (Ed), Mosby-Year Book, St. Louis 1996.",
"    </li>",
"    <li>",
"     Weiss RD. Orbital disease. In: Oculoplastic Surgery, 3rd ed, McCord CD, Tanenbaum M, Nunery WR (Eds), Raven Press, New York 1995. p.417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/31\">",
"      Margo CE, Habal MB. Large congenital melanocytic nevus. Light and electron microscopic findings. Ophthalmology 1987; 94:960.",
"     </a>",
"    </li>",
"    <li>",
"     McCormick SA, DeLuca RL. Tumors of melanocytic origin. In: Eye and skin disease, Mannis MJ, Macsai MS, Huntley AC (Eds), Lippincott-Raven, Philadelphia 1996. p.381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/33\">",
"      Garner A, Koornneef L, Levene A, Collin JR. Malignant melanoma of the eyelid skin: histopathology and behaviour. Br J Ophthalmol 1985; 69:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/34\">",
"      Dummer R, Graf P, Greif C, Burg G. Treatment of vascular lesions using the VersaPulse variable pulse width frequency doubled neodymium:YAG laser. Dermatology 1998; 197:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/35\">",
"      Kushner BJ. Intralesional corticosteroid injection for infantile adnexal hemangioma. Am J Ophthalmol 1982; 93:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4088/abstract/36\">",
"      Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol 1990; 22:1237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6898 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4088=[""].join("\n");
var outline_f3_63_4088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENIGN NODULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Xanthelasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chalazion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hordeolum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MALIGNANT NODULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sebaceous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      WART-LIKE LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Squamous papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Seborrheic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cutaneous horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CYSTIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Milia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Epidermal inclusion cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Dermoid cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PIGMENTED LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Benign nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VASCULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Port wine stain or nevus flammeus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Superficial hemangiomas of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6898|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23778\" title=\"picture 1\">",
"      Xanthelasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/21/31058\" title=\"picture 2\">",
"      Chalazion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/54/2916\" title=\"picture 3\">",
"      Hordeolum stye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/42/7841\" title=\"picture 4\">",
"      Mollusca contagiosa in HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/22/16739\" title=\"picture 5\">",
"      Basal cell carcinoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/42/9891\" title=\"picture 6\">",
"      Squamous cell carcinoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/20/15685\" title=\"picture 7\">",
"      Sebaceous cell carcinoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/25/28051\" title=\"picture 8\">",
"      Keratoacanthoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/9/21652\" title=\"picture 9\">",
"      Squamous papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/15/5363\" title=\"picture 10\">",
"      Seborrheic keratosis eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/20/22850\" title=\"picture 11\">",
"      Actinic keratosis eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/4/19521\" title=\"picture 12\">",
"      Cutaneous horn eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18848\" title=\"picture 13\">",
"      Epidermal cysts on eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/37/21073\" title=\"picture 14\">",
"      Dermoid cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/14/20707\" title=\"picture 15\">",
"      Kissing nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/53/22367\" title=\"picture 16\">",
"      Adult with SWS and port wine stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/45/722\" title=\"picture 17\">",
"      Port wine stain - V2 child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/35/32307\" title=\"picture 18\">",
"      Kaposis sarcoma eyelid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39045?source=related_link\">",
"      Eyelid lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=related_link\">",
"      Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=related_link\">",
"      Keratoacanthoma: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/56/18305?source=related_link\">",
"      Patient information: Chalazion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/51/818?source=related_link\">",
"      Patient information: Seborrheic keratosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34417?source=related_link\">",
"      Patient information: Stye (hordeolum) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=related_link\">",
"      Skin nodules in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4089="Placental infections";
var content_f3_63_4089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placental infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Drucilla J Roberts, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4089/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/63/4089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta and fetal membranes are the interface between the fetal graft and the maternal host. This interface has two vulnerable portals for passage of infectious agents from mother to fetus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fetal membranes overlying the cervix provide direct access to pathogens ascending from the vagina and cervix",
"     </li>",
"     <li>",
"      The placental intervillous space and fetal villi provide hematogenous access",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly, infectious agents enter the uterus as a result of invasive procedures (eg, amniocentesis, fetoscopy, cordocentesis, chorionic villus sampling) or via the fallopian tubes from an infectious process in the peritoneal cavity.",
"   </p>",
"   <p>",
"    Histological examination of the placenta after delivery can often document the presence of intrauterine infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/1\">",
"     1",
"    </a>",
"    ], the portal of access, and the fetal or maternal immunological response, if present. The placental aspects of infection will be reviewed here. The diagnosis, prognosis, and treatment of obstetrical and neonatal infections are discussed elsewhere (see individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASCENDING INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the most common route for intrauterine infection. The cervix, mucous plug, fetal membranes, and maternal immune system together generally form an effective barrier to the intrauterine migration of normal and pathogenic cervicovaginal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/2\">",
"     2",
"    </a>",
"    ]. However, this barrier is not impermeable, especially in cases of premature rupture of membranes or cervical insufficiency.",
"   </p>",
"   <p>",
"    Infectious pathogens that ascend through the cervix may be confined to the fetal membranes or may infect the amniotic fluid, fetus, and parenchyma of the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/3\">",
"     3",
"    </a>",
"    ]. The process can occur with either intact or ruptured fetal membranes and prior to or during labor. As an example, in one large review of women with intact membranes undergoing cesarean delivery, approximately 30 percent of those in labor and 15 percent of those not in labor had positive chorioamniotic cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/4\">",
"     4",
"    </a>",
"    ]. One half of these women also had organisms in the amniotic fluid, but only a small number of fetuses were infected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of the chorion laeve and amnion (ie, chorioamnionitis) is the most frequent histopathological result of ascending transcervical infection and occurs with both symptomatic and silent infections (",
"    <a class=\"graphic graphic_picture graphicRef56454 \" href=\"UTD.htm?0/35/562\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study of 1252 placentas from a high-risk population, histologic evidence of chorioamnionitis was found in 40 percent of patients with clinically apparent infection at delivery and in 15 percent of asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/6\">",
"     6",
"    </a>",
"    ]. Chorioamnionitis was diagnosed in 6 percent of 43,940 deliveries evaluated in the Collaborative Perinatal Project [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/7\">",
"     7",
"    </a>",
"    ]. The rate increased with decreasing gestational age: 15 percent at 28 to 32 weeks; 8 percent at 33 to 36 weeks; and 5 percent after 36 weeks of gestation. Similarly, another series describing the histopathology of 3928 placentas from pregnancies at 20 to 34 weeks of gestation found histologic chorioamnionitis in 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence fell from 50 to 65 percent before 28 weeks to 16 percent at 34 weeks.",
"   </p>",
"   <p>",
"    These studies are from high risk individuals and have broad diagnostic criteria for the diagnosis of chorioamnionitis (see below). Some studies have suggested that the rate of histologically confirmed chorioamnionitis at term in healthy women is likely to be significantly lower and much less strongly associated with amnionic infections. Term histologic chorioamnionitis may be related to clinical factors other than infection, such as epidural anesthesia, and may reflect an individual's cytokine response to a stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic diagnosis of chorioamnionitis requires that the inflammatory infiltrate involve either or both the chorion and the amnion (",
"    <a class=\"graphic graphic_picture graphicRef51447 graphicRef54320 \" href=\"UTD.htm?40/43/41657\">",
"     picture 2A-B",
"    </a>",
"    ). The inflammatory cells are usually maternal leukocytes, but mixed cell types also occur. Although it is normal to find a mixed inflammatory cell infiltrate in the maternal decidua, especially if there has been labor, inflammatory cells in the membranes or in the villi are pathological.",
"   </p>",
"   <p>",
"    Chorioamnionitis or inflammation in the membranes can be either acute (neutrophils) or chronic (mononuclear cells, eg, plasma cells). Acute chorioamnionitis is more common than chronic. The acute form is usually mediated by bacteria, while chronic chorioamnionitis can be due to an abnormal immune reaction, a viral or protozoal infection, or, in most cases, an unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute chorioamnionitis is associated with an acute inflammatory infiltrate typically consisting of neutrophils or a mixture of neutrophils and mononuclear cells; eosinophils also may be present. The infiltrate involves one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chorionic plate",
"     </li>",
"     <li>",
"      Amnion of the placental membranes",
"     </li>",
"     <li>",
"      Fetal surface of the placental disk (",
"      <a class=\"graphic graphic_picture graphicRef54320 \" href=\"UTD.htm?0/40/645\">",
"       picture 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional feature may include inflammatory infiltrate of the vascular portion of the umbilical cord or Wharton's jelly. There is a 70 to 90 percent correlation between the presence of leukocytes in the fetal membranes and associated placental and funic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/11\">",
"     11",
"    </a>",
"    ]. Fetal membranes also occasionally contain a large number of eosinophils; these are likely to be fetal inflammatory cells.",
"   </p>",
"   <p>",
"    Inflammatory infiltrates in the maternal decidua and confined to the chorionic epithelium can be normal. Decidua usually has an inflammatory infiltrate, typically leukocytic or mixed",
"    <span class=\"nowrap\">",
"     leukocytic/monocytic,",
"    </span>",
"    during all stages of gestation and labor may induce inflammatory cell migration into the chorion. In contrast, plasma cells are",
"    <strong>",
"     not",
"    </strong>",
"    normally present and should be considered pathological.",
"   </p>",
"   <p>",
"    The clinical diagnosis of chorioamnionitis is not always confirmed by histological or microbiological studies. In one study of 139 pregnancies with clinical findings of chorioamnionitis, histologic examination of the placenta did not support the clinical diagnosis in approximately one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/12\">",
"     12",
"    </a>",
"    ]. The investigators suggested that noninflammatory events (eg, epidural anesthesia, abruption) could be responsible for maternal fever, tachycardia, uterine tenderness, or foul smelling amniotic fluid. We believe that clinically significant chorioamnionitis diagnosed histopathologically should be reserved for those cases with significant inflammation: diffuse or multifocal involvement of the membranes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chorionic plate with large numbers of inflammatory cells present. Minute foci of &lt;10 neutrophils in the membranes should be ignored.",
"   </p>",
"   <p>",
"    Conversely, histological evidence of placental inflammation may not always be associated with microbiological evidence of an infectious organism. Cultures of the amniotic fluid or membranes do not document a bacterial infection in 25 to 30 percent of placentas with histologic chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Negative cultures in the presence of histologic inflammation may be due to suboptimal microbiological techniques for fastidious organisms such as Mycoplasma sp., administration of intrapartum antibiotics, or a noninfectious process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the neutrophilic infiltrate that characterizes acute chorioamnionitis, chronic chorioamnionitis is associated with a mononuclear infiltrate in the amnion and chorion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine infection is often polymicrobial; the bacteria most commonly cultured are: Streptococcus sp., Escherichia coli, Ureaplasma sp., Fusobacterium sp., Mycoplasma sp., and anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/5\">",
"     5",
"    </a>",
"    ]. Fungal infections are typically introduced via an ascending route, but this is an uncommon pathway for most viruses (other than genital pathogens after membrane rupture). The characteristic features of selected specific pathogens are discussed individually below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies have suggested several risk factors associated with histological",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical chorioamnionitis (",
"    <a class=\"graphic graphic_table graphicRef68158 \" href=\"UTD.htm?17/9/17563\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]. The extreme heterogeneity among these reports is the result of diverse patient populations, interdependent risk factors, dissimilar microbiologic techniques, and different criteria for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorioamnionitis is an important factor in perinatal and maternal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/14\">",
"     14",
"    </a>",
"    ]. Sequelae of chorioamnionitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature rupture of membranes",
"     </li>",
"     <li>",
"      Premature labor",
"     </li>",
"     <li>",
"      Prolonged labor",
"     </li>",
"     <li>",
"      Premature delivery",
"     </li>",
"     <li>",
"      Fetal and newborn infection",
"     </li>",
"     <li>",
"      Endomyometritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic chorioamnionitis also appears to be a marker of fetal growth restriction, particularly among infants born before 33 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fetal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascending genital tract infections induce fetal infection by infiltrating the chorionic plate or umbilical cord vessels and spreading hematogenously to the fetus or by infecting the amniotic fluid and gaining access to the fetal gastrointestinal or respiratory tract when the fetus swallows or \"breathes\". Alternatively, infectious agents in the amniotic fluid may enter the fetus through the skin. Since the immature fetal immune system is compromised by its inability to efficiently defend against infectious pathogens, overwhelming sepsis can occur in spite of prompt antibiotic treatment before or after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link&amp;anchor=H18#H18\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Fetal and neonatal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INFECTIONS FROM HEMATOGENOUS SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood borne maternal pathogens that reach the uteroplacental circulation and intervillous space can seed the fetus via the villous capillaries. Before the disease is widespread, hematogenously disseminated infections can often be distinguished from ascending ones by the location of inflammation. Isolated chorioamnionitis is characteristic of ascending infection while a hematogenous source displays greater inflammation of the villi (ie, villitis) and intervillous space (ie, intervillositis).",
"   </p>",
"   <p>",
"    The exact mechanism for transplacental passage of infectious agents is not known. The infectious agent may cross the trophoblastic barrier by endocytosis, or via an injured villous surface. As an example, two mechanisms have been described for malarial placentitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subpopulation of parasite-infected red blood cells (RBCs) adhere to chondroitin 4-sulfate on the surface of trophoblastic villi [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/17\">",
"       17",
"      </a>",
"      ]. RBCs of this phenotype become sequestered and multiply in the intervillous spaces, eliciting the accumulation of inflammatory leukocytes and necrosis of adjacent placental tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malarial parasites alter the erythrocyte membrane so that it sticks to hyaluronic acid, whose concentration is especially high on the surface of trophoblastic villi [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/19\">",
"       19",
"      </a>",
"      ]. This process appears to be facilitated by the low pressure environs of the intervillous space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral pathogens most commonly produce hematogenous infection of the placenta, although bacteria, spirochetes, fungi, and protozoa can also cause infection via this route. Almost any viral infection that occurs during pregnancy can infect the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic histologic finding in hematogenously spread placentitis is chronic villitis, although most chronic villitis is",
"    <strong>",
"     not",
"    </strong>",
"    due to an infectious etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link&amp;anchor=H18#H18\">",
"     \"Histopathology of placental disorders\", section on 'Villitis'",
"    </a>",
"    .) Villitis is typically a histologic diagnosis and is not apparent grossly, unless there is abscess formation. Chronic villitis is usually multifocal and has the following histologic features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased cellularity of the villi",
"     </li>",
"     <li>",
"      Sclerosis of the villi due to collapse of the villous vessels",
"     </li>",
"     <li>",
"      Clumping of the involved villi",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On low power histopathology, these changes will appear as multifocal clusters of dark blue cellular avascular villi, often clumped together and surrounded by fibrin (",
"    <a class=\"graphic graphic_picture graphicRef64413 \" href=\"UTD.htm?37/4/37958\">",
"     picture 3",
"    </a>",
"    ). The inflammatory infiltrate in viral infections is typically mononuclear and can contain plasma cells or giant cells. The inflammatory cells are maternal in origin and may \"spill out\" of the villi to cause an intervillositis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/21\">",
"     21",
"    </a>",
"    ]. At higher magnification, a viral inclusion (eg, cytomegalovirus) (",
"    <a class=\"graphic graphic_picture graphicRef70713 \" href=\"UTD.htm?2/7/2164\">",
"     picture 4",
"    </a>",
"    ), granuloma, or giant cells may be detected that help to determine a more precise etiology for the infection.",
"   </p>",
"   <p>",
"    By comparison, an acute inflammatory infiltrate in the villi is observed in syphilis, listeriosis and other bacterial infections of the placenta. The inflammatory cells are primarily maternal leukocytes, but mixed cell types also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY OF SPECIFIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic features of the histopathology associated with the more common placental infections is described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600473\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental pathology in malaria can be striking because the pigment-laden maternal red blood cells and macrophages aggregate in the intervillous space. In some cases, the placenta \"sequesters\" the organisms, thus making the placenta look like a malarial abscess (",
"    <a class=\"graphic graphic_picture graphicRef51415 \" href=\"UTD.htm?22/7/22648\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. There is a strong association between placental malarial sequestration and congenital malarial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/24\">",
"     24",
"    </a>",
"    ]",
"    <br/>",
"    <br/>",
"    The infected red blood cells impair oxygen transfer from mother to fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This effect is exacerbated by concurrent maternal anemia due to malaria, and often by other maternal morbidities, particularly",
"    <span class=\"nowrap\">",
"     HIV/AIDs",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of the infected red blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pigment in hematopoietic cells in the fetal circulation is diagnostic of congenital infection. Grading and staging schema have been described, generally for P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/30\">",
"     30",
"    </a>",
"    ], although P. vivax likely also shows some of these features [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/31\">",
"     31",
"    </a>",
"    ]. The onset of clinical signs and symptoms in the infant is often delayed by several days and up to months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is the most common congenital viral infection, affecting approximately 1 percent of live births. Intrauterine growth restriction, severe clinical sequelae, and death can occur, although most congenital infections are subclinical at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic histopathological findings in the placenta include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphoplasmacytic villitis",
"     </li>",
"     <li>",
"      Sclerosis of the villous capillaries",
"     </li>",
"     <li>",
"      Chorionic vessel thromboses",
"     </li>",
"     <li>",
"      Necrotizing villitis",
"     </li>",
"     <li>",
"      Hemosiderin deposition in the villous stroma",
"     </li>",
"     <li>",
"      Normoblastemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral inclusions (",
"    <a class=\"graphic graphic_picture graphicRef70713 \" href=\"UTD.htm?2/7/2164\">",
"     picture 4",
"    </a>",
"    ), which can be subtle, are observed in 10 percent of cases, but are more often visible in cases associated with stillbirth. Immunohistochemistry will detect many inclusions not identified with routine hematoxylin-eosin stains.",
"   </p>",
"   <p>",
"    In one study that used molecular methods to identify CMV, 16 percent of the 130 stillbirths &gt;20 weeks gestational age evaluated showed evidence of CMV DNA in either or both fetal",
"    <span class=\"nowrap\">",
"     organs/tissues",
"    </span>",
"    and placental tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/34\">",
"     34",
"    </a>",
"    ]. When immunohistochemistry was used to confirm CMV infection, 75 percent of cases showed immunoreactivity. The authors stated that often the only placental findings were fetal thrombotic vasculopathy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    ), which is a very common finding in all placentas from non-recent fetal demise (ie, a fetal demise that occurred two or more days before histopathological examination) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis of latent viral infections in the endometrium leading to infection of the placenta and pregnancy loss is not new [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Detection of viral DNA via molecular or immunohistochemistry in autolyzed tissue is difficult to interpret. To attribute fetal demise to congenital infection, there should be documentation of clean controls, additional findings suggestive of infection (eg, inflammation), and a plausible clinical correlation. Many nuclear histologic findings are due to autolysis alone and may be interpreted (even with molecular techniques) as &ldquo;viral inclusions,&rdquo; which I believe likely accounts for many of the findings reported in this study and others [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/38\">",
"     38",
"    </a>",
"    ]. Infection postmortem is another possibility. Additional studies reproducing these findings in other populations are needed to determine whether the prevalence of CMV in stillbirths is as high as reported in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/34\">",
"     34",
"    </a>",
"    ] and a causal factor in the demise.",
"   </p>",
"   <p>",
"    We recommend immunohistochemistry of the placenta in all stillbirths, sick neonates (eg, unexplained petechiae, hepatosplenomegaly, jaundice, ocular defects), and placentas with chronic villitis. Features predictive of congenital CMV infection include: prematurity, persistent normoblastemia, diffuse chronic villitis with plasma cells, plasma cell deciduitis, chorionic plate vascular thromboses, thick placenta (&gt;3.5 cm in maximal thickness of the disk), and hemosiderin in the villi. Three or more of these features warrant either additional investigation with immunohistochemistry, or preferably, maternal clinical evaluation and CMV titers. We do not employ immunohistochemistry on all cases of villitis, as it is not cost-effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal candidiasis is common, but intrauterine candidal infections are rare. Unlike most ascending infections, intrauterine candidiasis often occurs without rupture of the fetal membranes. The specific maternal risk factors associated with intrauterine candidal infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Sickle cell disease",
"     </li>",
"     <li>",
"      Presence of a cerclage",
"     </li>",
"     <li>",
"      Retained intrauterine contraceptive device",
"     </li>",
"     <li>",
"      Immunocompromise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe funisitis (ie, inflammation of the umbilical cord) and acute chorioamnionitis without villitis are the hallmarks of candidal infection. Grossly, the classic finding is multiple small green",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white abscesses on the surface of the umbilical cord. Microscopically, microabscesses with hyphae are usually present only on the cord's surface, but invasion into Wharton's jelly can occur (",
"    <a class=\"graphic graphic_picture graphicRef58878 graphicRef74230 \" href=\"UTD.htm?18/29/18905\">",
"     picture 6A-B",
"    </a>",
"    ). The presence of invasive hyphae in the cord is a risk factor for hematogenous dissemination to the fetus, in whom infection is rare and often catastrophic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fusobacterium",
"    </span>",
"    &nbsp;&mdash;&nbsp;This gram negative anaerobe has a strong association with acute chorioamnionitis and appears to play a role in the pathogenesis of spontaneous preterm birth, but is not a cause of neonatal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Histopathology shows a severe, typically necrotizing, infiltrate (",
"    <a class=\"graphic graphic_picture graphicRef53331 \" href=\"UTD.htm?18/47/19189\">",
"     picture 7",
"    </a>",
"    ). Long filamentous fusiform bacilli can be readily identified with standard hematoxylin-eosin or bacterial stains (eg, Gram).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major mode of human immunodeficiency virus (HIV) transmission to children worldwide is perinatal acquisition. Data suggest that most transmission occurs near the time of or during delivery and can be reduced by intrapartum administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. For the smaller number of fetuses infected earlier in pregnancy, ZDV may reduce transplacental infection by inhibiting HIV replication within placental cells, since ZDV is metabolized into its active triphosphate form in the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/43\">",
"     43",
"    </a>",
"    ]. Newer antiretroviral agents appear to have even better efficacy for preventing transplacental infection.",
"   </p>",
"   <p>",
"    One focus of investigation has been to identify a pathologic lesion in the placenta that would predict transplacental transmission of HIV. Many large studies have documented that the presence of acute, nonspecific chorioamnionitis is related to an increased risk of congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/42,44,45\">",
"     42,44,45",
"    </a>",
"    ]. Chronic villitis and chorangiosis also may play a role in transplacental infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/46\">",
"     46",
"    </a>",
"    ]. Most HIV-positive pregnant women who are treated with ZDV during pregnancy will have normal placentas and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital herpes simplex virus (HSV) infection typically results from direct fetal exposure to infected cervicovaginal secretions during labor and vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/48\">",
"     48",
"    </a>",
"    ]. In utero disease from transplacental or ascending infection has been reported anecdotally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placental histopathology has the following features (",
"    <a class=\"graphic graphic_picture graphicRef52458 \" href=\"UTD.htm?26/10/26791\">",
"     picture 8",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma cell deciduitis (often the most prominent finding)",
"     </li>",
"     <li>",
"      Necrotizing funisitis",
"     </li>",
"     <li>",
"      Lymphoplasmacytic villitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Demonstration of the virus by immunohistochemistry or by molecular techniques is necessary for diagnosis, since the above findings are nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Listeria monocytogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;L. monocytogenes are aerobic and facultatively anaerobic, short Gram positive rods, which produce beta-hemolysis when grown on blood agar plates. Listerial infection may precipitate labor, leading to premature birth of an infected or dead baby.",
"   </p>",
"   <p>",
"    A characteristic severe in-utero infection, granulomatosis infantiseptica, may result from transplacental transmission. Infants with this disorder have disseminated abscesses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    granulomas in multiple internal organs (liver, spleen, lungs, kidneys, brain). Skin lesions, papular or ulcerative, may develop. Most neonates with granulomatosis infantiseptica are stillborn or die soon after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=see_link\">",
"     \"Epidemiology and pathogenesis of Listeria monocytogenes infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Listeriosis has a predilection for the placenta and fetal central nervous system, although the pathogenesis is not well understood. The placental pathology is distinctive as there is both a pronounced chorioamnionitis and an acute villitis with abscess formation (",
"    <a class=\"graphic graphic_picture graphicRef61548 \" href=\"UTD.htm?7/49/7959\">",
"     picture 9",
"    </a>",
"    ). The organisms are often visible within the amnion epithelium without special stains, but are clearly demonstrated with gram or silver stains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Streptococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both group B and A streptococci can produce placental infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Group B streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS; Streptococcus agalactiae) is a gram positive coccus that frequently colonizes the human genital and gastrointestinal tracts. It can cause chorioamnionitis, postpartum endometritis, and sepsis in the mother; the neonate is at risk for generalized sepsis, pneumonia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"     \"Group B streptococcal infection in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no specific placental histopathologic features of GBS infection. Funisitis accompanies up to one third of cases with chorioamnionitis. However, histopathology often does not show chorioamnionitis, despite well-documented cases of neonatal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/50\">",
"     50",
"    </a>",
"    ]. This may be due to the virulence of even short-term fetal exposure to GBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Group A streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcus (GAS) can cause fulminant maternal infection and death [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/51\">",
"     51",
"    </a>",
"    ]. GAS appears to invade the myometrium as a result of bacteremia associated with nongenital tract infection (eg, upper respiratory tract). The predominant histopathologic feature is acute purulent myometritis. This infection is different from classical puerperal sepsis because the illness typically starts before delivery, without evidence of an ascending bacterial infection (eg, acute endometritis or chorioamnionitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from Treponema pallidum infections occur at all stages of pregnancy and include spontaneous abortion, stillbirth, hydrops fetalis, and congenital syphilis. Hematogenous dissemination of the spirochetes can seed the placenta and, subsequently, the fetus. The stigmata of congenital syphilis appear to be based upon the ability of the fetal immune system to respond to the organism. The immunological incompetence of the first trimester (and possibly early second trimester) fetus may prevent anatomic defects related to inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic placental findings include (",
"    <a class=\"graphic graphic_picture graphicRef59074 \" href=\"UTD.htm?27/17/27929\">",
"     picture 10",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hydrops placentalis",
"     </li>",
"     <li>",
"      Chronic villitis (plasma cells, mixed acute and chronic infiltrate)",
"     </li>",
"     <li>",
"      Perivillous fibrous proliferation (onion skin vessels)",
"     </li>",
"     <li>",
"      Normoblastemia",
"     </li>",
"     <li>",
"      Necrotizing funisitis",
"     </li>",
"     <li>",
"      Acute chorioamnionitis",
"     </li>",
"     <li>",
"      Plasma cell deciduitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Silver stain should reveal the spirochetes, but these are often very difficult to identify. The best yield is often in the decidua basalis or capsularis where there are plasma cells or, in cases of fetal death, in the vitreous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal parasitemia from Toxoplasma gondii occurs during the initial stage of infection and is usually asymptomatic. The risk of placental colonization appears to be related to the volume of uteroplacental blood flow, maternal immunocompetence, and parasitemia. Placental infection is more common with advancing gestational age at the time of maternal parasitemia. A prospective study involving 542 women who acquired toxoplasmosis during the first, second, and third trimesters of pregnancy reported congenital toxoplasmosis in approximately 14, 30, and 60 percent of offspring, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the risk appears to be lower in the periconceptional period and even higher near term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The placental findings of toxoplasmosis include (",
"    <a class=\"graphic graphic_picture graphicRef52889 \" href=\"UTD.htm?11/19/11576\">",
"     picture 11",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Granulomatous villitis",
"     </li>",
"     <li>",
"      Cysts",
"     </li>",
"     <li>",
"      Plasma cell deciduitis",
"     </li>",
"     <li>",
"      Villous sclerosis",
"     </li>",
"     <li>",
"      Chorionic vascular thromboses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Free trophozoites may be observed in villous stroma, amniotic epithelium, chorion, and Wharton's jelly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mycoplasma hominis and Ureaplasma urealyticum",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether these infectious agents have a role in human reproductive pathology; however, their pathogenicity in other animal species has been well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. M. hominis has been isolated from numerous women with premature labor and severe chorioamnionitis and from approximately 30 percent of children with birth weights below 2500 g who are born by cesarean delivery with intact membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/56\">",
"     56",
"    </a>",
"    ]. Although these observations suggest that intrauterine colonization or infection is common, the role of M. hominis as a cause of premature labor, stillbirth, abortion, and placentitis remains incompletely understood and is of debatable significance. In addition, cases in which one of these pathogens was isolated from the placenta typically showed either no histopathology or nonspecific acute chorioamnionitis. Since these pathogens are rarely isolated in the absence of other common bacterial pathogens, their contribution to pregnancy complications is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chlamydia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia infection during pregnancy appears to be associated with both obstetrical and neonatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. As an example, in one large study 21 percent of patients who had a positive C. trachomatis culture at their first prenatal visit, of whom 46 percent were treated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/57\">",
"     57",
"    </a>",
"    ]. Compared to those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or those with negative cultures, the untreated colonized patients had significantly more pregnancy complications and adverse outcomes, including premature rupture of the membranes, low birth weight, and neonatal mortality. However, genital tract colonization with C. trachomatis is not a risk factor for histologic chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/59\">",
"     59",
"    </a>",
"    ]. C. trachomatis has been demonstrated only rarely in the human placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, Chlamydia psittaci does infect the placenta and can cause significant fetomaternal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Placental histopathologic findings consist of an intense, acute intervillositis, perivillous fibrin deposition with villous necrosis, and large irregular basophilic intracytoplasmic inclusions within the syncytiotrophoblast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/63\">",
"     63",
"    </a>",
"    ]. These changes can impair fetoplacental blood flow and enable embolization of bacteria to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4089/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=see_link\">",
"     \"Psittacosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Most placental infections arise from pathogens that ascend from the vagina and go through the cervix. These pathogens may be confined to the fetal membranes (chorioamnionitis) or may infect the amniotic fluid, fetus, and placenta. They are associated with a variety of maternal and fetal complications. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Ascending infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Blood borne maternal pathogens that reach the uteroplacental circulation and intervillous space can seed the fetus via the villous capillaries. Viral pathogens most commonly produce hematogenous infection of the placenta, although bacteria, spirochetes, fungi, and protozoa can also cause infection via this route. Almost any viral infection that occurs during pregnancy can infect the placenta. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Infections from hematogenous spread'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Individual infections have characteristic histopathologic features.(See",
"    <a class=\"local\" href=\"#H12\">",
"     'Histopathology of specific infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest placental examination by a pathologist when infection is being considered as a causal or contributing factor for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preterm delivery",
"     </li>",
"     <li>",
"      Fetal tachycardia",
"     </li>",
"     <li>",
"      Maternal signs of endomyometritis (eg, fever, uterine tenderness, leukocytosis, tachycardia)",
"     </li>",
"     <li>",
"      Neonatal intensive care unit admission",
"     </li>",
"     <li>",
"      Malodorous placenta",
"     </li>",
"     <li>",
"      Retained placenta or postpartum hemorrhage (often severe chorioamnionitis is associated with placental",
"      <span class=\"nowrap\">",
"       retention/postpartum",
"      </span>",
"      hemorrhage)",
"     </li>",
"     <li>",
"      Stillbirth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Placental examination can help confirm clinical impressions that led to obstetrical intervention. As an example, placental histology may confirm a clinical diagnosis of an infectious etiology for nonreassuring fetal heart rate patterns or neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality.",
"    </span>",
"    However, a specific infectious agent is rarely diagnosed by placental examination.",
"   </p>",
"   <p>",
"    It is possible to culture the placenta for bacteria, but we usually reserve this only for cases associated with stillbirth in which autopsy permission is declined. To culture the placenta, the amnion is peeled from the chorionic plate while keeping the exposed chorion \"sterile.\" Using a sterile swab, the exposed chorion is swabbed multiple times and the swab sent for microbiologic testing. If listeria is suspected, this information should be provided to the microbiology laboratory. Tissue samples from the placenta can also be used for viral cultures, if indicated.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kradin, RL. Perinatal Infections. In: Diagnostic Pathology of Infectious Disease: Expert Consult, Saunders, 2010. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/2\">",
"      Becher N, Adams Waldorf K, Hein M, Uldbjerg N. The cervical mucus plug: structured review of the literature. Acta Obstet Gynecol Scand 2009; 88:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/3\">",
"      Onderdonk AB, Hecht JL, McElrath TF, et al. Colonization of second-trimester placenta parenchyma. Am J Obstet Gynecol 2008; 199:52.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/4\">",
"      Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/5\">",
"      Hillier SL, Krohn MA, Kiviat NB, et al. Microbiologic causes and neonatal outcomes associated with chorioamnion infection. Am J Obstet Gynecol 1991; 165:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/6\">",
"      Beebe LA, Cowan LD, Altshuler G. The epidemiology of placental features: associations with gestational age and neonatal outcome. Obstet Gynecol 1996; 87:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/7\">",
"      Williams MC, O'Brien WF, Nelson RN, Spellacy WN. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants. Am J Obstet Gynecol 2000; 183:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/8\">",
"      Lahra MM, Jeffery HE. A fetal response to chorioamnionitis is associated with early survival after preterm birth. Am J Obstet Gynecol 2004; 190:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/9\">",
"      Gersell DJ. Chronic villitis, chronic chorioamnionitis, and maternal floor infarction. Semin Diagn Pathol 1993; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/10\">",
"      Jacques SM, Qureshi F. Chronic chorioamnionitis: a clinicopathologic and immunohistochemical study. Hum Pathol 1998; 29:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/11\">",
"      Dong Y, St Clair PJ, Ramzy I, et al. A microbiologic and clinical study of placental inflammation at term. Obstet Gynecol 1987; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/12\">",
"      Smulian JC, Shen-Schwarz S, Vintzileos AM, et al. Clinical chorioamnionitis and histologic placental inflammation. Obstet Gynecol 1999; 94:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/13\">",
"      Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/14\">",
"      Armer TL, Duff P. Intraamniotic infection in patients with intact membranes and preterm labor. Obstet Gynecol Surv 1991; 46:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/15\">",
"      Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol 1996; 175:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/16\">",
"      Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993; 36:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/17\">",
"      Fried M, Duffy PE. Maternal malaria and parasite adhesion. J Mol Med (Berl) 1998; 76:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/18\">",
"      Gowda DC, Ockenhouse CF. Adherence of Plasmodium falciparum-infected erythrocytes to chondroitin 4-sulfate. Biosci Rep 1999; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/19\">",
"      Beeson JG, Rogerson SJ, Cooke BM, et al. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria. Nat Med 2000; 6:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/20\">",
"      Labarrere C, Althabe O. Chronic villitis of unknown aetiology in recurrent intrauterine fetal growth retardation. Placenta 1987; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/21\">",
"      Redline RW, Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. Am J Pathol 1993; 143:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/22\">",
"      Bray RS, Sinden RE. The sequestration of Plasmodium falciparum infected erythrocytes in the placenta. Trans R Soc Trop Med Hyg 1979; 73:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/23\">",
"      Ordi J, Ismail MR, Ventura PJ, et al. Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol 1998; 22:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/24\">",
"      Uneke CJ. Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: I: introduction to placental malaria. Yale J Biol Med 2007; 80:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/25\">",
"      Muthusamy A, Achur RN, Bhavanandan VP, et al. Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. Am J Pathol 2004; 164:2013.",
"     </a>",
"    </li>",
"    <li>",
"     Remington JS, Klein, JO. Infectious Diseases of the Fetus and Newborn Infant, Elsevier Saunders, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/27\">",
"      van Eijk AM, Ayisi JG, Ter Kuile FO, et al. HIV, malaria, and infant anemia as risk factors for postneonatal infant mortality among HIV-seropositive women in Kisumu, Kenya. J Infect Dis 2007; 196:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/28\">",
"      Walker-Abbey A, Djokam RR, Eno A, et al. Malaria in pregnant Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections and multiple parasite genotypes. Am J Trop Med Hyg 2005; 72:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/29\">",
"      Muehlenbachs A, Mutabingwa TK, Edmonds S, et al. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med 2006; 3:e446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/30\">",
"      Muehlenbachs A, Fried M, McGready R, et al. A novel histological grading scheme for placental malaria applied in areas of high and low malaria transmission. J Infect Dis 2010; 202:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/31\">",
"      Parekh FK, Davison BB, Gamboa D, et al. Placental histopathologic changes associated with subclinical malaria infection and its impact on the fetal environment. Am J Trop Med Hyg 2010; 83:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/32\">",
"      Hindi RD, Azimi PH. Congenital malaria due to Plasmodium falciparum. Pediatrics 1980; 66:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/33\">",
"      Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/34\">",
"      Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/35\">",
"      Genest DR. Estimating the time of death in stillborn fetuses: II. Histologic evaluation of the placenta; a study of 71 stillborns. Obstet Gynecol 1992; 80:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/36\">",
"      Robb JA, Benirschke K, Barmeyer R. Intrauterine latent herpes simplex virus infection: I. Spontaneous abortion. Hum Pathol 1986; 17:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/37\">",
"      Robb JA, Benirschke K, Mannino F, Voland J. Intrauterine latent herpes simplex virus infection: II. Latent neonatal infection. Hum Pathol 1986; 17:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/38\">",
"      Schwartz DA, Caldwell E. Herpes simplex virus infection of the placenta. The role of molecular pathology in the diagnosis of viral infection of placental-associated tissues. Arch Pathol Lab Med 1991; 115:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/39\">",
"      Mikamo H, Kawazoe K, Sato Y, et al. Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of Fusobacterium nucleatum. Am J Obstet Gynecol 1998; 179:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/40\">",
"      Hill GB. Preterm birth: associations with genital and possibly oral microflora. Ann Periodontol 1998; 3:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/41\">",
"      Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995; 142:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/42\">",
"      Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/43\">",
"      Qian M, Bui T, Ho RJ, Unadkat JD. Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol 1994; 48:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/44\">",
"      Wabwire-Mangen F, Gray RH, Mmiro FA, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999; 22:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/45\">",
"      Moussa M, Mognetti B, Dubanchet S, et al. Vertical transmission of HIV: parameters which might affect infection of placental trophoblasts by HIV-1: a review. Biomed Group on the Study of in Utero Transmission of HIV 1. Am J Reprod Immunol 1999; 41:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/46\">",
"      Menu E, Mognetti B, Moussa M, et al. Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1. Early Pregnancy 1997; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/47\">",
"      Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol 1999; 73:9673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/48\">",
"      Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 1987; 317:1246.",
"     </a>",
"    </li>",
"    <li>",
"     Armstrong, D. Listeria monocytogenes. In: Principles and Practice of Infectious Diseases, 4th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Churchill Livingstone, New York 1995. p.1880.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/50\">",
"      Novak RW, Platt MS. Significance of placental findings in early-onset group B streptococcal neonatal sepsis. Clin Pediatr (Phila) 1985; 24:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/51\">",
"      Udagawa H, Oshio Y, Shimizu Y. Serious group A streptococcal infection around delivery. Obstet Gynecol 1999; 94:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/52\">",
"      Ooe K, Udagawa H. A new type of fulminant group A streptococcal infection in obstetric patients: report of two cases. Hum Pathol 1997; 28:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/53\">",
"      Desmonts G, Couvreur J. [Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy]. Ann Pediatr (Paris) 1984; 31:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/54\">",
"      Quinn PA, Butany J, Chipman M, et al. A prospective study of microbial infection in stillbirths and early neonatal death. Am J Obstet Gynecol 1985; 151:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/55\">",
"      Trichard CJ, Jacobsz EP. Mycoplasmas recovered from bovine genitalia, aborted foetuses and placentas in the Republic of South Africa. Onderstepoort J Vet Res 1985; 52:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/56\">",
"      Cassell GH, Davis RO, Waites KB, et al. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy. Sex Transm Dis 1983; 10:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/57\">",
"      Ryan GM Jr, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gynecol 1990; 162:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/58\">",
"      Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA 1990; 263:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/59\">",
"      Paul VK, Dawar R, Gupta SD, et al. Histologic chorioamnionitis &amp; its association with prematurity in a hospital-based study. Indian J Med Res 1998; 108:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/60\">",
"      Gencay M, Puolakkainen M, Wahlstr&ouml;m T, et al. Chlamydia trachomatis detected in human placenta. J Clin Pathol 1997; 50:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/61\">",
"      Dong ZW, Li Y, Zhang LY, Liu RM. Detection of Chlamydia trachomatis intrauterine infection using polymerase chain reaction on chorionic villi. Int J Gynaecol Obstet 1998; 61:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/62\">",
"      Gherman RB, Leventis LL, Miller RC. Chlamydial psittacosis during pregnancy: a case report. Obstet Gynecol 1995; 86:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4089/abstract/63\">",
"      Hyde SR, Benirschke K. Gestational psittacosis: case report and literature review. Mod Pathol 1997; 10:602.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6822 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4089=[""].join("\n");
var outline_f3_63_4089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASCENDING INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fetal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INFECTIONS FROM HEMATOGENOUS SPREAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HISTOPATHOLOGY OF SPECIFIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24600473\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Candida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fusobacterium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Listeria monocytogenes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Group B streptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Group A streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mycoplasma hominis and Ureaplasma urealyticum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chlamydia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6822|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/562\" title=\"picture 1\">",
"      Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/16/15622\" title=\"picture 2A\">",
"      Normal membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/40/645\" title=\"picture 2B\">",
"      Chorioamnionitis light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/4/37958\" title=\"picture 3\">",
"      Chronic villitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/7/2164\" title=\"picture 4\">",
"      Placental CMV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/7/22648\" title=\"picture 5\">",
"      Placental malaria infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/48/2823\" title=\"picture 6A\">",
"      Candidiasis of cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/41/28305\" title=\"picture 6B\">",
"      Candidal hyphae in cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/47/19189\" title=\"picture 7\">",
"      Fusobacterium chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/10/26791\" title=\"picture 8\">",
"      Herpes placentitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/49/7959\" title=\"picture 9\">",
"      Listeria placentitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/17/27929\" title=\"picture 10\">",
"      Syphilis of the placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/19/11576\" title=\"picture 11\">",
"      Toxoplasmosis of placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/9/17563\" title=\"table 1\">",
"      Risk factors chorioamnionitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=related_link\">",
"      Epidemiology and pathogenesis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=related_link\">",
"      Psittacosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4090="Keratoacanthoma: Epidemiology, risk factors, and diagnosis";
var content_f3_63_4090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4090/contributors\">",
"     Jerry D Brewer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4090/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/63/4090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/63/4090/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/63/4090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5186444\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratoacanthoma (KA) is a cutaneous tumor that most commonly presents as a dome-shaped nodule with a central keratin-filled crater (",
"    <a class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \" href=\"UTD.htm?43/19/44346\">",
"     picture 1A-E",
"    </a>",
"    ). KA most frequently develops on hair-bearing, sun-exposed skin. Middle-aged and elderly adults with fair complexions are most frequently affected [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinguishing feature of KA is a clinical course characterized by rapid initial growth followed by a variable period of lesion stability and subsequent spontaneous resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1\">",
"     1",
"    </a>",
"    ]. The recognition of this unique characteristic in a tumor with clinical and histopathologic features that closely resemble cutaneous squamous cell carcinoma has led to significant debate over the classification of this lesion.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, and diagnosis of KA will be discussed here. The management and prognosis of KA is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=see_link\">",
"     \"Keratoacanthoma: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5186451\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although KA is a common tumor, the potential for spontaneous resolution, the variability in documentation of lesions as KA or squamous cell carcinoma, and the relative paucity of epidemiological studies performed on this disease hinder definitive conclusions on tumor incidence. The vast majority of reported cases of KA have occurred in fair-skinned individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1923380\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    KA can occur at any age, and may present as a solitary lesion (the most common presentation) or infrequently in the context of specific disorders associated with multiple KAs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/3-6\">",
"     3-6",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H2295938\">",
"     'Multiple keratoacanthomas'",
"    </a>",
"    below). Solitary KA has a peak incidence between the ages of 50 and 69 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1\">",
"     1",
"    </a>",
"    ]; rarely, lesions develop in individuals under the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/3\">",
"     3",
"    </a>",
"    ]. Data on the distribution of KA among the sexes vary. Estimates of the sex ratio range from a similar incidence in both sexes to a three times greater risk for KA among males [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether the incidence of KA is subject to seasonal variation in temperate climates. A retrospective study at a medical center in Rhode Island that analyzed patient data obtained between 1990 and 1992 found that more lesions were diagnosed in the summer months than in the winter (incidence ratio 1.38:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/9\">",
"     9",
"    </a>",
"    ]. However, retrospective studies in Minnesota and Texas have failed to confirm these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923751\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of KA is poorly understood. It is generally accepted that KA is most likely derived from the follicular infundibulum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the mechanisms behind the characteristic phenomenon of rapid lesion growth followed by spontaneous resolution are not well defined. Based upon the available data, changes in the expression of genes and proteins involved in epidermal cell proliferation, cell adhesion, and cell survival may play significant roles in lesion development. Proposed contributors to lesion regression include the upregulation of factors that promote apoptosis, events related to normal cycling of the hair follicle, and activation of an immunologic response against the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Examples of specific factors identified as potentially relevant in the life cycle of KA include the homeodomain interacting protein kinase 2 (HIPK2) gene (a regulator of cell cycling and apoptosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/12\">",
"     12",
"    </a>",
"    ], the p53 tumor suppressor protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/13\">",
"     13",
"    </a>",
"    ], the H-ras protooncogene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], the adhesion molecules beta-catenin and CD44 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/16\">",
"     16",
"    </a>",
"    ], and levels of the bcl-2 apoptosis regulatory protein and bak proapoptotic protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/13,17-19\">",
"     13,17-19",
"    </a>",
"    ]. Additional potential contributors include granzyme B, a serine protease expressed by cytotoxic T cells and natural killer cells that promotes apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/20\">",
"     20",
"    </a>",
"    ], and p27 (kip), an inhibitor of cyclin dependent kinases that may promote lesion regression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/21\">",
"     21",
"    </a>",
"    ]. Further study is necessary to clarify the mechanisms involved in the development and involution of KA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923197\">",
"    <span class=\"h1\">",
"     RELATIONSHIP WITH SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between KA and squamous cell carcinoma is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. While some authors perceive KA as a distinct follicular-based squamous proliferation that usually follows a benign clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], others counter that KA is actually a clinical variant of cutaneous squamous cell carcinoma prone to spontaneous regression and occasional aggressive behavior and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/4,28-30\">",
"     4,28-30",
"    </a>",
"    ]. Dissolution of this controversy is hampered by the lack of histopathologic criteria that definitively differentiate KA and squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/31\">",
"     31",
"    </a>",
"    ]. Reports documenting transformation of KA to squamous cell carcinoma also raise questions about whether these lesions represent a continuum of a single disease rather than distinct entities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H256623\">",
"     'Differentiation from SCC'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923380\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors may influence the likelihood that an individual will develop KA. Examples include skin pigmentation; exposure to ultraviolet radiation trauma, chemical carcinogens, or certain medications; and genetic abnormalities. These factors are discussed in greater detail below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Skin color",
"      </strong>",
"      &ndash; The risk for KA decreases with increasing skin pigmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1,8,34\">",
"       1,8,34",
"      </a>",
"      ]. Among 22,000 patients seen at a specialized surgical skin cancer practice in Houston, Texas between 1998 and 2006, all 234 patients with KA were Caucasian with Fitzpatrick skin phototypes I, II, or III (",
"      <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, the differences in disease incidence reported in the late 20",
"      <sup>",
"       th",
"      </sup>",
"      century in the predominantly fair-skinned population of Australia (150 per 100,000 individuals), Japanese-Hawaiians (22 per 100,000 individuals), and Filipinos in Hawaii (7 per 100,000 individuals) also lend support to an important role for skin type [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. KA is rare among individuals with deeply pigmented skin [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ultraviolet radiation &ndash;",
"      </strong>",
"      Although human studies that definitively link exposure to ultraviolet radiation to the development of KA are lacking, the observation that KA most frequently occurs on sun-exposed skin and in fair-skinned individuals supports a role for ultraviolet radiation as a contributing factor [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"       8",
"      </a>",
"      ]. Moreover, high numbers of treatments with psoralen plus ultraviolet A (PUVA) phototherapy have been linked to an increased risk for KA. In a retrospective study of approximately 500 patients with psoriasis who were treated with PUVA, patients who received high cumulative doses of PUVA were significantly more likely to develop KA than those who received lesser amounts of PUVA therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Trauma &ndash;",
"      </strong>",
"      Infrequently, KA develops in sites of iatrogenic (eg, surgery, laser therapy, cryotherapy) or accidental trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/39-47\">",
"       39-47",
"      </a>",
"      ]. Although most reported cases of trauma-induced KA have occurred in adults, this phenomenon has also been documented in an adolescent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/40\">",
"       40",
"      </a>",
"      ]. Post-surgical KA usually appears one to three months after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. Treatment with ionizing radiation has also been linked with the development of multiple KAs in a patient with multiple self-healing squamous epithelioma (MSSE, also known as Ferguson-Smith disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2295938\">",
"       'Multiple keratoacanthomas'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The explanation for the development of KA at sites of trauma is unknown. Some authors have speculated that in skin previously exposed to carcinogens such as ultraviolet radiation, factors associated with the wound-healing response may promote the development of these tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Genetics &ndash;",
"      </strong>",
"      Several genetic syndromes are associated with KA, including the variant of Lynch syndrome known as Muir-Torre syndrome, xeroderma pigmentosum, and MSSE. Muir-Torre syndrome may present with KA, sebaceous tumors, and visceral malignancy. In this syndrome, tumor formation occurs as a result of germline mutations in DNA mismatch repair genes.",
"      <br/>",
"      <br/>",
"      KAs may develop early in life in both xeroderma pigmentosum and MSSE. Xeroderma pigmentosum is an autosomal recessive syndrome associated with defects in DNA repair [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. In contrast, MSSE is an autosomal dominant disorder associated with loss-of-function mutations in the transforming growth factor beta receptor 1 gene (TGFBR1 or ALK5) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Muir-Torre and Turcot variants of Lynch syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H523750964#H523750964\">",
"       \"The genodermatoses\", section on 'Xeroderma pigmentosum'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2295938\">",
"       'Multiple keratoacanthomas'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Drug exposure &ndash;",
"      </strong>",
"      BRAF inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      , dabrafenib) are molecularly targeted agents used in the treatment of multiple malignancies. The development of KA or cutaneous squamous cell carcinoma is a potential adverse effect of these therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. A paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway resulting the proliferation and survival of abnormal cells may contribute to the occurrence of these lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/55\">",
"       55",
"      </a>",
"      ]. Additional agents that have been associated with the development of KA include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , a tyrosine kinase inhibitor used in the treatment of cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/56,57\">",
"       56,57",
"      </a>",
"      ], and immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/58-63\">",
"       58-63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472985#H100472985\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'BRAF inhibition'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H11#H11\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Squamoproliferative lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chemical carcinogens &ndash;",
"      </strong>",
"      Exposure to chemical carcinogens, such as tar, pitch, polyaromatic hydrocarbons in mineral oils, and cigarette smoking may increase risk for KA [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/7,22,64\">",
"       7,22,64",
"      </a>",
"      ]. Smoking was associated with increased risk for solitary KA in a case-control study of 78 patients with KA and 199 controls; 69 verus 22 percent of subjects were smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/7\">",
"       7",
"      </a>",
"      ]. A contributory effect of acid refined mineral oils is supported by a Swedish study that found higher than expected rates of KA on the hands or forearms of workers exposed to these substances [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/64\">",
"       64",
"      </a>",
"      ]. Concordant with an inciting effect of these particular oils, KAs were no longer detected after a switch to solvent-refined mineral oils, which contain much lower concentrations of polyaromatic hydrocarbons.",
"     </li>",
"     <li>",
"      <strong>",
"       Human papillomavirus infection &ndash;",
"      </strong>",
"      Similar to cutaneous squamous cell carcinoma, the role of human papilloma virus (HPV) in KA is uncertain. Although multiple serotypes of HPV have been detected in lesions from immunocompetent and immunocompromised patients with KA, data are insufficient to confirm a causative association between KA and this ubiquitous virus [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/22,65-67\">",
"       22,65-67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H22#H22\">",
"       \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'HPV infection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5186472\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical presentations of KA are described in the literature including solitary KA (the most common manifestation) and several less common variants characterized by isolated or multiple lesions (",
"    <a class=\"graphic graphic_table graphicRef76410 \" href=\"UTD.htm?20/60/21452\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2295744\">",
"    <span class=\"h2\">",
"     Solitary keratoacanthoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary KA usually, but not always, develops on sun-exposed areas of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/33\">",
"     33",
"    </a>",
"    ]. The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"     11",
"    </a>",
"    ]. Findings of consistent sun damage (eg, dyspigmentation, telangiectasias, and atrophy) are often present in the surrounding skin.",
"   </p>",
"   <p>",
"    Although solitary KA is classically described as a dome-shaped, bud-shaped, or berry-shaped 1 to 2 cm papule with a central keratinous plug, the appearance of lesions varies with the stage of lesion development (",
"    <a class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \" href=\"UTD.htm?43/19/44346\">",
"     picture 1A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"     8",
"    </a>",
"    ]. Three phases characterize the evolution of KA: proliferation, maturation, and involution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Proliferation &ndash;",
"      </strong>",
"      Proliferation, the first stage of KA development, is defined by rapid growth that may persist for up to six to eight weeks. The initial lesion is usually a small pink macule that subsequently takes on a papular quality and eventually forms a circumscribed nodule. The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"       8",
"      </a>",
"      ]. The center of the nodule typically demonstrates a prominent keratinous core. Removal of this core results in a crateriform appearance.",
"      <br/>",
"      <br/>",
"      Solitary KA typically grows to a diameter of 1 to 2 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/28,68\">",
"       28,68",
"      </a>",
"      ]. Lesions that exceed 2 cm in size are classified as giant KAs (",
"      <a class=\"graphic graphic_picture graphicRef66180 \" href=\"UTD.htm?41/63/42995\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15906018\">",
"       'Clinical variants'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Maturation &ndash;",
"      </strong>",
"      In the maturation phase, growth ceases. The KA maintains the nodular or crateriform appearance but may begin to demonstrate signs of fragmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8,33,69\">",
"       8,33,69",
"      </a>",
"      ]. This phase often lasts for several weeks to several months.",
"     </li>",
"     <li>",
"      <strong>",
"       Involution &ndash;",
"      </strong>",
"      The involution stage is characterized by spontaneous lesion regression. This process often takes four to six weeks, but may take longer. During involution, the remaining central keratin plug is expelled. The tumor eventually completely resolves leaving an atrophic, often hypopigmented scar [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The time course for lesions to proceed through the three phases is usually around four to nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1,8,72\">",
"     1,8,72",
"    </a>",
"    ]. However, some KAs persist for greater than one year, complicating the clinical distinction of these lesions from cutaneous squamous cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=see_link&amp;anchor=H770593#H770593\">",
"     \"Keratoacanthoma: Management and prognosis\", section on 'Deferring therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15906018\">",
"    <span class=\"h2\">",
"     Clinical variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical variants of solitary KA include giant KA, subungual KA, mucosal KA, and keratoacanthoma centrifugum marginatum (KCM).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Giant KA &ndash;",
"      </strong>",
"      KAs can develop into large lesions, with diameters ranging from greater than 2 cm to up to 15 cm (",
"      <a class=\"graphic graphic_picture graphicRef66180 \" href=\"UTD.htm?41/63/42995\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/73-78\">",
"       73-78",
"      </a>",
"      ]. Such lesions are referred to as giant KAs. Giant KA has a predilection for the nose and eyelids [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/77\">",
"       77",
"      </a>",
"      ]. Although spontaneous resolution usually eventually occurs, these lesions can cause considerable cosmetic disfigurement via the destruction of underlying structures [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/75,79\">",
"       75,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Subungual KA &ndash;",
"      </strong>",
"      Subungual KA develops on the nail beds and may present with pain, swelling, and inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. As with classic KA, lesions develop quickly. The thumbs, index fingers, and middle fingers are the most frequently affected digits [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, erosion of underlying bone is frequently evident on radiologic examination. Compared with classic KAs, spontaneous resolution is less likely to occur in this variant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/81\">",
"       81",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Mucosal KA &ndash;",
"      </strong>",
"      Rarely, KAs develop on mucosal surfaces. The oral mucosa, conjunctiva, genitalia, or nasal mucosa may be affected [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/6,8,82,83\">",
"       6,8,82,83",
"      </a>",
"      ]. Mucosal lesions may also be seen in patients with generalized eruptive keratoacanthomas of Grzybowski. (See",
"      <a class=\"local\" href=\"#H2295938\">",
"       'Multiple keratoacanthomas'",
"      </a>",
"      below.) Spontaneous resolution of mucosal lesions usually does not occur.",
"     </li>",
"     <li>",
"      <strong>",
"       Keratoacanthoma centrifugum marginatum (KCM) &ndash;",
"      </strong>",
"      KCM is distinguished from giant KA by its prominent horizontal growth pattern. The lesion exhibits progressive peripheral growth accompanied by central involution. Lesions of KCM may reach diameters of 20 or more centimeters and may occur on the face, trunk, or extremities (",
"      <a class=\"graphic graphic_picture graphicRef73851 \" href=\"UTD.htm?28/36/29254\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"       8",
"      </a>",
"      ]. Spontaneous resolution is unlikely [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these four major subtypes of solitary KA, other uncommon presentations have been described, including vulvar KA in women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/85-89\">",
"     85-89",
"    </a>",
"    ] and KA within nevus sebaceous, a presentation primarily reported in children and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2295938\">",
"    <span class=\"h2\">",
"     Multiple keratoacanthomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several named disorders may present with multiple KAs (",
"    <a class=\"graphic graphic_picture graphicRef50780 \" href=\"UTD.htm?21/10/21668\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76410 \" href=\"UTD.htm?20/60/21452\">",
"     table 2",
"    </a>",
"    ). The major disorders characterized by this presentation are multiple self-healing squamous epithelioma (MSSE) and generalized eruptive keratoacanthomas of Grzybowski.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Multiple self-healing squamous epithelioma (MSSE, Ferguson-Smith disease, OMIM #132800) &ndash;",
"      </strong>",
"      MSSE is an autosomal dominant disorder attributed to loss-of-function mutations in the transforming growth factor beta receptor 1 (TGFBR1 or ALK5) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/52\">",
"       52",
"      </a>",
"      ]. TGFBR1 mutations may lead to defects in TGF-beta function that result in the deregulation of cell proliferation and migration. Most affected families are of Scottish origin. (See",
"      <a class=\"local\" href=\"#H1923380\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Features of MSSE most frequently appear during adolescence or early adulthood, but may also first occur earlier or later in life [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8,92\">",
"       8,92",
"      </a>",
"      ]. Affected patients develop several KAs to hundreds of KAs that spontaneously resolve, often leaving deep, destructive scars [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/22\">",
"       22",
"      </a>",
"      ]. Sun-exposed areas are most frequently affected, but may not be the only sites of involvement. Exacerbation of this disorder has been reported following radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Generalized eruptive keratoacanthomas of Grzybowski &ndash;",
"      </strong>",
"      Generalized eruptive keratoacanthomas of Grzybowski is a rare, sporadic disorder characterized by the abrupt appearance of numerous KAs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8,93,94\">",
"       8,93,94",
"      </a>",
"      ]. The disorder usually occurs between the fifth and seventh decades of life [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/95\">",
"       95",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with generalized eruptive keratoacanthomas of Grzybowski abruptly develop hundreds to thousands of follicular-based 1 to 5 mm papules with central keratotic cores on the trunk and extremities [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"       11",
"      </a>",
"      ]. Palm, sole, genital, and mucosal involvement may also be present [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"       8",
"      </a>",
"      ]. Affected individuals may experience pruritus, ectropion due to eyelid involvement, and sclerodermoid changes of the face due to extensive involvement in this area [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1,8,22,96\">",
"       1,8,22,96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rare presentation of multiple KAs characterized by features of both MSSE and generalized eruptive keratoacanthomas of Grzybowski has been reported, and is referred to as multiple familial keratoacanthoma of Witten and Zak [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/93,97\">",
"     93,97",
"    </a>",
"    ]. Patients with the variant of Lynch syndrome known as Muir-Torre syndrome, a genetic autosomal dominant condition characterized by KA, sebaceous tumors, and visceral malignancies, may also present with several KAs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/96,98-103\">",
"     96,98-103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Muir-Torre and Turcot variants of Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H772735\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although observation of lesions with clinical features consistent with KA from the proliferative phase through spontaneous resolution has been used by some clinicians to diagnose and manage KA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/71\">",
"     71",
"    </a>",
"    ], this process typically takes at least several months, and the diagnosis remains in question until lesion regression. A major concern related to this approach is the misdiagnosis of cutaneous squamous cell carcinoma, a lesion with a relatively greater risk for metastasis and death. Due to the difficulty in clinically distinguishing KA from cutaneous squamous cell carcinoma, we biopsy and treat all lesions suspicious for KA. The recognition of both clinical and histopathologic features consistent with KA is used to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564594\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical assessment of patients with lesions suspicious for KA should always involve obtaining a clear account of the lesion time course since a history of rapid growth within weeks favors this diagnosis. Patients should also be questioned regarding a history of prior similar lesions, sebaceous tumors, and visceral malignancies. These questions may help to identify the presence of a syndromic disorder. (See",
"    <a class=\"local\" href=\"#H2295938\">",
"     'Multiple keratoacanthomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since extensive sun-exposure is likely a precipitating factor for KA as well as multiple other cutaneous tumors, careful examination of the entire skin surface should be performed. In addition, the incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Muir-Torre and Turcot variants of Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dermoscopy may aid in clinically distinguishing KA from other lesions, but cannot reliably distinguish KA from SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/104\">",
"     104",
"    </a>",
"    ]. White circles, keratin, blood spots, and white structureless zones are common dermoscopic findings in both KA and SCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H772753\">",
"    <span class=\"h2\">",
"     Performing the biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of the classic pathological architecture of KA is a key component of diagnosis, and thus, performing the appropriate biopsy procedure is crucial for accurate assessment. Whenever feasible, biopsies should involve removal of the entire lesion.",
"   </p>",
"   <p>",
"    The preferred method for obtaining a biopsy specimen is an excisional biopsy extending into the subcutaneous fat. At least a 4 mm margin is usually taken when feasible to concurrently suffice for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=see_link&amp;anchor=H380984#H380984\">",
"     \"Keratoacanthoma: Management and prognosis\", section on 'First-line therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative method for obtaining the tissue specimen is the performance of a deep shave biopsy (also known as a saucerization procedure) that removes the entire lesion and extends into the subcutaneous fat. Since improperly performed shave biopsies are often inadequate for diagnosis, shave biopsies of KA should only be performed by clinicians with extensive experience with the shave procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/1\">",
"     1",
"    </a>",
"    ]. Punch biopsies do not allow for the examination of the lesion architecture, and therefore, are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Removal of the entire lesion for diagnosis may be impossible in patients with giant lesions or keratoacanthoma centrifugum marginatum (KCM). In such cases, a fusiform incisional biopsy through the center of the lesion that includes a cross-section of the lesion (periphery and center) and extends into the underlying fat can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/8,105\">",
"     8,105",
"    </a>",
"    ]. This provides a specimen that represents the lesion architecture without total removal of the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5186479\">",
"    <span class=\"h2\">",
"     Interpretation of the biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no single histopathologic finding reliably confirms a diagnosis of KA, an overall picture of consistent histopathologic and clinical findings is used to support the diagnosis. The histopathological features that typically characterize KA include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/31,106\">",
"     31,106",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidermal hyperplasia with large eosinophilic keratinocytes",
"     </li>",
"     <li>",
"      Central invagination with a keratotic core (this may be less evident in early stage lesions)",
"     </li>",
"     <li>",
"      &ldquo;Lipping&rdquo; or &ldquo;buttressing&rdquo; of the epidermis over the peripheral rim of the central keratotic plug",
"     </li>",
"     <li>",
"      Sharp demarcation between the tumor and the surrounding stroma",
"     </li>",
"     <li>",
"      Mixed inflammatory infiltrate in the dermis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of keratinocytes in KA do not exhibit signs of atypia, and mitoses are not a prominent feature, though they may be observed in the deepest components of some lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/31\">",
"     31",
"    </a>",
"    ]. Islands of tumor cells may be present underlying the main portion of the tumor. The tumor islands usually do not extend beyond the depth of the eccrine glands.",
"   </p>",
"   <p>",
"    Aggressive features such as perineural invasion and intravascular involvement may be seen in a minority of specimens from lesions of KA, and have been used by some authors to support the classification of KA as a variant of cutaneous squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/28,107\">",
"     28,107",
"    </a>",
"    ]. The significance of perineural invasion, a negative prognostic factor in cutaneous squamous cell carcinoma, is unclear in KA. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=see_link&amp;anchor=H1564345#H1564345\">",
"     \"Keratoacanthoma: Management and prognosis\", section on 'Metastasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256623\">",
"    <span class=\"h3\">",
"     Differentiation from SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating KA from cutaneous squamous cell carcinoma based upon histopathologic examination is challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. An analysis of approximately 300 KAs and squamous cell carcinomas found that no histopathologic criterion was sufficiently sensitive or specific to reliably distinguish between these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/31\">",
"     31",
"    </a>",
"    ]. However, among the pathologic features typically ascribed to KA, the presence of an epithelial lip and a sharp outline between the tumor and stroma appeared to be the most useful factors for the diagnosis of KA. In contrast, the presence of ulceration, mitoses, and pleomorphism or anaplasia favored a diagnosis of squamous cell carcinoma.",
"   </p>",
"   <p>",
"    Due to the lack of histopathologic features that definitively distinguish KA from squamous cell carcinoma, studies of specific biomarkers and genetic analyses have attempted to identify additional methods for differentiating these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/24,27,108-123\">",
"     24,27,108-123",
"    </a>",
"    ]. Promising examples include recognition of the labelling pattern of the cytolytic calcium channel receptor p2X",
"    <sub>",
"     7",
"    </sub>",
"    , a marker of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/24\">",
"     24",
"    </a>",
"    ], and the detection of specific chromosomal aberrations within these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/27\">",
"     27",
"    </a>",
"    ]. Further studies are necessary to determine whether these tests and other studies will be useful for diagnosis in the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256506\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of KA is broad and includes other nodular tumors and growths of the skin. The combination of a history of rapid growth, central keratotic crater formation, and consistent histopathologic findings are often helpful for distinguishing KA from other disorders.",
"   </p>",
"   <p>",
"    As noted above, squamous cell carcinoma is the most difficult disorder to distinguish from KA due to the multiple clinical and histopathologic similarities between these lesions. Examples of additional lesions to consider in the differential diagnosis of solitary KA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef65704 \" href=\"UTD.htm?16/56/17283\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Merkel cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef70535 \" href=\"UTD.htm?1/61/2001\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prurigo nodule (",
"      <a class=\"graphic graphic_picture graphicRef53475 \" href=\"UTD.htm?5/32/5633\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Giant molluscum contagiosum (",
"      <a class=\"graphic graphic_picture graphicRef62590 \" href=\"UTD.htm?5/45/5848\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep fungal infection (eg, sporotrichosis) (",
"      <a class=\"graphic graphic_picture graphicRef74515 \" href=\"UTD.htm?6/59/7094\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodular Kaposi&rsquo;s sarcoma (",
"      <a class=\"graphic graphic_picture graphicRef54707 \" href=\"UTD.htm?16/37/16979\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cutaneous metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/124,125\">",
"       124,125",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of clinical assessment and biopsies are also useful for narrowing the differential diagnosis for other presentations of KA. The possibility of paronychia, periungual squamous cell carcinoma, viral warts, and subungual tumors associated with incontinentia pigmenti [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/126\">",
"     126",
"    </a>",
"    ] should be considered in patients with lesions suspicious for subungual KA. In addition, the clinical appearance of KCM may resemble giant porokeratosis of Mibelli, a deep fungal infection, or halogenoderma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/63/4090/abstract/127\">",
"     127",
"    </a>",
"    ]. In patients with suspected multiple KA syndromes, the possibility of other disorders that may present with widespread nodular lesions, including prurigo nodularis and perforating disorders (eg, Kyrle&rsquo;s disease), should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256997\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratoacanthoma (KA) is a cutaneous tumor that most commonly occurs in middle-aged and elderly individuals with fair skin. Controversy exists over whether KA represents a distinct disease entity or a variant of cutaneous squamous cell carcinoma. (See",
"      <a class=\"local\" href=\"#H5186451\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1923197\">",
"       'Relationship with squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of KA is poorly understood. Factors that influence epidermal cell proliferation, cell adhesion, cell survival, and apoptosis have been identified as potential contributors to these lesions. (See",
"      <a class=\"local\" href=\"#H1923751\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with KA include fair skin, exposure to ultraviolet radiation or chemical carcinogens, genetic abnormalities, and certain medications. The role of human papillomavirus in KA remains uncertain. (See",
"      <a class=\"local\" href=\"#H1923380\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solitary KA is the most common manifestation of KA. Lesions are usually 1 to 2 cm in diameter and are most commonly found on sun-exposed skin (",
"      <a class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \" href=\"UTD.htm?43/19/44346\">",
"       picture 1A-E",
"      </a>",
"      ). Solitary KAs undergo three phases of evolution: a proliferative period of several weeks, a maturation phase that may persist for several months, and eventual lesion regression. (See",
"      <a class=\"local\" href=\"#H2295744\">",
"       'Solitary keratoacanthoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of additional variants of KA have been described, including giant KA (",
"      <a class=\"graphic graphic_picture graphicRef66180 \" href=\"UTD.htm?41/63/42995\">",
"       picture 2",
"      </a>",
"      ), subungual KA, mucosal KA, and keratoacanthoma centrifugum marginatum. KAs may also present as a feature of multiple KA syndromes, such as multiple self-healing squamous epithelioma (Ferguson-Smith disease) and generalized eruptive keratoacanthomas of Grzybowski. In addition, the Muir-Torre variant of Lynch syndrome may present with KA, sebaceous tumors, and visceral cancer. (See",
"      <a class=\"local\" href=\"#H15906018\">",
"       'Clinical variants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2295938\">",
"       'Multiple keratoacanthomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We biopsy lesions of KA due to the difficulty in clinically distinguishing KA from squamous cell carcinoma. Although histopathologic findings cannot definitively differentiate these lesions, the combined assessment of clinical and histopathologic findings is useful for determining the appropriate diagnosis. (See",
"      <a class=\"local\" href=\"#H772735\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete removal of the lesion via surgical excision is the preferred biopsy procedure for lesions suspicious for KA. Shave biopsies may be inadequate if performed with improper technique and should only be performed by clinicians experienced in this procedure. (See",
"      <a class=\"local\" href=\"#H772753\">",
"       'Performing the biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/1\">",
"      Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004; 30:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/2\">",
"      Vergilis-Kalner IJ, Kriseman Y, Goldberg LH. Keratoacanthomas: overview and comparison between Houston and minneapolis experiences. J Drugs Dermatol 2010; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/3\">",
"      Buescher L, DeSpain JD, Diaz-Arias AA, Roller JA. Keratoacanthoma arising in an organoid nevus during childhood: case report and literature review. Pediatr Dermatol 1991; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/4\">",
"      Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993; 15:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/5\">",
"      Maruani A, Michenet P, Lagasse JP, et al. [Keratoacanthoma of the anal margin]. Gastroenterol Clin Biol 2004; 28:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/6\">",
"      Perdig&atilde;o FB, Pierre-Filho Pde T, Natalino RJ, et al. Conjunctival keratoacanthoma. Rev Hosp Clin Fac Med Sao Paulo 2004; 59:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/7\">",
"      Miot HA, Miot LD, da Costa AL, et al. Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J 2006; 12:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/8\">",
"      Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/9\">",
"      Dufresne RG, Marrero GM, Robinson-Bostom L. Seasonal presentation of keratoacanthomas in Rhode Island. Br J Dermatol 1997; 136:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/10\">",
"      Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. J Invest Dermatol 1995; 104:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/11\">",
"      Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol 2010; 28:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/12\">",
"      Cao Z, Yoon JH, Nam SW, et al. Mutational analysis of the HIPK2 gene in keratoacanthoma and squamous cell carcinoma of the skin. APMIS 2011; 119:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/13\">",
"      Batinac T, Zamolo G, Coklo M, et al. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol Res Pract 2006; 202:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/14\">",
"      Corominas M, Sloan SR, Leon J, et al. ras activation in human tumors and in animal model systems. Environ Health Perspect 1991; 93:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/15\">",
"      Corominas M, Leon J, Kamino H, et al. Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model. Oncogene 1991; 6:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/16\">",
"      Tataroglu C, Karabacak T, Apa DD. Beta-catenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin. Tumori 2007; 93:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/17\">",
"      Ribeiro D, Narikawa S, Marques ME. Expression of apoptotic and cell proliferation regulatory proteins in keratoacanthomas and squamous cell carcinomas of the skin. Pathol Res Pract 2008; 204:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/18\">",
"      Batinac T, Zamolo G, Brumini G, et al. Cell apoptosis as assessed by M30 expression in keratoacanthoma and squamous cell carcinoma. Coll Antropol 2008; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/19\">",
"      Tan KB, Lee YS. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology. Histopathology 2009; 55:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/20\">",
"      Batinac T, Zamolo G, Coklo M, Hadzisejdic I. Possible key role of granzyme B in keratoacanthoma regression. Med Hypotheses 2006; 66:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/21\">",
"      Hu W, Cook T, Oh CW, Penneys NS. Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma. J Am Acad Dermatol 2000; 42:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/22\">",
"      Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 2007; 46:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/23\">",
"      Weedon D. Keratoacanthoma: a personal perspective. Curr Diagn Pathol 2003; 9:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/24\">",
"      Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/25\">",
"      Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1996; 73:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/26\">",
"      Weedon D, Malo J, Brooks D, Williamson R. Keratoacanthoma: is it really a variant of squamous cell carcinoma? ANZ J Surg 2010; 80:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/27\">",
"      Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/28\">",
"      Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol 1998; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/29\">",
"      Ackerman AB. Squamous-cell carcinoma vs. keratoacanthoma. J Dermatol Surg Oncol 1982; 8:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/30\">",
"      Ackerman CC. Keratoacanthomas: a new classification based on morphologic findings and on anatomic site. Dermatopathol Pract Concept 2001; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/31\">",
"      Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999; 199:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/32\">",
"      Poleksic S, Yeung KY. Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease? Cancer 1978; 41:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/33\">",
"      S&aacute;nchez Yus E, Sim&oacute;n P, Requena L, et al. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant. Am J Dermatopathol 2000; 22:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/34\">",
"      Heyl T, Morrison JG. Keratoacanthoma in a Bantu patient. Br J Dermatol 1975; 93:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/35\">",
"      Sullivan JJ. Keratoacanthoma: the Australian experience. Australas J Dermatol 1997; 38 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/36\">",
"      Chuang TY, Reizner GT, Elpern DJ, et al. Non-melanoma skin cancer and keratoacanthoma in Filipinos: an incidence report from Kauai, Hawaii. Int J Dermatol 1993; 32:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/37\">",
"      Reizner GT, Chuang TY, Elpern DJ, et al. Keratoacanthoma in Japanese Hawaiians in Kauai, Hawaii. Int J Dermatol 1995; 34:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/38\">",
"      Chuang TY, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/39\">",
"      Pattee SF, Silvis NG. Keratoacanthoma developing in sites of previous trauma: a report of two cases and review of the literature. J Am Acad Dermatol 2003; 48:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/40\">",
"      Janik JP, Bang RH. Traumatic keratoacanthoma arising in a 15-year-old boy following a motor vehicle accident. Pediatr Dermatol 2006; 23:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/41\">",
"      Epstein EH Jr, Epstein EH. Keratoacanthoma recurrent after surgical excision. J Dermatol Surg Oncol 1978; 4:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/42\">",
"      Goldberg LH, Silapunt S, Beyrau KK, et al. Keratoacanthoma as a postoperative complication of skin cancer excision. J Am Acad Dermatol 2004; 50:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/43\">",
"      Kimyai-Asadi A, Shaffer C, Levine VJ, Jih MH. Keratoacanthoma arising from an excisional surgery scar. J Drugs Dermatol 2004; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/44\">",
"      Bunker CB. Keratoacanthoma, trauma, and cryotherapy. Dermatol Surg 2011; 37:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/45\">",
"      Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol 2006; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/46\">",
"      Gewirtzman A, Meirson DH, Rabinovitz H. Eruptive keratoacanthomas following carbon dioxide laser resurfacing. Dermatol Surg 1999; 25:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/47\">",
"      Mamelak AJ, Goldberg LH, Marquez D, et al. Eruptive keratoacanthomas on the legs after fractional photothermolysis: report of two cases. Dermatol Surg 2009; 35:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/48\">",
"      Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self-healing squamous epithelioma (Ferguson-Smith disease) with radiotherapy, which was successfully treated with acitretin. Clin Exp Dermatol 2010; 35:e100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/49\">",
"      Chowdhury RK, Padhi T, Das GS. Keratoacanthoma of the conjunctiva complicating xeroderma pigmentosum. Indian J Dermatol Venereol Leprol 2005; 71:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/50\">",
"      Bhutto AM, Shaikh A, Nonaka S. Incidence of xeroderma pigmentosum in Larkana, Pakistan: a 7-year study. Br J Dermatol 2005; 152:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/51\">",
"      Tennstedt D, Lachapelle JM. [Keratoacanthomas and xeroderma pigmentosum (author's transl)]. Ann Dermatol Venereol 1977; 104:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/52\">",
"      Goudie DR, D'Alessandro M, Merriman B, et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 2011; 43:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/53\">",
"      Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/54\">",
"      Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/55\">",
"      Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/56\">",
"      Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/57\">",
"      Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/58\">",
"      Dessoukey MW, Omar MF, Abdel-Dayem H. Eruptive keratoacanthomas associated with immunosuppressive therapy in a patient with systemic lupus erythematosus. J Am Acad Dermatol 1997; 37:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/59\">",
"      Euvrard S, Chardonnet Y, Hermier C, et al. [Warts and epidermoid carcinoma after renal transplantation]. Ann Dermatol Venereol 1989; 116:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/60\">",
"      Jacobsson S, Linell F, Rausing A. Florid keratoacanthomas in a kidney transplant recipient. Case report. Scand J Plast Reconstr Surg 1974; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/61\">",
"      Lowry WS, Clark DA, Hannemann JH. Skin cancer and immunosuppression. Lancet 1972; 1:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/62\">",
"      Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet 1971; 2:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/63\">",
"      Washington CV Jr, Mikhail GR. Eruptive keratoacanthoma en plaque in an immunosuppressed patient. J Dermatol Surg Oncol 1987; 13:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/64\">",
"      J&auml;rvholm B, Fast K, Lavenius B, Tomsic P. Exposure to cutting oils and its relation to skin tumors and premalignant skin lesions on the hands and forearms. Scand J Work Environ Health 1985; 11:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/65\">",
"      Viviano E, Sorce M, Mantegna M. Solitary keratoacanthomas in immunocompetent patients: no detection of papillomavirus DNA by polymerase chain reaction. New Microbiol 2001; 24:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/66\">",
"      Forslund O, DeAngelis PM, Beigi M, et al. Identification of human papillomavirus in keratoacanthomas. J Cutan Pathol 2003; 30:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/67\">",
"      Hsi ED, Svoboda-Newman SM, Stern RA, et al. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction. Am J Dermatopathol 1997; 19:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/68\">",
"      Kwittken J. A histologic chronology of the clinical course of the keratocarcinoma (so-called keratoacanthoma). Mt Sinai J Med 1975; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/69\">",
"      Hundeiker M. [Clinical variations of keratoacanthomas]. Z Hautkr 1978; 53:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/70\">",
"      Seifert A, Nasemann T. [Keratoacanthoma and its clinical variants. Review of the literature and histopathologic analysis of 90 cases]. Hautarzt 1989; 40:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/71\">",
"      Griffiths RW. Keratoacanthoma observed. Br J Plast Surg 2004; 57:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/72\">",
"      Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002; 119:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/73\">",
"      Hofer SO, Jackson IT. Self-involution of giant keratoacanthoma on the tip of the nose. Plast Reconstr Surg 2004; 113:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/74\">",
"      Moriyama M, Watanabe T, Sakamoto N, et al. A case of giant keratoacanthoma of the auricle. Auris Nasus Larynx 2000; 27:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/75\">",
"      Webb AJ, Ghadially FN. Massive or giant keratoacanthoma. J Pathol Bacteriol 1966; 91:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/76\">",
"      Saito M, Sasaki Y, Yamazaki N, Shimizu H. Self-involution of giant keratoacanthoma on the tip of the nose. Plast Reconstr Surg 2003; 111:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/77\">",
"      Browne F, O'Connell M, Merchant W, et al. Spontaneous resolution of a giant keratoacanthoma penetrating through the nose. Clin Exp Dermatol 2011; 36:369.",
"     </a>",
"    </li>",
"    <li>",
"     Cerroni L, Kerl H. Keratoacanthoma. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al.  (Eds), McGraw Hill, 2008. Vol 1, p.1049.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/79\">",
"      Leonard AL, Hanke CW. Treatment of giant keratoacanthoma with intralesional 5-fluorouracil. J Drugs Dermatol 2006; 5:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/80\">",
"      Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual keratoacanthoma with reossification of underlying distal lytic phalynx. Clin Exp Dermatol 2005; 30:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/81\">",
"      Oliwiecki S, Peachey RD, Bradfield JW, et al. Subungual keratoacanthoma--a report of four cases and review of the literature. Clin Exp Dermatol 1994; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/82\">",
"      Janette A, Pecaro B, Lonergan M, Lingen MW. Solitary intraoral keratoacanthoma: report of a case. J Oral Maxillofac Surg 1996; 54:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/83\">",
"      Freedman PD, Kerpel SM, Begel H, Lumerman H. Solitary intraoral keratoacanthoma. Report of a case. Oral Surg Oral Med Oral Pathol 1979; 47:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/84\">",
"      Attili Sk, Attili VR. Keratoacanthoma centrifugum marginatum arising in vitiligo: a case report. Dermatol Online J 2006; 12:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/85\">",
"      Eversole LR, Leider AS, Alexander G. Intraoral and labial keratoacanthoma. Oral Surg Oral Med Oral Pathol 1982; 54:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/86\">",
"      Hood AF, Lumadue J. Benign vulvar tumors. Dermatol Clin 1992; 10:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/87\">",
"      Rhatigan RM, Nuss RC. Keratoacanthoma of the vulva. Gynecol Oncol 1985; 21:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/88\">",
"      Ozkan F, Bilgi&ccedil; R, Cesur S. Vulvar keratoacanthoma. APMIS 2006; 114:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/89\">",
"      Chen W, Koenig C. Vulvar keratoacanthoma: a report of two cases. Int J Gynecol Pathol 2004; 23:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/90\">",
"      Ujiie H, Kato N, Natsuga K, Tomita Y. Keratoacanthoma developing on nevus sebaceous in a child. J Am Acad Dermatol 2007; 56:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/91\">",
"      Ginzburg MA, Kol'tsova IA, Stepenski�� DB, Fedorova GIa. [Course of pulmonary tuberculosis in patients with diabetes mellitus according to roentgenological data]. Probl Tuberk 1977; :30.",
"     </a>",
"    </li>",
"    <li>",
"     file://us-east.omim.org/entry/132800 (Accessed on January 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/93\">",
"      Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol 2007; 46:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/94\">",
"      Kavanagh GM, Marshman G, Hanna MM. A case of Grzybowski's generalized eruptive keratoacanthomas. Australas J Dermatol 1995; 36:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/95\">",
"      Lu PD, Lee A, Cassetty CT, et al. Generalized eruptive keratoacanthomas of Grzybowski. Dermatol Online J 2009; 15:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/96\">",
"      Wee SA. Multiple eruptive keratoacanthomas, de novo. Dermatol Online J 2004; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/97\">",
"      Agarwal M, Chander R, Karmakar S, Walia R. Multiple familial keratoacanthoma of Witten and Zak - A report of three siblings. Dermatology 1999; 198:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/98\">",
"      Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/99\">",
"      Yoshikawa R, Utsunomiya J. [Muir-Torre syndrome]. Nihon Rinsho 1995; 53:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/100\">",
"      Ponti G, Ponz de Leon M, Losi L, et al. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol 2005; 152:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/101\">",
"      Akhtar S, Oza KK, Khan SA, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 1999; 41:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/102\">",
"      Hartig C, Stieler W, Stadler R. [Muir-Torre syndrome. Diagnostic criteria and review of the literature]. Hautarzt 1995; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/103\">",
"      Nishizawa A, Nakanishi Y, Sasajima Y, et al. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature. Am J Dermatopathol 2006; 28:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/104\">",
"      Rosendahl C, Cameron A, Argenziano G, et al. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch Dermatol 2012; 148:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/105\">",
"      Popkin GL, Brodie SJ, Hyman AB, et al. A technique of biopsy recommended for keratoacanthomas. Arch Dermatol 1966; 94:191.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Tumors of the epidermis. In: Weedon's Skin Pathology, 3rd Ed, Elsevier Limited, 2010. p.667.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/107\">",
"      Gottfarstein-Maruani A, Michenet P, Kerdraon R, et al. [Keratoacanthoma: two cases with intravascular spread]. Ann Pathol 2003; 23:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/108\">",
"      Melendez ND, Smoller BR, Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol 2003; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/109\">",
"      Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001; 158:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/110\">",
"      Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/111\">",
"      Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol 1995; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/112\">",
"      Putti TC, Teh M, Lee YS. Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 2004; 17:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/113\">",
"      Sk&aacute;lov&aacute; A, Michal M. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections. Am J Dermatopathol 1995; 17:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/114\">",
"      Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol 1991; 127:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/115\">",
"      Kaabipour E, Haupt HM, Stern JB, et al. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med 2006; 130:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/116\">",
"      Kuivanen TT, Jeskanen L, Kyll&ouml;nen L, et al. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol 2006; 19:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/117\">",
"      Tran TA, Ross JS, Sheehan CE, Carlson JA. Comparison of oncostatin M expression in keratoacanthoma and squamous cell carcinoma. Mod Pathol 2000; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/118\">",
"      Kannon G, Park HK. Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma. Am J Dermatopathol 1990; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/119\">",
"      Ariano MC, Wiley EL, Ariano L, et al. H, peanut lectin receptor, and carcinoembryonic antigen distribution in keratoacanthomas, squamous dysplasias, and carcinomas of skin. J Dermatol Surg Oncol 1985; 11:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/120\">",
"      Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol 2002; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/121\">",
"      Biesterfeld S, Josef J. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry. Anticancer Res 2002; 22:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/122\">",
"      Asch PH, Basset P, Roos M, et al. Expression of stromelysin 3 in keratoarcanthoma and squamous cell carcinoma. Am J Dermatopathol 1999; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/123\">",
"      Corbal&aacute;n-V&eacute;lez R, Mart&iacute;nez-Barba E, L&oacute;pez-Poveda MJ, et al. [The value of laminin-322 staining in distinguishing between keratoacanthoma, keratoacanthoma with areas of squamous cell carcinoma, and crateriform squamous cell carcinoma]. Actas Dermosifiliogr 2012; 103:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/124\">",
"      Riahi RR, Cohen PR. Clinical manifestations of cutaneous metastases: a review with special emphasis on cutaneous metastases mimicking keratoacanthoma. Am J Clin Dermatol 2012; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/125\">",
"      Reich A, Kobierzycka M, Wo��niak Z, et al. Keratoacanthoma-like cutaneous metastasis of lung cancer: a learning point. Acta Derm Venereol 2006; 86:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/126\">",
"      Montes CM, Maize JC, Guerry-Force ML. Incontinentia pigmenti with painful subungual tumors: a two-generation study. J Am Acad Dermatol 2004; 50:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/63/4090/abstract/127\">",
"      Divers AK, Correale D, Lee JB. Keratoacanthoma centrifugum marginatum: a diagnostic and therapeutic challenge. Cutis 2004; 73:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13718 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4090=[""].join("\n");
var outline_f3_63_4090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H256997\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5186444\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5186451\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1923751\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1923197\">",
"      RELATIONSHIP WITH SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1923380\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5186472\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2295744\">",
"      Solitary keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15906018\">",
"      Clinical variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2295938\">",
"      Multiple keratoacanthomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H772735\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1564594\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H772753\">",
"      Performing the biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5186479\">",
"      Interpretation of the biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256623\">",
"      - Differentiation from SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256506\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256997\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13718|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35347\" title=\"picture 1A\">",
"      Keratoacanthoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19592\" title=\"picture 1B\">",
"      Keratoacanthoma on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/33/43539\" title=\"picture 1C\">",
"      Keratoacanthoma on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18949\" title=\"picture 1D\">",
"      Solitary keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38262\" title=\"picture 1E\">",
"      Keratoacanthoma on eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/63/42995\" title=\"picture 2\">",
"      Giant keratoacanthoma on nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29254\" title=\"picture 3\">",
"      Keratoacanthoma centrifugum marginatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/10/21668\" title=\"picture 4\">",
"      Multiple keratoacanthomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/56/17283\" title=\"picture 5\">",
"      Nodular basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2001\" title=\"picture 6\">",
"      Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/32/5633\" title=\"picture 7\">",
"      Prurigo nodularis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/45/5848\" title=\"picture 8\">",
"      Giant molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/59/7094\" title=\"picture 9\">",
"      Fixed cutaneous sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/37/16979\" title=\"picture 10\">",
"      Classic Kaposi sarcoma - nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21452\" title=\"table 2\">",
"      Multiple keratoacanthoma clinical variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24632?source=related_link\">",
"      Keratoacanthoma: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_63_4091="Dose equivalents";
var content_f3_63_4091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate dose equivalents of antidepressants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxetine",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"       <td>",
"        50-75 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citalopram",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venlafaxine",
"       </td>",
"       <td>",
"        75 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4091=[""].join("\n");
var outline_f3_63_4091=null;
var title_f3_63_4092="Fetal leukocyte count by GA";
var content_f3_63_4092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Total leukocyte count, 10",
"    <sup>",
"     9",
"    </sup>",
"    /L",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GA",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1.73",
"       </td>",
"       <td>",
"        2.82",
"       </td>",
"       <td>",
"        4.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        2.07",
"       </td>",
"       <td>",
"        3.23",
"       </td>",
"       <td>",
"        4.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        2.33",
"       </td>",
"       <td>",
"        3.56",
"       </td>",
"       <td>",
"        5.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        2.56",
"       </td>",
"       <td>",
"        3.84",
"       </td>",
"       <td>",
"        5.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        2.81",
"       </td>",
"       <td>",
"        4.16",
"       </td>",
"       <td>",
"        5.81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        3.15",
"       </td>",
"       <td>",
"        4.58",
"       </td>",
"       <td>",
"        6.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        3.65",
"       </td>",
"       <td>",
"        5.21",
"       </td>",
"       <td>",
"        7.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        4.45",
"       </td>",
"       <td>",
"        6.19",
"       </td>",
"       <td>",
"        8.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        5.71",
"       </td>",
"       <td>",
"        7.75",
"       </td>",
"       <td>",
"        10.26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        7.73",
"       </td>",
"       <td>",
"        10.26",
"       </td>",
"       <td>",
"        13.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        10.98",
"       </td>",
"       <td>",
"        14.45",
"       </td>",
"       <td>",
"        18.77",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4092=[""].join("\n");
var outline_f3_63_4092=null;
var title_f3_63_4093="Instrumental methods measuring body composition";
var content_f3_63_4093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Instrumental methods for measuring body composition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"35%\">",
"     </colgroup>",
"     <colgroup span=\"5\" width=\"13%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cost",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ease of use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Accuracy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Can measure regional fat",
"       </td>",
"       <td class=\"subtitle1\">",
"        External radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrodensitometry (underwater weighing)",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air displacement plethysmography (Bod PodR)",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dual x-ray absorptiometry (DXA)",
"       </td>",
"       <td>",
"        $$$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        tr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotope dilution (",
"        <sup>",
"         3",
"        </sup>",
"        H",
"        <sub>",
"         2",
"        </sub>",
"        O, D",
"        <sub>",
"         2",
"        </sub>",
"        O, H",
"        <sub>",
"         2",
"        </sub>",
"        <sup>",
"         18",
"        </sup>",
"        O)",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impedance (BIA)",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Easy",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K40 counting (",
"        <sup>",
"         40",
"        </sup>",
"        K)",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conductivity (TOBEC)",
"       </td>",
"       <td>",
"        $$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT scan at lumbar 4-5 interspace",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI scan at lumbar 4-5 interspace",
"       </td>",
"       <td>",
"        $$$$",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutron activation",
"       </td>",
"       <td>",
"        $$$$+",
"       </td>",
"       <td>",
"        Difficult",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound",
"       </td>",
"       <td>",
"        $$",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     $: inexpensive; $$: some expense; $$$: expensive; $$$$: very expensive; tr: trace.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George A Bray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4093=[""].join("\n");
var outline_f3_63_4093=null;
var title_f3_63_4094="Natural history of AS";
var content_f3_63_4094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Natural history of aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the natural history of aortic stenosis and of the major impact of aortic valve replacement. Survival is excellent during the prolonged asymptomatic phase. After the development of symptoms, however, mortality exceeds 90 percent within a few years. Aortic valve replacement prevents this rapid downhill course.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_63_4094=[""].join("\n");
var outline_f3_63_4094=null;
var title_f3_63_4095="Contents: Depressive disorders";
var content_f3_63_4095=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Depressive disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Depressive disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antidepressant medication",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/33/26135\">",
"           Antidepressant medication in adults: Switching and discontinuing medication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5417\">",
"           Atypical antidepressants: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43783\">",
"           Effect of antidepressants on suicide risk in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7574\">",
"           Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5129\">",
"           Serotonin modulators: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5578\">",
"           Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2039\">",
"           Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/56/31626\">",
"           Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36169\">",
"           Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/3/17464\">",
"           Unipolar depression in adults: Anxiolytics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27175\">",
"           Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9850\">",
"           Unipolar depression in adults: Continuation and maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bipolar disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43065\">",
"           Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19639\">",
"           Bipolar disorder in adults: Epidemiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/9/27802\">",
"           Bipolar disorder in adults: Maintenance treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44088\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/8/38026\">",
"           Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Depression",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5017\">",
"           Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43928\">",
"           Catatonia in adults: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11481\">",
"           Clinical manifestations and diagnosis of depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28328\">",
"           Depression in adults: Psychodynamic psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/13/16601\">",
"           Depression in adults: Supportive psychotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29735\">",
"           Depression in pregnant women: Clinical features and consequences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/0/28682\">",
"           Depression in pregnant women: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/37/39514\">",
"           Diagnosis and management of late-life depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18025\">",
"           Family and couples therapy for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40074\">",
"           Initial treatment of depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17674\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/20/4425\">",
"           Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8584\">",
"           Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/21/41305\">",
"           Overview of electroconvulsive therapy (ECT) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22936\">",
"           Seasonal affective disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13128\">",
"           Technique for performing electroconvulsive therapy (ECT) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27609\">",
"           Treatment of resistant depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37481\">",
"           Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/30/6633\">",
"           Unipolar depression in adults: Overview of neuromodulation procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38201\">",
"           Unipolar depression in adults: Prognosis and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/50/17192\">",
"           Unipolar depression in adults: Treatment with lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31993\">",
"           Unipolar depression in adults: Treatment with second-generation antipsychotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/62/5097\">",
"           Unipolar depression in adults: Treatment with surgical approaches",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16682\">",
"           Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41416\">",
"           Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4105\">",
"           Unipolar major depression with psychotic features: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/15/5368\">",
"           Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8055\">",
"           Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26025\">",
"           Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35015\">",
"           Unipolar minor depression in adults: Management and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4745\">",
"           Using scales to monitor symptoms and treatment of depression (measurement based care)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-3D677551E1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_63_4095=[""].join("\n");
var outline_f3_63_4095=null;
